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EXECUTIVE SUMMARY 
The medical device industry sector encompasses an extremely large variety of products and 
technologies. It covers hundreds of thousands of products that range from more traditional products, 
such as bandages or syringes, to sophisticated devices that incorporate bioinformatics, 
nanotechnology and engineered cells. These are designed for use by practitioners, patients and 
healthy individuals in a variety of settings: hospitals, surgeries and private homes. 
Besides being a vital and innovative industry, medical devices are a key component of healthcare 
systems and represent, together with pharmaceuticals, the bulk of “medical technology”. The 
analysis of the sector must therefore investigate medical devices as an industry – an innovative 
contributor to the economy – as well its key input to healthcare systems. 
This Study provides an analytical overview of the state of the European Union medical device 
industry with regard to the following aspects: a) the impact of innovation in medical devices on 
health costs and expenditure; b) the innovativeness of the European medical device industry; c) the 
competitiveness of the European medical device industry as compared to that of the United States 
and Japan. 
The worldwide medical device market in 2003 is valued at over €184 billion, with an estimated 
nominal increase of about 16 percent from the previous year. The US constitutes the largest world 
market for medical devices, representing a world share of 38-43 percent. The European market, at 
30-34 percent of the world share, is the second largest market; here the two main national markets, 
namely Germany and France, account for half of its size. 
Medical devices are a key component and provide a key input to health systems. In Europe, 6.2 
percent of total health expenditure goes on medical devices. This percentage is higher for new 
Member States (7.6 percent) than for the EU-15 aggregate (5.4 percent). As compared to Europe, 
the share of medical devices over total health expenditure is lower both in the US and in Japan 
(about 5.1 percent).  
Medical devices are also an important part of the European manufacturing sector. Despite growing 
pressures from national cost-containment policies that have curbed the positive trend of growth of 
the sector, the industry is extremely vital, driven by growing income, aging populations and in 
general societies’ commitment to improving the quality of life. The industry – that contributes to at 
least 1.1 percent of total EU-25 manufacturing value added and to 1.3 percent of total EU-25 
manufacturing employment – has shown a dynamic performance also during the recent years of 
economic slowdown. In 2001 and 2002 (the most recent year available) medical device production 
in the EU-25 has recorded strong growth rates (12.5 percent in 2001 and 7.8 percent in 2002), well 
above the average of the manufacturing sector (1.8 percent and 0.3 percent). The bright outlook for 
the sector is confirmed by its positive performance on the stock market, where medical devices have 
systematically outperformed the average market trend. 
However, it is important to immediately point out that, in this vital and strategic sector of the 
economy, European industry is lagging behind the US, both in terms of competitiveness and 
innovativeness (see the summary statistics in Table 1). 
On the international scene, data on trade in medical devices shows that the position of the US is 
more competitive than that of European countries, and especially Japan. However the US trade 
balance has decreased in recent years, while the position of European countries has not changed 
substantially over time. Moreover, the analysis at the sub-market level reveals the existence of high 
heterogeneity across sub-sectors and shows the “vocation” of the EU as a producer (and net-
exporter) of electro-diagnostic equipment, a segment where the EU maintains a leading position.  
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Interesting differences emerge from the analysis of the industry structure. The European industry is 
characterised by a larger share of small firms than the US and Japan. In particular the average size 
of  European medical device firms turns out to be smaller than the European total manufacturing 
sector, while the reverse is true for the US. In addition, US firms are more diversified than their 
European counterparts, even though high heterogeneity exists across European countries. This 
evidence has relevant implications in terms of access to resources and funding for research 
activities. 
Indeed, when comparing R&D intensity of the European and US firms, the R&D intensity of US 
firms is much higher than the European level, the latter being roughly comparable to Japan.  
In addition, the US plays a pivotal role as a supplier of technologies, as highlighted by the analysis 
of the international market for medical technologies. Again, it is important to notice that the 
medical device industry is extremely diversified and European countries turn out to be net exporters 
of technologies related to implantable devices, and, with respect to the US, of therapeutic 
equipment and supplies. 
The leading role of the US in medical technologies is confirmed by the analysis of scientific 
productivity. The US has a leading position in terms of patent and publication counts, and more 
importantly, the gap with European countries widens when we consider the number of citations 
received by patents and the impact factor of publications.  
Finally, the composition of US production highlights a larger share of high-risk devices 
commercialised by US corporations. 
As compared to the pharmaceutical and biotechnology sectors, the medical device innovation 
system is characterised by smaller innovative firms, higher levels of interdisciplinarity and lower 
levels of cumulativeness of the knowledge basis. 
The continuous flow of innovation in medical devices and related medical practices revealed in this 
Study through a number of case studies and statistical analyses, shows that medical devices are able 
to detect diseases earlier and offer more effective treatment options for leading causes of disability 
and mortality. Innovation in medical technology and devices appears correlated to the trend of 
improved health outcomes recorded for most countries in the world where patients are able to live 
longer, be healthier, and where they can be productive for longer over their lifespan. 
The pressure on public budgets from accelerated healthcare spending that has affected most 
countries, in particular in recent years of economic slowdown, has opened the floor to new debate 
on the economic and financial impact – besides the medical one - of technological progress in 
medicine. Economic theory and models provide mixed indications on the medical technology–
health expenditure link: the effect of cost-reducing technologies, increasingly stimulated by 
constrained health insurers, could in principle offset the cost-increasing interaction between 
growing health insurance schemes and technological innovations. It is then necessary to switch to 
empirical analysis in order to collect empirical evidence on these dynamics, and on the significance 
of the link.  
The review of the increasing number of applied studies shows that although single new technologies 
may exert both upward and downward pressures on health costs and spending, new medical 
technology is believed to have generated expenditure increases in the aggregate. It is important to 
point out that the focus of the analysis here is on the cost of technological change, which is rising 
health expenditure. The side of the benefits of medical technology improvements – longer life, 
improved quality of life, prolonged working ability and so on – is not considered in this literature. 
As a consequence, no conclusions can be drawn here on the issue of the net value that patients and 
society in general derive from innovations. 
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Innovation in medical technology and devices is thus normally associated with rising healthcare 
expenditure. Despite their proved benefits, are innovations in medical devices and medicine then 
financially sustainable? What kind of policy measures should be enacted to sustain these 
improvements without constraining the number of beneficiaries and the acquisition and access to 
significant technologies? 
The Study shows that the best way to approach these issues is to frame them into the broader debate 
on welfare system reforms that EU Member States will need to adopt over the next few years. In 
particular the Study is in line with a vast body of literature that suggests a mix of coordinated 
policies, often referred to as “triple diversification of the expenditure”: I) a rebalancing within the 
components of public social expenditure, at present too concentrated on pensions; II) a rebalancing 
between public and private sources of financing through the adoption of co-payment schemes; III) a 
rebalancing within the composition of private social expenditure, in order to strengthen the 
organised institutional pillars of pension and healthcare funds. EU Member States appear to have 
margins to strengthen the diversification of the financing sources for the long-term sustainability of 
healthcare expenditures. With the appropriate use of market regulation, fiscal incentives and support 
to the disadvantaged categories of patients, this structural change can take place preserving the 
fundamental social choices. This could partially loosen budget constraints on health systems as well 
as the focus on cost-containment, and allow more room for high price-performance products both in 
the public and private markets. The industry of medical devices and of high-tech medicine could 
become one of the investment targets for health funds, and benefit from a significant financial 
source for R&D and innovation. 
The provision of health insurance – public and private – has been key to innovation in medical 
technology and devices. The expansion of healthcare insurance in all national systems has 
nourished innovation in medical technology; and vice versa new technologies and new medical 
capabilities have expanded demand for insurance i.e. insurance that includes more people and 
encompasses more health procedures and products. Theoretical and empirical analysis shows that 
the diffusion of a number of existing technologies has been highly responsive to insurance-related 
incentives. In the past, the incentives injected in the market favoured the development of 
sophisticated medical technologies, regardless of their costs. The change in the incentives, marked 
by the move to prospective-based insurance systems, altered the direction of medical innovation 
towards the development of efficiency-enhancing and cost-reducing medical devices and practices. 
Measures that affect the incentives to innovation, such as reimbursement regulations, have proved 
to be policy tools for cost-conscious health insurers, capable of directing R&D incentives and 
innovation towards cost-reducing/quality-enhancing trajectories. Member States should enhance 
their coordination with the objective of engaging in coordinated policies, in order to send consistent 
signals to the market, reduce uncertainty, orient R&D and innovation toward cost-reducing 
technologies.  
In order to turn this powerful mechanism into an effective policy option, it is necessary that: 
1. these incentives are operated through reference criteria for “efficiency-enhancing” that can be 
addressed through technology assessment tools; 
2. a harmonised system of data collection and diffusion is implemented and maintained among 
different institutions and Member States. 
As far as the first point is concerned, it is useful to notice that despite the fact that the number of 
well-designed clinical trials have grown dramatically in the past years, and that medical journals 
now routinely publish cost-effectiveness analysis, the use of health technology assessment (HTA) 
by policymakers as an explicit part of the decisions on coverage, funding and clinical guidance, 
though increasing, is still limited, and confined to a minority of Member States. The process of 
implementation of HTA is at present progressing, with Member States adopting different 
methodologies and standards. Exchangeability and access to the evidence-based information for 
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policy-making and practice obtained through HTA would instead be enhanced by the harmonisation 
of the methodologies and standards of data compilation. The processes and initiatives in place, as 
for instance the ECHTA/ECAHI project, have so far led to partial results. On the one hand, 
Members States should enhance the use of evidence-based medicine and health technology 
assessment analysis as explicit parts of the coverage process for new medical devices. On the other 
hand, The Commission should reinvigorate this process of harmonisation and coordination through 
the enhancement and sponsorship of an effective and well-endorsed “European Network for 
Medical Technology Assessment”. 
Given the complexity and high level of heterogeneity of the medical device industry, a wide variety 
of data and information sources need to be combined to monitor the performance and role of the 
industry, at a national and international level. Given the severe shortage of reliable and harmonised 
data at the EU and international level, the conclusion of this Study should be carefully interpreted. 
The present lack of reliable and disaggregated data prevents the empirical assessment of the link 
between industry structural characteristics and international competition dynamics on the one side, 
and the level of competitiveness and innovativeness on the other. A major effort should be set forth 
to devise and develop a statistical framework for the analysis of the medical device sector, from the 
R&D and innovation stage to the market stage. Throughout this Study we have proposed ways to 
improve the quality of the data for the sector in order to sustain robust statistical analysis and 
evidence-based policy implications. As a first step, it would be very useful, within the revision of 
the NACE classification due out in 2007, to consider more disaggregated classes allowing the 
identification of relevant medical device segments. In addition, it would be extremely important to 
complete and make accessable the European Database on Medical Devices (EUDAMED). 
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Table 1. Summary statistics 
 Year US Europe EU-15 EU-25 
Market (% World)      
Pharmaceutical Market 2002 46.5 25 21.6  
Medical Devices, Eucomed 2002 43 30   
Medical Devices, Datamonitor 2002 38 34   
      
Production      
Pharmaceutical (US$ millions) 2001 130,012  126,908 130,712 
Medical Devices (constant 1995 € millions) 2001 55,002  31,059 32,139 
Pharmaceutical (ratio w.r.t. US) 2001 1.00  0.98 1.01 
Medical Devices (ratio w.r.t. US) 2001 1.00  0.56 0.58 
      
Trade balance (export/import ratio)      
Pharmaceutical 2001 0.78  2.42  
Medical Devices 2001 1.46  1.15  
      
Value added over employees      
Pharmaceuticals (US$ thousands in 1997-PPP) 2001 319.6  193.2  
Pharmaceuticals (1995 € thousands) 2000 239.5  93,0  
Medical Devices (1995 € thousands) 2001 106.6  40.5  
Pharmaceuticals (PPP; ratio w.r.t. US) 2001 1.00  0.60  
Pharmaceuticals (x-rate; ratio w.r.t. US) 2001 1.00  0.39  
Medical Devices (ratio w.r.t. US) 2001 1.00  0.38  
      
R&D expenditures      
Pharmaceutical (R&D/production) 2000 10.96  10.91  
Medical Devices (R&D/Sales) 1999 US 
2000-2002 EU 
12.9  6.35 
 
Pharmaceutical (ratio w.r.t. US) 2001 1.00  0.99  
Medical Devices (ratio w.r.t. US) 2001 1.00  0.49  
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 Year US Europe EU-15 EU-25 
Share of patents (by inventor nationality)      
Pharmaceutical 1974-2003 57.32  26.80  
Biotechnology 1974-2003 60.1  24.26  
Medical Devices 1974-2003 73.5  13.37 13.5 
Pharmaceutical 1994-2003 59.62  25.64  
Biotechnology 1994-2003 63.15  22.35  
Medical Devices 1994-2003 74.3  13.35 13.44 
      
Share of patents (by assignee nationality)      
Pharmaceutical 1974-2003 57.32  n.a. n.a. 
Biotechnology 1974-2003 60.1  n.a. n.a. 
Medical Devices 1974-2003 74.6  12.37 12.51 
Pharmaceutical 1994-2003 59.62  n.a. n.a. 
Biotechnology 1994-2003 63.15  n.a. n.a. 
Medical Devices 1994-2003 75.54  11.76 11.85 
      
Share of citations (by assignee nationality)      
Pharmaceutical 1974-2003 71.4  5.52  
Biotechnology 1974-2003 77.4  12.35  
Medical Devices 1974-2003 81.43  9.04 9.13 
Pharmaceutical 1994-2003 74.3  16.02  
Biotechnology 1994-2003 89.0  4.79  
Medical Devices 1994-2003 84.7  7.54 7.58 
      
R&D licensing agreements      
Pharmaceuticals (% as licensor) 1991-2003 69.15 21.19 19.57 19.65 
Pharmaceuticals (% as licensee) 1991-2003 60.87 26.79 22.25 22.34 
Medical Devices (% as licensor) 1991-2003 73.76 17.16 15.33 15.37 
Medical Devices (% as licensee) 1991-2003 71.5 19.94 15.63 15.72 
      
Publications      
Pharmaceutical Preparations 1984-2003 44,193  43,514 45,948 
Ratio over US publications  1.00  0.98 1.04 
Equipment and Supplies 1984-2003 99,693  94,095 96,403 
Ratio over US publications  1.00  0.94 0.97 
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1. INTRODUCTION AND STRUCTURE OF THE STUDY 
This Study on “medical devices: competitiveness and impact on public health expenditure” 
contributes to the implementation of Article 157 of the treaty establishing the European 
Community. Title XVI (“Industry”) of the article states that: “The Community and Member States 
shall ensure that the conditions necessary for the competitiveness of the Community’s industry 
exist” and that “For that purpose, in accordance with a system of open and competitive markets, 
their action shall be aimed at fostering better exploitation of the industrial potential of policies of 
innovation, research and technological development”. 
Besides being a vital and innovative industry, medical devices are a key component of healthcare 
systems and represent, together with pharmaceuticals, the bulk of “medical technology”. 
Technological progress in medical care has been the main driver of improvements in healthcare 
systems in order to prevent, diagnose and treat diseases, as well as enhancing health status and 
quality of life. Yet at the same time, medical technology is often quoted as one of the main reasons 
behind increasing healthcare costs and expenditure. 
The analysis of the sector must therefore investigate medical devices as an industry – an innovative 
contributor to the economy – as well as offering a key input to healthcare systems. The links 
between these two aspects which involve health institutions, policies and regulations, also need to 
be assessed. 
This Study aims to provide a coherent analytical overview of the state of the EU medical device 
industry covering the following issues: 
I.  The impact of innovation in medical devices on health costs and expenditure; 
II. The innovativeness of the European medical device industry; 
III. The competitiveness of the European medical device industry as compared to the United 
States and Japan. 
Furthermore, the Study provides suggestions on how to overcome the current statistical 
shortcomings that represent a severe limitation to the possibility of implementing a coherent and 
unified framework for policy awareness and intervention at an EU level. 
In so doing, the Study clearly distinguishes between “medical devices” and “medical technologies”. 
Medical technologies include medical devices as one of its constituents, and can be defined as “the 
drugs, devices and medical and surgical procedures used in medical care, and the organisational 
and supportive systems within which such care is provided” (OTA, 1984). 
The reference concept and definition for medical devices in the Study is the one adopted in the 
European Union Medical Devices Directive (93/42/ECC), article 1, which covers “any instrument, 
apparatus, appliance, material or other article, whether used alone or in combination, including 
the software necessary for its proper application intended by the manufacturer to be used for 
human beings for the purpose of: 
 diagnosis, prevention, monitoring, treatment or alleviation of disease; 
 diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap; 
 investigation, replacement or modification of the anatomy or of a physiological process; 
 control of conception; 
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its function by 
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such means.”1 In vitro diagnostics (IVD) are covered by the Study in the definition and concept 
adopted in the In Vitro Diagnostic Medical Devices Directive (98/79/EC), where IVD are defined 
as “any medical device which is a reagent, reagent product, calibrator, control material, kit 
instrument, apparatus, equipment, or system, whether used alone or in combination, intended by the 
manufacturer to be used in vitro for the examination of specimens, including blood and tissue 
donations, derived from the human body, solely or principally for the purpose of providing 
information: concerning a physiological or pathological state; or concerning a congenital 
abnormality; or to determine the safety and compatibility with potential recipiens; or to monitor 
therapeutic measures”.  
 
BOX 1: Examples of medical devices 
 Anaesthetic machines and 
monitors 
 Apnoea monitors 
 Artificial eyes 
 Artificial limbs 
 Blood transfusion and 
filtration devices 
 Breast implants 
 Cardiac monitors 
 Cardiopulmonary bypass 
devices 
 Clinical thermometers 
 Condoms 
 Contact lenses and 
prescribable spectacles 
 CT scanners 
 Defibrillators 
 Dental equipment and dentures 
 Dental material and 
restoratives 
 Diagnostic imaging equipment 
 Diagnostic kits and tests 
 Dialysers 
 Electrosurgery devices 
 Endoscopes 
 Enteral and parenteral feeding 
systems 
 Equipment for disabled people 
 Examination gloves 
 Foetal monitors 
 Hearing aids and inserts 
 Heart valves 
 Hospital beds 
 Hydrocephalus shunt 
 Incontinence pads 
 Infusion pumps and 
controllers 
 Intra-uterine devices 
 Intravascular catheters and 
cannulae 
 Laboratory equipment 
 Lithotripters 
 Medical lasers 
 Medical textiles, dressings, 
hosiery and surgical supports 
 Orthopaedic implants 
 Operating tables 
 Ostomy and incontinence 
applicances 
 Pacemakers 
 Physiotherapy equipment 
 Prescribable footwear 
 Pressure sore relief devices 
 Radiotherapy machines 
 Resuscitators 
 Scalpels 
 Special support seating 
 Sphygmomanometers 
 Stents 
 Suction devices 
 Surgical instruments and 
gloves 
 Sutures, clips and staples 
 Syringes and needles 
 Ultrasound imagers 
 Urinary catheters, vaginal 
speculae and drainage bags 
 Ventilators 
 Walking aids 
 Wheelchairs 
 
Source: Healthcare Industry Task Force (2004). 
Note: the list is not exhaustive and is intended to illustrate the range of of products manufactured by the industry. 
 
Nevertheless, in some sections of the Study it has been necessary to adopt broader or narrower 
definitions of medical devices, in order to address specific issues or, for the empirical analysis, to 
account for data availability. Departures from the EU Directive definition of medical devices are 
always highlighted and circumstantiated. 
The framework and objectives outlined above are developed along nine chapters: 
 Chapter 1: Introduction and structure of the Study. 
 Chapter 2: The medical technology marketplace at the macro level. This chapter defines 
the broad picture and provides an overview of the world and European medical device 
markets. Throughout this chapter, the medical device industry is put in perspective by 
                                                 
1  
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highlighting its role as a component of national healthcare systems on the one side, and of 
industrial systems on the other. 
 Chapter 3: Long term trends of health expenditure and the impact of new technologies. 
This chapter illustrates the relationship between technological change in medicine and health 
expenditure, first from a theoretical point of view, and then through the review of a large 
number of empirical studies on the subject. It finally frames the issue of the sustainability of 
medical device innovations into the debate on social expenditure composition and overall 
reform. 
 Chapter 4: Economic evaluation of medical devices: some case studies. The objective of 
this chapter is to present some examples of the impact of medical device innovations on the 
whole health system. In most of the cases, Chapter 3 reveals at the aggregate level evidence of 
a significant effect of innovation in medical technology on health costs and expenditure. 
However, at the micro level, single innovations have proven to save healthcare resources, 
mainly through the reduction of hospitalisation, early detection and diagnosis of diseases and 
syndromes, reduction of invasiveness of medical intervention, and improvement of citizens’ 
quality of life. Costs/expenditures constitute only one of the economic dimensions on which 
innovation produces its impact. Medical innovations need to be evaluated with respect to 
either the effectiveness of the innovation (as measured by clinical indicators) or its benefits (in 
terms of utility, specified in various ways).  
In this chapter, some case studies of major technological innovations in medicine are set out. 
The aim of this exercise is to expand the reference scenario in order to illustrate the net effect 
of innovation in medical devices when the effectiveness factor and the societal perspective 
(that includes quality of life aspects) are taken into account. 
Four case studies are investigated:  
a) Interventional cardiology market: drug eluting stents;  
b) Diabetes treatment and blood glucose control;  
c) Osteoarthritis and total hip replacement;  
d) Imaging devices for mammography. 
The analysis of specific examples of major innovation in the medical device industry helps us 
in identifying key aspects that are functional to the following sections of the Study, such as the 
extent and heterogeneity of the knowledge base on which the innovation processes draws 
upon, the post-launch market dynamics of innovative products, and the properties and 
structure of the reference markets. 
 Chapter 5: Productivity, competitiveness and industry structure. In Chapters 5 and 6, the 
focus shifts to medical devices as an industry, in order to identify its structural characteristics 
and international competition dynamics. 
The industry structure is analysed in terms of size distribution and diversification within and 
between medical device sub-markets. In addition, the main competitiveness indicators – 
production, productivity, value added, and trade indicators – are presented for the relevant 
aggregates (EU, US and Japan), and the relative competitiveness of the different industries are 
assessed.  
This chapter shows that the European medical device industry is lagging behind the US, both 
in terms of production capabilities and international competitiveness.  
Even though the analysis of product flows between countries shows the leading role of the US 
on the international scene, European firms hold a competitive position in most of the 
diagnostic equipment segment of the industry. However, as European firms are smaller and 
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less diversified than US counterparts, they are likely to experience more constraints in 
accessing resources and financing for innovation and internationalisation. 
 Chapter 6: R&D and innovation. This chapter analyses different aspects of the European 
innovation system in the medical device industry from R&D to the uptake and diffusion of 
medical innovations. This analysis is performed in order to assess the level of innovativeness 
of the European medical device industry as compared to the US and Japan. Patent analysis 
highlights the key role played by small firms and individuals in the medical device innovation 
process and the high level of heterogeneiety of the relevant knowledge bases. European firms 
lag behind their US counterparts in terms of R&D intensity. However, it is worthwhile 
noticing that R&D intensity varies considerably among Member States and sectors of the 
medical device industry with some countries (Germany and France) and sectors (in-vitro 
diagnostics on above all) that show a high level of R&D intensity. The analysis of the market 
for medical technologies confirms the pivotal role of the US system even if Europeans still 
hold a comparative advantage in technologies related to implantable devices, and therapeutic 
equipments and supplies.  
All in all, Chapters 5 and 6 show that the European medical device industry is less innovative 
and competitive than the US one. 
 Chapter 7: Statistical shortcomings for the sector: analysis and proposals. The lack of a 
systematic effort at the international level to collect, integrate, update and diffuse primary data 
and information on the state and the evolution of the medical device industry represents a 
severe limitation to this Study as well as to previous analytical efforts. Data limitations also 
dramatically reduce the efficacy of public policies to enhance the competitiveness and 
productivity of the EU medical device industry, and the development of a European system of 
innovation. After describing the main characteristics and shortcomings of the available data 
sources at the international level, Chapter 7 proposes a statistics framework for the 
implementation of a data collection strategy for the European medical device industry.  
First of all, single national offices of statistics, regulatory bodies and international institutions 
urge the identification of a common definition for the sector and an industry classification of 
medical device sub-sectors based on both market and technological factors.  
Secondly, national offices of statistics of Member States and Eurostat should adopt the same 
classification and provide disaggregated figures for relevant segments of the medical device 
industry. 
Finally, regulatory bodies and public institutions in general should provide private incentives 
to collect micro-level data on the industry and market structure and strengthen their efforts to 
harmonise data and information at the EU level. 
 Chapter 8: Policy recommendations. This chapter proposes strategic recommendations to 
the European Commission and Member States on policy options for the sector, identified on 
the basis of the analysis of the previous chapters. The starting point for this activity has been 
the recognition of the inherent complexities of the sector, as highlighted in this Study, 
whereby a heterogeneous and vital innovative industry is also a component of healthcare 
systems. This means that no easy-menu exists for policies aimed at controlling costs while 
enhancing the quality of health services, innovation and competitiveness. The endorsement of 
these distinct objectives involves trade-offs and difficult resource allocation decisions. Indeed, 
the clear recognition and political statement of these distinct objectives and the trade-offs can 
be considered as a policy recommendation per se. 
The main policy issues, options and recommendations to Member States and the European 
Commission are identified and presented with regard to: a) reconciling the objective of 
expenditure control with the improvement of healthcare performance through new 
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technologies; b) preserving and enhancing the innovativeness of the European medical device 
industry and, more generally, c) its competitiveness in the world market. 
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2. THE MEDICAL DEVICE MARKETPLACE AT MACRO LEVEL 
Summary of the chapter 
This chapter provides an overview of the worldwide and European medical device sector, and puts 
it in perspective by highlighting its role as a component of national healthcare systems, on the one 
side, and of the industrial systems on the other. 
The worldwide medical device market in 2003 is valued at over €184 billion - US$220 billion, with 
an estimated nominal increase of about 16 percent from the previous year. The US constitutes the 
largest world market for medical devices, representing a world share of 38-43 percent. The 
European market, at 30-34 percent of the world share, is the second largest market, followed by 
Japan. The rest of the world market represents 14-16 percent of the global market. Within Europe, 
Germany is the leading market, followed by France, Italy and the UK. The two largest markets, 
Germany and France, account for half of the European market, and the four largest accounts for 
over 70 percent of it. 
Medical devices are a key component and input to health systems. In Europe, 6.2 percent of total 
health expenditure goes on medical devices (with health expenditures accounting on average for 7.8 
percent of the GDP). Both the US and Japan spend some 5.1 percent of total health expenditure on 
medical devices (with health expenditures accounting for respectively 13.9 and 7.6 percent of 
GDP). The data on per capita expenditure on medical devices (calculated using the purchasing 
power parity correction) show the US with the highest per capita expenditure, at €278 in 2002; the 
figures for the EU-15 and Japan are less than half the figure for the US, at respectively €124 and 
€136. The data available for the EU new Member States reveal significantly lower per capita 
expenditure than that for the EU-15. 
Medical devices are also an important part of the EU manufacturing sector. Data available for a 
subset of the total aggregate show that the they constitute at least 0.8 percent of total production of 
the EU-25 manufacturing sector and 1.2 percent of total EU-25 manufacturing employment.  
Despite growing pressures from national cost-containment policies that have curbed the positive 
trend of growth of the sector, the industry is extremely vital, driven by growing income, aging 
populations and in general societies’ commitment to improving the quality of life. In the EU-25, 
medical device production has recorded top growth rates in recent years (12.5 percent in 2001 and 
7.8 percent in 2002), well above the average of the manufacturing sector (1.8 percent and 0.3 
percent). The good outlook for the sector is confirmed by its positive performance in the stock 
markets, where medical devices have systematically outperformed the average market trend. 
2.1 Medical device markets 
The medical device aggregate is composed of a wide range of different products, and is therefore 
difficult to quantify. As a consequence the figures presented in this chapter come from a multitude 
of heterogeneous sources – national and official statistics, companies, industry associations, market 
intelligence firms – and have not been fully validated and should be interpreted as illustrative only. 
The lack of a harmonised cross-country data collection standard, on a global and EU level, severely 
restricts the possibility of mapping the industry at the international level and of making 
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comparisons2. All these circumstances should prompt the reader to be careful when making 
comparisons across countries, markets and over time. 
Global markets 
The worldwide medical device market in 2003 is valued at over €184 billion - US$220 billion 
(Eucomed 2004; Standard & Poor’s, 2004a), a nominal increase of about 16 percent from the 
previous year (Standard & Poor’s, 2004a).  
Table 1. Medical device world market 
Standard & Poor’s Eucomed 
2003: $220 bill 
2002: $190 bill 
2003: > €184 bill 
2002: > €184 bill 
Source: Eucomed (2003; 2004), Standard & Poor’s (2004a). 
Note: definition of medical devices for each source in footnote3. 
Medical device products can be grouped into medical high-tech products and more conventional 
products. The segment of high tech products is composed of sophisticated devices designed for 
specific therapeutic and diagnostic uses. These are associated with costly and risky R&D activities, 
clinical trials, administrative and regulatory procedures for marketing clearance. Products from this 
segment have strong growth potential and are at significant risk of becoming obsolete. For 
companies specialising in the high-tech sector, new products (those introduced within the preceding 
two years) typically account for more than 30 percent of sales (Standard & Poor’s, 2004a). 
However, it must be noted that for some companies new products introduced within the preceding 
12 months account for more than 60 percent of sales. The market of more conventional devices 
consists of items such as syringes, gauze, and intravenous products as well as a wide range of other 
conventional diagnostic and therapeutic products. This segment is associated with low margins and 
high volumes. 
The US market constitutes the largest world market, representing a share estimated at 38-43 
percent. The European market, at 30-34 percent of the world share, is the second largest market, 
followed by Japan. The rest of the world market represents 14-16 percent of the global market (see 
Table 2). 
                                                 
2 “… As there is little reliable data on the (medical devices) industry, the figures used in this study came from a number 
of different sources. As a result, there are inconsistencies which cannot be easily reconciled…” (UK Healthcare 
Industries Task Force, 2004, page 15). 
3 Definitions of the medical devices aggregate: 
 Eucomed: the reference definition corresponds to that of the EU Medical Devices Directive (93/42/ECC); the 
figures are from Eucomed's calculations and estimations based on their data sources, reported in Eucomed (2003, 
see the Appendix; or at http://www.eucomed.be/docs/Overview%20sources.pdf). 
 Standard & Poor’s: “..include commodity-type items such as kits, trays, gloves, gowns, syringes, and other 
disposable medical supplies, as well as higher technology products, among which are infusion and related 
intravenous supplies and equipment, diagnostic and laboratory products, wound-management supplies, 
orthopaedic reconstructive implants, spinal devices, surgical devices, cardiac products, and diagnostic 
equipment.”  
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Table 2. Shares of medical device world market, 2002 
  Eucomed Datamonitor 
  Expenditure (€bill) Share Expenditure ($ bill) Share 
Europe 55 30 63 34 
US 79 43 71 38 
Japan  20 11 25 13 
Rest of the world 30 16 26 14 
     
World 184 100 186 100 
Source: Datamonitor (2003a), Eucomed (2003). 
Note:  Datamonitor definition of medical devices in footnote4 
As will be seen in the next chapter, demographics (aging population), income growth (that can 
sustain increasing demand for high-tech health services) and increasingly extensive health insurance 
systems, are regarded as long-term drivers of the medical device market. These factors have 
sustained strong market growth for medical devices in the past years and decades. In recent years, 
cost-containment policies adopted by increasingly cost-conscious healthcare systems and providers 
affected by growing budget deficits have put medical device markets under pressure in most 
countries. 
In Europe, large budget deficits have pressured Governments to lower healthcare spending and, 
together with it, spending on medical devices and associated medical procedures. In the US, 
markets have registered the restrictive impact of the expansion of managed care in the healthcare 
marketplace, that at present account for about 70 percent of all medical device purchases in the US. 
Managed care providers use their purchasing power to obtain discounts on bulk purchases of 
medical products, and employ various typologies of gatekeepers to direct access to diagnosis or 
therapeutic procedures based on medical devices. Government efforts to control healthcare 
spending are heavily affecting the medical device market also in Japan. In the 2000 biennial price 
revision of the reimbursement prices for medical devices, an average price reduction of 4.5 percent 
was implemented for three major categories (arterial catheters, pacemakers and orthopaedic 
implants), and in 2002 a new pricing policy on implants was instituted, which includes 
reimbursement cuts based on foreign reference pricing.  
Market dynamics for the major market reflect the evolving interaction of these driving factors: 
Figure 1 shows the long-term growth of the industry, and its contraction in recent years, explained 
by most analysts as the result of the intensification of national cost-containment policies. 
                                                 
 4 Health care equipment and supplies “include active implants, aids for the disabled, anaesthetic & respiratory 
devices, dental devices, drug delivery systems, emergency medical equipment, electro-medical devices, hospital 
equipment, imaging & radiotherapy devices, ophthalmic & optical devices, passive implants, single use 
disposables, and surgical instruments”. Market value is calculated at manufacturers selling price. 
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Figure 1. Growth of medical device major markets (%) 
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Source: AdvaMed (2004)5; Datamonitor (2003a). 
European market 
The European medical device market for 2002 is estimated at €55 billion-$63 billion. Within 
Europe, Germany is the leading market, followed by France, Italy and the UK. The two largest 
markets, Germany and France, account for half of the European market, and the four largest account 
for over 70 percent of it. 
Table 3. European medical device markets ranked by size, 2002 
 Expenditure (€mil) Share 
Germany 19,000 34.4 
France 9,000 16.3 
Italy 6,160 11.2 
United Kingdom 5,800 10.5 
Spain 3,000 5.4 
Netherlands 2,500 4.5 
New EU Member States 1,950 3.5 
Switzerland 1,360 2.5 
Sweden 1,080 2.0 
Norway 930 1.7 
Denmark 870 1.6 
                                                 
5 Data for the US do not account for outsourcing/off shoring where a manufacturer is manufacturing finished products 
in another country. 
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 Expenditure (€mil) Share 
Belgium 820 1.5 
Austria 730 1.3 
Portugal 600 1.1 
Greece 540 1.0 
Finland 450 0.8 
Ireland 360 0.7 
Luxembourg 50 0.1 
Source: Eucomed (2004); most but not all figures refer to year 2002. 
The ten new Member States account as a whole for 3.5 percent of the European market, of which 77 
percent is represented by Poland, Czech Republic and Hungary.  
Table 4. EU new Member States’ markets for medical devices ranked by size, 2002 
 Expenditure (mil €) Share 
Poland 770 39.5 
Czech Republic 370 19.0 
Hungary 360 18.5 
Slovenia 130 6.7 
Slovak Republic 110 5.6 
Latvia 60 3.1 
Lithuania 60 3.1 
Estonia 40 2.1 
Cyprus 30 1.5 
Malta 20 1.0 
Source: Eucomed (2004); most but not all figures refer to year 2002. 
The recent market contraction seen in Figure 1 is shared by most European countries, as can be seen 
from Figure 2 for a selection of countries (for which data is available). 
 20
Figure 2. Growth (%) of selected European markets of medical devices 
   Source: Datamonitor (2003a). 
The decline in the growth rate is noticeable for most sub-markets for which data is available, but 
has affected the different segments with heterogeneous intensity, as can bee seen from Table 5.  
Table 5. Growth (%) of selected sub-markets in Europe 
 1999 2000 2001 2002 2003 
Computed tomography n.a. 18 41 18 3 
Magnetic resonance n.a. 4 36 15 -4 
Ultrasound n.a. 15 19 13 12 
X-ray n.a. 21 -9 9 -13 
Radiology information systems (RIS) and picture 
archiving and communications systems (PACS)  n.a. n.a. n.a. 25 15 
In vitro diagnostics 3.8 4.6 7.3 6 5.6 
Orthopaedics 7 9 12 16 n.a. 
Dental n.a. 17 -6 12 -10 
Sources: COCIR (for computer tomography, magnetic resonance, ultrasound, X-ray, RIS and PACS); EDMA (2004; for 
in vitro diagnostics); ADDE & FIDE (2004; for dental); our estimates based on Datamonitor (2003b) and discussions 
with the industry (for orthopaedics) 6. 
                                                 
6 Computed tomography, magnetic resonance, ultrasound, X-ray: data only for France, Germany, Italy, UK (including 
Ireland from 2003); surveyed sample growing over time. 
- RIS and PACS: Europe is EU-15 plus the following: Switzerland, Norway, Turkey, Czech Republic, Hungary, Poland, 
Russia. 
- In vitro diagnostics: data for 14 European Countries, including Romania and Poland.  
- Dental: surveyed countries exclude all new Member States but Czech Republic. 
- Self-monitoring of blood glucose: data on volumes. 
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Durable large-scale equipment in particular appears to have suffered from intensified pressures to 
hold down costs. For instance, despite technological development resulting in diagnostic superiority 
compared to previous imaging techniques for magnetic resonance imaging, purchasers are 
hesitating to invest because of the difficulty to get a reimbursement for the funding for capital 
investment. 
Orthopaedic devices hold the trend firmly. These devices are used for the repair and replacement of 
skeletal problems and include products such as artificial body parts, joint replacement, products 
used for repairing broken bones, devices for spinal column repair and arthroscopic equipment for 
vision during procedures. The growth of the segment is believed to be strongly sustained by the 
phenomenon of an aging population and by the increasing demand for a better quality of life that 
involves implantable products for reconstruction in the hip, knee and spine (Standard and Poor’s, 
2004a). 
The in vitro diagnostic segment (IVD) produces the analytical instruments and the reagents that are 
used to perform various tests for diagnosis as well as for the monitoring and management of 
diseases. Behind the aggregated figure in Table 5, are different sub-sector trends: cardiac markers, 
glucose testing, nucleic acid-based reagents have experienced in recent years two-digit rates of 
growth; conversely, other sub-sectors, such as microbiology are suffering. Some analysts suggest 
that the growth in the market segment of diabetes testing and cardiac markers is related to the 
increasing awareness of the economic and clinical benefits of IVD testing in these areas. 
The sub-market of radiology information systems (RIS) and picture archiving and communication 
systems (PACS) shows two-digit growth rates, and is predicted to maintain a solid growth in the 
near future (TekPlus, 2002). The development of RIS and PACS has been the result of the need to 
store and manage the usage of the increasing number of images produced by different diagnostic 
scanners (computed tomography, magnetic resonance and nuclear imaging and others). The 
expansion of the sector, already well established in the US, is predicted to involve Europe in the 
next few years. Here, providers are now moving to a film-less environment, and governments have 
announced massive investments to enhance the efficiency of health systems through the injection of 
the processes of information technology tools (The Economist, 2005). 
2.2 Medical device expenditure as a component of European Union health 
systems 
European Countries spend on average 7.8 percent of GDP on health. This figure is on average 
higher for the EU-15 aggregate (8.3 percent) than for the new Member States (6.6 percent), and 
compares with a 13.9 percent for the US and a 7.6 percent for Japan. 
In Europe, 6.2 percent of total health expenditure goes to medical devices. This percentage is higher 
for new Member States (7.6) than for the EU-15 aggregate (5.4 percent). Both the US and Japan 
spend some 5.1 percent of total health expenditure on medical devices.  
The data on per capita expenditure on medical devices calculated with the purchasing power parity 
correction (PPP; here with respect to the US dollar), a procedure that takes into account the cost of 
living differentials across different countries, show a high degree of heterogeneity between and 
within areas. The US reports the highest per capita expenditure, at €278; the figures for the EU-15 
and Japan are less than half of that, at respectively €124 and €136. The data for the EU new 
Member States reveal significantly lower per capita expenditure than for the EU-15. 
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Table 6. Indicators of expenditure in medical devices, 2002 
 
MD expenditure as a 
% of total health 
expenditure 
Total health 
expenditure as a % of 
GDP 
MD expenditure 
per capita (€) 
 
MD expenditure 
per capita (€) 
at US$ PPP 
Austria 4.3 7.9 90 101 
Belgium 3.6 9.0 79 92 
Denmark 5.7 8.6 161 147 
Finland 4.8 7.0 86 90 
France 6.5 9.5 150 175 
Germany 8.6 10.7 230 246 
Greece 4.4 9.4 49 74 
Ireland 4.9 6.5 89 93 
Italy 5.8 8.6 107 133 
Luxembourg 4.1 5.6 111 115 
Netherlands 6.5 8.9 154 172 
Portugal 5.3 9.2 57 89 
Spain 6.1 7.5 73 100 
Sweden 5.1 8.7 120 121 
United Kingdom 4.8 7.6 97 103 
     
Cyprus 4.5 6.1 41 n.a. 
Czech Republic 7.9 7.3 36 80 
Estonia 10.8 5.8 30 n.a. 
Hungary 9.2 6.8 36 78 
Latria 11.5 5.8 26 n.a. 
Lithuania 8.3 5.7 17 n.a. 
Malta 1.7 8.8 50 n.a. 
Poland 6.1 6.3 20 43 
Slovak Republic 8.6 5.7 20 55 
Slovenia 7.1 8.0 65 n.a. 
      
Norway 6.2 8.0 206 174 
Switzerland 4.5 11.1 188 154 
      
EU-15 average 5.4 8.3 134 124  
New Member States average 7.6 6.6 26  n.a. 
EU-25 average 6.2 7.6 116  n.a. 
Europe average 6.2 7.8 118  n.a. 
      
US 5.1 13.9 278 278 
Japan 5.1 7.6 158 136 
Source: Our calculation based on Eucomed (2003; 2004); most but not all figures refer to year 2002. 
Notes: PPP values calculated through the 2002 GDP PPP exchange rate with the US$ (OECD Health Data, 2004). 
As Table 6 shows, the picture within the EU is quite heterogeneous, reflecting among other things 
different national choices towards the organisation and size of the health sector. Member States 
have full responsibility for this area, and “…European Union action shall respect the 
responsibilities of the Member States for the definition of their health policy and for the 
organisation and delivery of health services and medical care. The responsibilities of the Member 
States shall include the management of health services and medical care and the allocation of the 
resources assigned to them. …” (EU Constitution, Chapter V, Section I “Public Health”). 
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The heterogeneity in national choices on health system and organisation reflected in Table 6, is 
mirrored in Table 7, which shows cross-country penetration of a number of medical devices and use 
of high-technology medical procedures. No “technology-champions” can be identified among 
Member States when looking at the number of high-tech medical devices and procedures. Systems 
use different mixes of diagnostic and curative practices according to national protocols and medical 
standards. The ways in which various health systems in European countries organise and finance 
their medical technologies are influenced by a combination of factors that include the nation’s 
historical precedents, consumer pressures, country income, health infrastructures, market structure 
and the level of competition among providers (and factors affecting it). 
On an international level, the high endowment of Japan with imaging devices – MRI and especially 
CT - is remarkable, especially when considering that the country devotes a lower amount of 
resources (in GDP) that the EU (15) and the US to the health sector. The use rate of dialysis in 
Japan is also by far the largest of the countries listed in the table. On the other side, the US high 
propensity to perform high-tech medical procedures exceeds that of most other countries.  
 24
Table 7. Medical devices and medical technology penetration 
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year 2002 2002 2002 2002 2002 2001 2001 2001 2001 
          
Austria 13.4 27.3 4.5 n.a. 39.2 482.1 n.a. 0.8 5.2 
Belgium n.a. n.a. n.a. n.a. n.a. 464.7 118.2 1.1 3.5 
Czech Republic 2.2 12.1 9.2 13.2 n.a. n.a. n.a. 0.5 3.2 
Denmark 8.6 13.8 6 n.a. 43.9 328.9 56.7 0.6 3.0 
Finland 12.5 13.3 8.8 39.6 25.7 n.a. n.a. 0.3 3.3 
France 2.7 9.7 6 42.4 58 387.7 124.7 0.5 3.4 
Germany n.a. 13.3 10.6 n.a. 67.7 n.a. n.a. 0.5 2.9 
Greece 2.4 17.7 n.a. 29 71.9 207.2 50.8 0.0 1.5 
Hungary 2.5 6.8 n.a. n.a. n.a. 559.3 n.a. 0.1 2.6 
Ireland n.a. n.a. n.a. n.a. n.a. 134 52.1 0.3 3.1 
Italy 10.4 23 3.8 n.a. n.a. 35.9 10.4 0.5 2.7 
Luxembourg 4.5 24.7 4.5 22.4 81.4 353.1 n.a. n.a. n.a. 
Netherlands n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.2 3.3 
Portugal n.a. n.a. n.a. n.a. 74.7 108.5 28.9 0.2 3.5 
Slovak Republic 2 10.6 13.2 12.1 43.1 n.a. n.a. 0.1 1.9 
Spain 6.2 12.8 3.6 n.a. n.a. n.a. n.a. 0.8 4.7 
Sweden n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.3 3.5 
United Kingdom 4 5.8 3.3 n.a. 33.4 6.5 n.a. 0.3 2.9 
          
United States 8.2 12.8 4 11.9 n.a. 414.7 165.4 0.8 5.0 
Japan 35.3 92.6 6.6 n.a. 180.2 n.a. n.a. n.a. 0.6 
Source: OECD Health Data (2004). 
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2.3 Medical devices as a component of the European Union industrial system 
The medical device industry is an important contributor to the European Union manufacturing 
sector. Reliable data for assessing the position of the industry exist only for a subset of the medical 
device aggregate as defined by Directive 93/42. Eurostat provides figures on “Medical and surgical 
equipment and orthopaedic appliances” (NACE DL 33.1). This aggregate does not include, among 
others, high-tech chemical and biochemical-based devices such as in vitro diagnostics (that are 
grouped instead under “chemicals”) and medical-impregnated products such as gauzes and 
bandages (that are under “pharmaceutical preparations”). The inadequacy of the NACE 
classification in representing the whole medical device sector will be considered in Chapter 7. Here 
it is important to point out that the following data under-represent the sector, in magnitude and 
high-tech intensity. 
The manufacture of medical devices (medical and surgical equipment and orthopaedic appliances) 
generated in 2001 value added for €17.2 billion in the EU-25, from a turnover of €41.3 billion. The 
workforce in this sector was of about 350,000 workers. As such, the contribution of the sector was 
1.1 percent of total EU-25 manufacturing value added and 1.3 percent of total EU manufacturing 
employment. 
Table 8. Medical devices (NACE DL 33.1) in the EU-25 manufacturing sector, 2001 
  as a % of total EU-25 manufacturing 
Value added €17.2 billion 1.1 
Employment (units) 352,000 1.2 
Source: Eurostat (2004a). 
At the industry level, value added is the value of industry firms’ output minus the value of all the 
inputs purchased from firms of other sectors. Therefore, it represents a measure of the profit earned 
by a particular firm plus the wages it has paid i.e. the value of the labour and capital the industry 
uses. In the EU, medical devices are a top generator of value added compared to other 
manufacturing sectors: Figure 3 shows that almost 46 percent of the value of production is 
generated within the industry through the manufacturing process. This reflects the high value of the 
labour and capital the industry uses. 
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Figure 3. Value added created as a percentage of production value 
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   Source: Eurostat (2004a). 
The medical technology industry is R&D intensive. As it will be seen in Chapter 6, in the 
innovation process for medical devices, more than for most other industries, many fields of science 
converge. In addition, innovation for the sector is incremental, and is conducted both in-house to the 
manufacturer and at the clinical level, whereby physicians refine technologies through iterative 
experience. While being applicable to many healthcare technologies, the standard model of “linear 
and unidirectional innovation” (Gelijins and Rosenberg, 1994) – where basic research is input to 
applied research, which leads to development, manufacturing, marketing and finally adoption of a 
finished product – does not apply to medical device innovation. As a consequence, innovation 
processes and efforts for the industry are difficult to track and quantify, and standard measures, 
such as intramural R&D activities, can reflect only to a limited extent the innovative intensity and 
efforts for the industry (Gelijins and Rosenberg, 1994).  
Figure 4 depicts the R&D intensity of the medical device sector, and its relative position compared 
to other manufacturing sectors. Medical devices show a higher R&D intensity (5 percent of value 
added) than total manufacturing sector (3,8 percent of value added), but significantly lower than 
several other manufacturing sectors. The considerations above, and the absence within the NACE 
DL 33.1 aggregate of high-tech innovative products, determine an under-representation in these 
data of the R&D efforts of the sector. 
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Figure 4. Share of R&D in value added (%) 
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   Source: Eurostat (2004a). 
Even during the recent years of economic slowdown the industry has kept its pace. In the EU-25 
medical devices, together with pharmaceuticals, have recorded in 2001 and 2002 the highest 
production growth rates, while several sectors were showing negative figures (Table 9). 
Table 9. EU-25 growth rates for selected industries, % 
 2000 2001 2002 
Pharma and medicinal chemical n.a. 7.9 11.6 
Medical devices (NACE DL 33.1) n.a. 12.5 7.8 
Food and beverages 1.7 6.7 0.7 
Maufacturing total 9.5 1.8 0.3 
Paper. publishing and printing 10.3 -1.1 -0.3 
Basic chemical n.a. -1.9 -0.3 
Metals and metal products 9.9 0.3 -1.0 
Textiles 3.3 0.5 -3.0 
Electrical machinery 11.0 3.2 -4.5 
Radio, tv and communication equipment 32.6 -13.7 -12.3 
Office machinery and computers 13.5 -4.0 -18.1 
Source: Eurostat (2004a). 
The positive outlook for the sector is reflected in its performance on the stock market, where it has 
systematically outperformed the market average trend. Despite growing pressures from public 
budget problems, the fundamentals of the industry remain strong, driven in the major markets by 
the aging population that increasingly requires and demands medical procedures. The Morgan 
Stanley Healthcare Equipment and Supplies World Index gained 24 percent between September 
2003 and September 20047, outperforming the Morgan Stanley World Index (that reflects the world 
stock market performance) that was up 12.3 percent in the same period. The Healthcare Equipment 
                                                 
7 Precisely from 30 Sept. 2003 to 30 Sept. 2004. 
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and Supplies sector outperformed the market in all geographic areas. In recent years, the companies 
traded on the European stock markets performed better than their counterparts traded in the US and 
Japan, as shown at the bottom of the diagram.  
Most financial analysts agree on the view of a persisting positive fundamental outlook and 
continuing growth for the sector, driven by favourable demographics and under-penetration of key 
procedures. Nevertheless, future growth is predicted at a slower rate than in the past years (Morgan 
Stanley, 2004; Standard and Poor’s 2004a; Credit Suisse First Boston, 2004). 
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3. THE MEDICAL TECHNOLOGY - HEALTH EXPENDITURE LINK: THEORY 
AND EMPIRICAL EVIDENCE 
Summary of the chapter 
This chapter illustrates the relationship between technological change in medicine and health 
expenditure, first from a theoretical point of view, and then through the review of a large number of 
empirical studies on the subject. It finally frames the issue of the sustainability of medical device 
innovations into the debate on social expenditure composition and overall reform.  
Simple models that show the static impact of innovations on the demand and supply of medical 
care, do not determine a priori the overall net impact of technological progress on health 
expenditure, i.e. the result of the interplay of factors that may point to opposite directions. More 
complex frameworks of analysis have included institutional arrangements such as the provision of 
institutional health insurance in a dynamic context. These show that the long-run growth of 
healthcare expenditure is a by-product of the self-fulfilling interaction between expanding insurance 
and the development of new technologies.  
In general, both static and dynamic frameworks of theoretical analysis provide mixed indications on 
the medical technology–health expenditure link: the effect of cost-reducing technologies, 
increasingly incentivised by constrained health insurers, could in principle offset the demand-side 
effect and the self-fulfilling interaction. It is then necessary to switch to empirical analysis in order 
to collect evidence on the dynamics highlighted above, and on the sign of the link.  
To this end, economic and medical literature has been extensively researched and reviewed. This 
assessment shows that although single new technologies may exert both upward and downward 
pressures, the bulk of the evidence is consistent in showing that new technology is a major 
determinant in the rise of healthcare costs and expenditure. 
It is important to point out that the focus of the analysis here is on the cost of technological change, 
which is rising health expenditure. The benefits of medical technology improvements – longer life, 
improved quality of life, prolonged working ability, and so on – are not considered in this literature. 
Consequently, no conclusions can be drawn on the issue of the net value that patients and society in 
general derive from innovations. 
Since innovation in medical technology and devices is normally associated with rising healthcare 
expenditure, and despite their proved benefits, the chapter pushes forward in assessing the issues of 
whether technological innovations in medical devices and in medicine are financially sustainable. 
Moreover, we explore what kind of policy measures should be enacted to sustain these 
improvements without constraining the number of beneficiaries and the acquisition and access to 
significant technologies. The analysis shows that the best way to approach these issues is to frame 
them into the broader debate on welfare system reforms that EU Member States will need to adopt 
in the next few years. In particular, this Study is in line with a vast body of literature that suggests a 
mixture of coordinated policies, often referred to as “triple diversification of the expenditure”: i) a 
rebalancing within the components of public social expenditure, at present too concentrated on 
pensions; ii) a rebalancing between public and private sources of financing through the adoption of 
co-payment schemes; iii) a rebalancing within the composition of private social expenditure, in 
order to strengthen the organised institutional pillars of pension and healthcare funds.  
EU Member States appear to have margins to strengthen the diversification of the financing sources 
for the long-term sustainability of healthcare expenditures. With the appropriate use of market 
regulation and fiscal incentives and support to the disadvantaged categories of patients, this 
structural change can take place preserving the fundamental social choices. This could partially 
loosen budget constraints on health systems as well as the focus on cost-containment, and allow 
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increasing potential for high price-performance products both in the public and private markets. The 
industry of medical devices and of high-tech medicine could become one of the investment targets 
for health funds, and benefit from a significant financial source for R&D and innovation. 
3.1 Introduction 
Industrialised countries are spending record amounts on healthcare. In 2002, EU-15 and EU-198 
respectively spent on average 8.5 and 8.1 percent of their GDP on healthcare, both up by 0.4 from 
2000, and 1 percentage point from 1990 (figure available only for EU-15). The US is topping this 
trend, having passed from approximately 7 percent in 1970 to almost 15 percent in 20029.  
Figure 1. Total health expenditure as a percentage of GDP 
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Source: OECD Health Data (2004). 
Healthcare spending has out-paced economic growth over the past decades, and not only during the 
economic downturn spells. Trends in Figure 1 reveal some common patterns for the last decade: the 
first three years of the period (1990 to 1992) witnessed higher growth of the ratio than the following 
five years, when governments and insurers in several EU Member States, as well as in the US and 
Japan, applied cost-containment measures. For the EU and the US, the ratio remained roughly flat 
between 1993 and 1998 and started to rise again by the end of the 1990s, reflecting deliberate 
policies in several countries to relieve pressures arising from cost-containment in previous years. 
From 2001 slow economic growth determines the marked increase in the ratio.  
Due to the shortage of reliable long-term series on expenditure on medical devices, it not possible to 
assess the relationship between trends in health expenditure and medical device expenditure. Figure 
2 illustrates the series of total health expenditure and pharmaceutical expenditure (that together with 
                                                 
8 OECD Health Data 2004 provides figures only for OECD countries, which for the European Union are the EU-15 plus 
Czech Republic, Hungary, Poland and Slovak Republic (“EU-19”). 
9 An extensive analysis of health expenditure trends in OECD Countries can be found in Huber and Orosz (2003). 
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medical devices constitute the high-tech segment of the aggregate) that present in all cases a 
positive correlation.  
Figure 2. Total health expenditure and pharmaceutical expenditure as percentages of GDP 
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Source: OECD Health Data (2004). 
The pressure on public budgets from accelerated healthcare spending has been a major policy 
concern in all countries over the past two decades and in particular in the recent years of economic 
slowdown. Tracking and explaining the growth in medical spending in all national systems is a 
prominent issue in government, academia and industry research. A body of literature examining the 
determinants of healthcare expenditure has emerged in an effort to explain why health expenditure 
has risen so much in all health systems, and also to offer suggestions as to what variables can be 
influenced to reduce costs. The main driving forces identified by this large body of literature are 
ageing populations, income growth - which has gradually improved the level of well-being and as a 
result the demand for health treatments - and technology, which is the focus of the next paragraphs 
of this chapter. 
3.2 The medical technology - health expenditure link: theoretical aspects 
Demographics and income growth have been identified as drivers of health expenditure since early 
studies, both theoretical and empirical. On the contrary, the predictions from economic theory on 
the impact of innovation in medical technology are not clear-cut, and its relevance has gained wide 
acceptance only in more recent times10.  
The economic analysis of the interplay between medical technological change and health spending 
builds upon the basic impact that innovations may spur on demand and supply of medical care. 
Complexity may then be added to the basic framework in order to include dynamic aspects, 
                                                 
10 A synthetic but comprehensive review of the determinants of health expenditure growth can be found in Docteur and 
Oxley (2003). 
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institutional arrangements and the attitudes of, and incentive structures facing, healthcare policy-
makers and insurers, providers and patients. 
The standard static mechanism (a), and a model of long-run interaction (b), plus its dynamic 
evolution driven by changing attitudes of policy-makers and insurers (c) will be illustrated in the 
following. 
a. The single period impact 
From a static point of view, technological progress can in general be seen as something that lowers 
the cost of producing an industry’s output, and under normal conditions (if the price elasticity of 
demand is less than one, as it is generally thought to be in the health services industry), total 
spending should decrease. When new techniques generate a cheaper way of treating health 
outcomes, there could be expenditure reductions associated with technological change. 
However the demand for health services can be thought of as a derived demand, the fundamental 
commodity that is being valued by consumers (patients and doctors) being “good health” not health 
services. Therefore, if technical progress takes the form of progress in the ability to transform health 
services into “good health”, rather than reducing the resource cost of producing health services, then 
the demand curve for health services would shift out, so that total health spending could increase 
(even if the price elasticity was less than one). 
Figure 3. Dynamics of the impact of medical technology change on health expenditure growth 
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As a consequence, the overall net impact of technological progress on health expenditure in simple 
static models is not determined a priori, being the result of the interplay of factors that may point to 
opposite effects, namely a) the unit cost reducing versus the cost-increasing effect of the 
innovations (supply-side effect) and b) the derived impact on demand (demand-side effect). 
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b. Dynamic interactions with health insurance schemes 
As for most other sectors, static microeconomic models are unsuited to policy analysis of the 
medical and health market: the framework needs to account for dynamic multi-period effects and 
institutional factors. The fact that all national health systems provide some form of institutional 
health insurance – public and private – has spurred a stream of theoretical research and modelling 
on the relationship between technological change and expenditure in health through an 
“intermediate” dimension, healthcare insurance (Feldstein, 1977; Goddeeris, 1984; Pauly, 1986; 
Weisbrod 1991). In this framework, new technologies drive up both cost and demand for care (and 
expenditure), as well as demand for insurance. At the same time, expanding insurance, i.e. those 
including more people and encompassing more health procedures and products (with higher 
expenditure), provides increased incentives to the development of new technologies. A by-product 
of this process is the long-run growth of healthcare expenditure. 
It is important to point out that the focus of the present analysis in fact is not on the “traditional” 
effect of insurance in increasing utilisation of existing technologies (see Box 1), rather on the effect 
of insurance in enhancing the development of new technologies. 
 
BOX 1: The relationship between medical insurance and health expenditure 
In most national systems, a sizeable portion of all medical expenditure is covered by public 
(tax-financed and government-administered) or private insurance. The basis of this is the fact 
that the demand for medical care depends predominantly on a person’s state of health, and 
state of health is stochastic, to a relevant extent. Under these circumstances, insurance 
against the cost of care is expected to emerge, and has indeed done so, to such an extent that 
it has become the predominant form of payment for most medical services.  
The relationship between medical insurance and health expenditure has received a great deal 
of theoretical and empirical attention, starting from the milestone contributions of Arrow 
(1963), Pauly (1968) and Phelps (1973). 
Focus of most analyses has been the encouragement, in the presence of insurance and moral 
hazard, of inefficiently great utilisation. In insurance, moral hazard is defined as the 
alteration of individual behaviour due to the insurance coverage that affects the expected 
loss. It can occur because insurance affects either the probability of an event associated with 
a loss, or the size of the loss (conditional on the occurrence of the event). Applied to the 
health sector, this means that moral hazard arises when the purchase of health insurance 
encourages individuals to spend less on preventive medical care and/or induces and 
individual who has experienced an illness to spend more resources on its treatment. In the 
presence of moral hazard, insurance that reduces risk will also cause larger expected losses. 
In the health sector, these losses correspond to the consumption of units of medical care 
whose value to the consumer is less than their cost, because the insurance coverage reduces 
the user price below cost. This framework explains the concomitance of health insurance and 
higher health expenditures. 
Under this line of reasoning, as with insurance in health, technological change is, simultaneously, 
an independent variable – causing changes in the extent of insurance coverage – and a dependent 
variable – being affected by the incentives provided by the extent of the coverage. 
This interactive process can be disentangled following Weisbrod (1991): 
I. Insurance system as the independent variable; R&D and technological change as the 
dependent variable: the level and the direction of R&D efforts and of technological 
innovation depend among other things on the expected returns, i.e. on the expected size of the 
 34
market (utilisation) and on the expected price, that is determined by the private and public 
health insurance institutions. Policies and rules of health insurance institutions exert an 
important influence on which new technologies will be accepted into practice and how they 
will be used, and in turn on the rate and direction of innovation and R&D efforts. Since 
insurance removes the financial barriers of patients raising the demand for technology, wider 
insurance coverage will determine more intense incentives to innovate. 
II. R&D and technological change as the independent variable; insurance system as the 
dependent variable: demand for healthcare insurance depends on technological change: if 
due to innovation a previously untreatable condition becomes treatable at a positive cost, then 
individuals during their lifetime could encounter an additional unpredictable medical expense 
for the treatment. This determines an increase in the mean and variance of their expected 
health expenditures, and thus, under the standard economic hypothesis of behaviour under 
uncertainty, an increase in demand for insurance. As Weisbrod and LaMay (1999) report: 
“..at the close of World War II only nine percent of the US population had any hospital 
insurance, for the simple reason that medical science could do very little in a hospital. 
Today, when it is possible to replace a diseased liver, but at a cost of $200,000 or more, the 
demand for insurance has understandably soared. ..”.  
The stochastic properties of health conditions, and the non-homogeneous distribution within 
a community of the event “bad health conditions”11, make room for risk pooling. Demand for 
collective insurance is thus predicted to increase. The nature of the “merit good” of 
healthcare, due to its role in the preservation of life, will result in political pressures on 
governments to make the innovation accessible to all the needy population, regardless of the 
ability to pay. Beside private insurance, also public insurance coverage is then expected to 
rise. 
III. The growth of healthcare expenditure is a by-product of the self-fulfilling interaction between 
innovation and insurance (see Figure 4). New technologies and new treatments increase the 
risk and magnitude of health expenditure for individuals, and thus drive up demand for public 
and private health insurance (for expanded insurance coverage that includes not only more 
people, but also an increasingly wider definition of health assistance). Expanded coverage 
results also in higher (actual and expected) utilisation of new technologies – since insurance 
eases financial barriers to demand and utilisation – and thus in incentives to innovation; and 
so on, iteratively. 
                                                 
11 Excluding the case of epidemics, now extremely rare in Western Countries, and catastrophes. 
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Figure 4. Health insurance, innovation and expenditure: the interactive process 
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c. Insurance policies technology adoption and signals to medical innovation: the 
evolution of the interactive process 
In recent decades, most healthcare systems, public and private, affected by increasing public 
expenditures, have undergone major reforms and change of policies. Reforms aimed at improving 
the efficiency of the health systems at the micro level have been introduced by most countries 
(besides measures such as caps on spending, administered prices and volumes, and shift of costs 
onto the private sector through increased cost-sharing). 
A first area of efficiency-fostering reform within public integrated systems has concerned the 
budgetary separation of public insurers from healthcare providers (mainly hospitals), and the 
increased financial autonomy and responsibility of the latter. During the 1980s, OECD countries 
generally made hospital contracts better attuned to achieving the goals of cost control, efficiency 
and quality of care, with greater attention paid to the incentives inherent in specific payment 
methods (Docteur and Oxley, 2003). Most reforms at national level that continued through the 
1990s up until now, sought to deal with the ease with which medical providers can pass on costs 
when consumers pay for medical care through a third party. Under this trend, most systems have 
seen the move from “retrospective systems” – whereby healthcare providers are paid on the basis of 
costs incurred – to “prospective systems” – in which the sum paid are exogenous and independent 
from the costs incurred. 
Retrospective payments operated through the insurance system can encourage overuse of medical 
resources; on the contrary, under prospective payments, where revenues for patients admitted are 
largely exogenous and fixed, the organisation’s financial health depends on its ability to control cost 
of treatment. This induces healthcare providers to consider the cost consequences of their decisions 
(Feldstein and Friedman, 1977). The tendency, initiated in both the US public and private health 
insurance systems in the early 1980s, in subsequent years spread to most healthcare systems. Means 
of this current of reforms are schemes such as the Diagnosis-Related Groups (DRG) that have had 
several national applications and variations, but that in all systems consist of fixed reimbursements 
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to hospitals/providers per diagnosis/treatment (e.g. appendicitis) based on the average cost of the 
treatment12. 
The economic incentives – that drive circularly the interaction between insurance, R&D and 
innovation – are not invariant to these. Retrospective pricing sends the following signal to the 
innovation system: “develop new technologies that enhance the quality of care, regardless of the 
effects on costs”. While the new signal sent under perspective systems is: “develop new 
technologies that reduce costs, provided that quality does not suffer too much”13. 
High technology medicine is generally regarded as a source of significant professional prestige, and 
in general, social values favour its application, especially for life-threatening conditions. Before the 
tightening of the budgets and the switch to perspective mechanisms and in the presence of generous 
insurance, as long as new technologies were seen as offering even small health benefits compared 
with existing practices, these were adopted. Feedback signals were often in terms of shortcomings 
in efficacy and safety and problems with the ease of operation, not cost reduction. 
The growing budget pressures and the switch to perspective payment systems changed the 
incentives in the system. As a consequence, technology improvements started to be directed not just 
at enhancing performance but also at reducing costs, of equipment and of treatment (Gelijns and 
Rosenberg, 1991).  
 
BOX 2: Empirical evidence supporting the dynamic interaction 
Several authors have observed that the pattern of technological change in healthcare since World 
War II is the result of the interplay between health insurance systems and product development, and 
that it has nourished health-care costs and expenditure (Danzon and Pauly, 2001; Peden and 
Freeland, 1998 and 1995; Feldstein, 1995;; Weisbrod 1991). Feldstein (1971, 1977) for instance tests 
empirically a model of the hospital industry and finds that the explosion of hospital costs and 
expenditures, in the US during 1958-1973, reflects the increase in the demand for hospital care 
fuelled by technological innovation and sustained by the growth of private and public insurance. 
A handful of empirical studies confirm that health insurance schemes have influenced the adoption 
and the development of a range of high-technology medical services (Russell, 1979; Sloan, Valvona 
et al. (1986), Gelijns and Rosenberg, 1994; Hill and Wolfe, 1997; Baker and Wheeler, 1998; Cutler 
and Sheiner, 1998). Russell (1979) for instance finds statistical evidence of faster adoption of 
electroencephalography and cobalt radiation therapy in US regions where insurance coverage was 
higher, while Sloan et al. (1986) find evidence that insurance coverage affected the diffusion of some 
surgical techniques (among which hip arthoplasty, coronary bypass and cataract surgery). In addition 
several studies have validated the responsiveness of R&D and innovation efforts to specific 
insurance-related incentives. Gelijns and Rosenberg (1991) report that percutaneous transluminal 
coronary angioplasty (PTCA) were first granted in the US a reimbursement fee to the healthcare 
provider that exceeded the cost of the procedure. Together with a rapid adoption of PTCA, this 
stimulated a high level of incremental innovation in PTCA catheters. Cochlear implants instead were 
awarded a reimbursement level that covered only part of the intervention; this led not only to their 
under-diffusion, but also to a marked reduction of R&D investments (Kane and Manoukian, 1989). 
Following the development of dialysis, the US government in 1972 first enacted legislation to cover 
the treatment of all end-stage renal disease patients, then decreased the reimbursement rates to 
control the upsurge in expenditure; in line with the present argument, this stimulated research in cost-
reducing directions: Rettig and Levinsky (1991) estimate that as a consequence the equipment and 
supply (non-labour) component of the total cost per dialysis treatment was reduced from about one-
                                                 
12 An accurate description of the evolution of national healthcare policies and their move towards cost-containment and 
efficiency-enhancing schemes can be found in Docteur and Oxley (2003). 
13 Citations are from Weisbrod (1991). 
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third to less than one-fifth. 
Though more limited, empirical evidence also exists on the influence of improvements in medical 
technology on the diffusion of health insurance. Thomasson (2002) proves this looking at long-term 
trends and history of the US system. 
Evidence is also abundant on the change of adoption patterns and on the development of new 
technologies following the switch from retrospective to prospective schemes. Under retrospective 
systems, broadly speaking prior to the 1980s, even small technological improvements were often 
adopted by physicians, hospitals and providers, without regard to costs. This framework led to an un-
equalled wave of innovation in health technology accompanied by a rocketing expenditure on health. 
Russell (1979) shows that in the late 1960s and early 1970s an expansion in the adoption by hospitals 
of medical devices occurred despite a general lack of evidence on the efficacy for a number of these, 
among which were respiratory therapy and intensive care. The switch from retrospective to 
prospective systems determined new patterns of utilisation and of innovation in medical technology. 
Prospective reimbursement affected in a restrictive way the extent and speed of adoption of new 
technologies in hospitals (Romeo Wagner et al., 1984). Baker (2001) for instance finds that in the US 
the expansion of managed care during 1983-1993 was associated with slower diffusion and lower 
availability of MRI.  
The new incentives determined more emphasis on cost reduction and less on costly quality 
improvements, and hence to a new wave of cost-effective and efficiency enhancing innovations 
(Weisbrod, 1991; Goddeeris, 1987; Gelijns and Rosenberg, 1991). Expensive procedures, such as 
cholecystectomies, became preferred R&D targets of device manufacturers, aimed at developing a 
variety of minimally invasive devices. Manufacturers of lithotriptors replaced the expansive X-ray 
system and short-lived electrode configurations originally embedded in the device with less costly 
alternatives. Along the same line, the development of percutaneous transluminar coronary 
angioplasty (PTCA) – safer and less expensive (mainly due to shorter hospitalisation) than surgical 
bypass – was reinforced by the mid-70s by emerging limitations in the financial capacity of the 
surgical bypass alternative14. When the ceiling for US government payment for kidney dialysis was 
placed in the 1970s a new generation of dialysers were developed, that cut the time required per 
session nearly in half (from 6-8 hours to 3,5-4,5 hours) leading to substantial savings in professional 
labour costs, a major cost component (Weisbrod, 1991).  
The direction of the interactive process involving insurance, R&D and innovation is thus 
increasingly influenced by the change in incentives associated with the tightening of the insurance 
budget (reflected in the shift from retrospective and cost-based insurance reimbursement, to 
prospective and exogenous insurance reimbursement). In this industry, for several aspects and 
reasons that we have shown, insurance has done considerably more than just transfer resources from 
the “lucky” to the “unlucky”. It has shaped the structure and direction of the market itself. 
3.3 The medical technology – health expenditure link: review of the empirical 
literature and of the evidence 
Static and dynamic frameworks of analysis illustrated in the previous paragraphs provide mixed 
indications on the medical technology – health expenditure link: the effect of cost-reducing 
technologies, increasingly incentivised by constrained health insurers, could in principle offset the 
demand-side effect and the self-fulfilling interaction. It is then necessary to switch to empirical 
analysis in order to collect evidence on the dynamics highlighted above, and on the sign of the link. 
                                                                                                                                                                  
14 Later studies revealed smaller cost differences between the two procedures, partly because the initial analyses had not 
incorporated the cost of dealing with restenosis that is associated with PTCA, see the case-study on drug eluting stents 
in Chapter 4.  
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Starting from the 1990s, an increasing number of studies have included technological change in 
healthcare among the key drivers of health expenditure growth, beside “traditional” factors such as 
income growth, aging and demographic changes15.  
The empirical assessment of the impact of technological progress on healthcare expenditure is not 
straightforward, for several reasons, the main two being the complexity of: 
1. representing and measuring technological change; 
2. identifying and measuring all the dimensions, direct and indirect, of the impact of a 
technology. 
Technology in healthcare can be defined as the stock of usable knowledge regarding healthcare 
treatment, that is incorporated in drugs, devices and medical and surgical procedures used in 
medical care as in the organisational and supportive systems within which such care is delivered. 
Applied more narrowly to medical devices, this reference definition covers not only innovation in 
the products/devices, but also in the processes for their use (new surgical procedures), as well as in 
the skills and support systems through which they are operated and dispensed. In this large 
connotation, technology cannot be measurable or quantifiable, and proxies need to be sought out 
and selected. Several proxies have been adopted in the literature - such as indicators reflecting the 
stock and usage of the devices, R&D indicators (R&D expenditure or number of dedicated 
employees), patents, time indexes (since technological change occurs over time) – but all of them 
present some limits, as reviewed in Kleinknecht et al. (2002). 
Also the identification and measurement of all the dynamics, direct and indirect, generated by a 
technological innovation is a complex task. In many cases just the assessment and measurement of 
the direct costs of a technology may present methodological and practical difficulties. For a capital-
embodied technology for instance, direct costs are substantially broader than the mere purchasing 
cost of the device, and include the cost of the space, of the supervisory personnel, training, 
maintenance, supplies, and so on. 
BOX 3: The technology-expenditure link: beyond income growth and demographics 
Medical technology as a factor in explaining health expenditure trends is still neglected by a 
number of relevant studies and exercises on the issue. Despite the increasing evidence that 
technology is an important force driving health spending, as is argued in this chapter, 
difficulty in defining and measuring health technologies is cited as the primary reason for the 
lack of consideration. This omission, as it will be shown here, may determine significant 
biases in the outcome of the empirical work on the subject. 
Pammolli and Salerno (2004) have assessed the potential under-estimation in the long-term 
projections of healthcare expenditure on GDP performed by the Ecofin (Ageing Working 
Group of the Economic Policy Committee of Ecofin, the Council of Economics and Finance 
Ministers of the European Union), that have included only demographics and income growth 
as driving factors. 
The Ageing Working Group (AWG) has been created within the Economic Policy 
Committee of Ecofin with the mandate of developing, for all Member States, long term 
projections of the principal budget items affected by population aging, such as healthcare, 
pensions, education and unemployment allowances (European Union Economic Policy 
Committee, 2001 and 2003). These projections are assuming greater importance as 
instruments to assess future budget constraints and adequate supply of benefits and services. 
Projected health expenditure is mainly driven by income growth and demographic factors. In 
                                                 
15 A complete review of the methodologies and main results of the empirical literature on health expenditure 
determinants is in Gerdtham and Jonsson (2002). 
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particular per capita public healthcare expenditure (PHE) is assumed to grow at the same rate 
of per capita GDP. In the base year and for each age bracket, AWG calculates the value of 
per capita PHE; then, this value is projected under income growth estimates and 
demographic extrapolations.  
In order to assess this methodology and its results, Pammolli and Salerno test backwards the 
hypothesis of identity of growth in per capita GDP and per capita PHE. Their analysis shows 
that on average the growth rate of per capita PHE has been higher than that for per capita 
GDP, by approximately one percentage point. The hypothesis at the base of the AWG 
projections, according to their calculations, is thus not empirically confirmed. 
Building upon this finding, they perform a simple sensitivity exercise. Starting from the 
AWG projections of the ratio between per capita PHE and per capita GPD, for each Member 
State the average compound annual rate of growth of the ratio over the 2050-horizon is first 
calculated, then is augmented by 0.5-1.0 percentage points to account for the discrepancy 
found above. 
This sensitivity analysis enlarges the projection set to include other driving factors of health 
expenditure. Technological enhancements and investments in medical devices are surely part 
of these “residuals”. 
The results show the AWG projected health expenditure-GDP ratio at 2050 (column a) 
becomes significantly higher when the projections are augmented by 0.5 (column b) and 1.0 
(column c) percentage points to account for the “other factors”. In particular the incidence of 
healthcare expenditure on GDP would be higher by 2 and 5-6 percentage points when, 
respectively, the rate of growth is augmented by 0.5 and 1.0 percentage points. 
Limiting the projection set of health expenditure on GDP to demographics and income 
growth may lead to a significant under-estimation of this ratio. 
Incidence of healthcare expenditure on GDP (percent) 
 Projections at 2050 
 
Base year 
2000 
AWG 
 
(a) 
+0,5% 
 
(b) 
+1,0% 
 
(c) 
Difference 
under 
+0,5% 
(d) 
Difference 
under 
+1,0% 
(e) 
Austria 5.8 8.5 10.9 13.9 2.4 5.4 
Belgium 6.1 8.1 10.4 13.3 2.3 5.2 
Denmark 8.1 10.7 13.7 17.5 3.0 6.8 
Finland 6.2 9.0 11.5 14.7 2.5 5.7 
France 6.9 8.5 10.9 14.0 2.4 5.5 
Italy 5.5 7.4 9.5 12.1 2.1 4.7 
Netherlands 7.2 10.3 13.2 16.9 2.9 6.6 
Sweden 8.8 11.8 15.1 19.4 3.3 7.6 
UK 6.3 8.2 10.5 13.5 2.3 5.3 
Average 6.8 9.4 11.7 15.0 2.3 5.6 
Source: Pammolli and Salerno (2004). 
The empirical studies have approached the assessment of the connection between technology and 
rising healthcare expenditures with different methodologies, summarised in Table 1. 
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Some studies have used a “determinants approach”, where healthcare expenditure is 
econometrically regressed (or co-integrated) on variables that are believed to affect its growth, such 
as income or demographics, plus variables representing technological progress. Some others have 
employed the so-called “residual approach”. This first evaluates or estimates the impact of more 
easily identifiable factors, such as rising incomes and changing demographics; then it attributes the 
portion of health spending not accounted for to technological change. Other researchers have 
identified specific diseases and technologies and have attempted clinically meaningful measures of 
the role that technology plays in healthcare cost growth.  
All of the different approaches present advantages and limits. Since technological progress is not 
measurable, the determinants approach requires measurable proxies, which might be imperfect 
substitutes. On the other hand, the residual approach leaves some authors with perplexities 
(Neumann and Weinstein, 1991; Gelijns and Rosenberg, 1994; Goldsmith, 1994), since, among 
other things, it does not pinpoint the precise cause of increases and, most importantly, the reliability 
of any estimates derived as a residual depends upon the confidence that all other factors and their 
interaction effects have been fully captured. Case studies, however illuminating, have the 
methodological problem of sampling and of generalisation from them (Rettig, 1994). 
Table 1. Main methodologies of study of the impact of medical technological change on health 
expenditure 
Methodology Advantages Limits 
Econometric analysis of 
determinants, including 
technological change of health 
expenditure. 
Rigorous assessment of 
significance and magnitude of 
impact. 
Need to represent 
technological change through 
measurable proxies that might 
alter its representation. 
Residual approach: estimation of 
the impact on health expenditure 
of easily identifiable factors 
(income, demographics) and 
residual attribution of unexplained 
expenditure growth to 
technological change. 
Incorporation of technological 
change in full (no limitation in 
representation as in case studies or 
use of proxies). 
No identification of the effect 
of single technology 
components; impact of 
technology overestimated in 
the likely event of mis-
specification of all other 
determinants.  
Descriptive analysis of data and/or 
facts and evidence from them. 
Potential for analysis of relevant 
relationships not assessable 
through other methodologies. 
Risk of identifying spurious 
relationships. Non-rigorous 
assessment of quantification 
and direction of the 
relationship. 
Case studies on cost of specific 
technologies and procedures over 
time. 
Potential for rigorous assessment 
of impact on costs and expenditure 
for single technologies. 
Sampling bias. Difficulty in 
generalisation of results. 
Case studies on cost of specific 
diseases and conditions over time. 
Potential for rigorous assessment 
of impact on costs and 
expenditures associated to single 
diseases. 
Sampling bias. Difficulty in 
generalisation of results. 
Surveys and interviews with 
experts in the field. 
Potential for synthetic 
representation of processes and 
effects, through the view of 
experts. 
Individual view bias. 
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Economic and medical literature has been extensively researched for studies that have addressed the 
issue of the relationship between medical technological change and health expenditure growth. 
Healthcare and economic databases (MEDLINE, EconLit) were searched using keywords such as 
health expenditure or health cost plus technology, technological change, productivity, innovation. 
Bibliographies of retrieved articles were screened to identify additional publications. In addition the 
following journals have been hand-searched for articles on the matter, published from year 1990 to 
October 2004: 
 
 American Economic Review  Journal of Economic Perspectives 
 American Journal of Public Health  Journal of Health Economics 
 European Economic Review  Journal of Human Resources 
 Health Affairs  Journal of Public Economics 
 Health Economics  Medical Care 
 Health Care Financing Review  Medical Care Research and Review 
 Health Care Management Review  New England Journal of Medicine 
 Int. Journal of Health Planning and Management  Quarterly Review of Economics and Finance 
 Journal of the American Medical Association  Quarterly Journal of Economics 
 Journal of Econometrics  The Lancet 
Relevant studies found through this search are synthetically reviewed in Table 2. 
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Table 2. Analysis and assessments of the impact of technological innovation medical technology and medical devices on health 
expenditure 
Author Typology of work and analysis Findings 
Bentkover, Stewart, 
Ignaszewski et al. (2003) 
Estimation through an economic model of the 
potential savings that could result from the 
introduction of new technogies such as cardiac 
resynchronisation therapy for class III/IV hearth 
failure patients (in Canada). 
Potential savings in Canada for this group of patients could reduce the total annual costs by 
approximately 10%. 
Binder, Schiel, Binder et 
al. (1998) 
Analysis of clinical outcome and associated costs of 
a sample of patients with haematologic malignancies 
undergoing antibiotic regimen. 
Significant dependence of clinical outcome on aminoglycoside peak concentrations, detectable 
through in vitro diagnostics (drug therapy monitoring), that allow dosage adjustment. 
Considerable cost savings result with the application of drug therapy monitoring (costs for 
patients with low aminoglycoside peak concentrations were 1.8 times higher than for patients 
with adequate concentrations).  
Blomqvist and Carter 
(1997) 
Econometric analysis of time series on national 
health expenditure for 18 countries. Inclusion in the 
model of a linear trend to account for technological 
change. 
Real expenditure on healthcare grows by roughly 2% per year, net of the impact of 
determinants such as income growth. This independent time trend is interpreted as being 
principally due to technological progress. 
Bradley and Kominsky 
(1992) 
Analysis of inpatient costs and utilisation patterns for 
a large sample of US hospitals (1984-1987). 
Technology-related factors accounted for approximately one-third of the real increase in 
costs. 
Braunschweig (2000) Analysis of heart failure-related hospital days 
associated with cardiac resynchronisation in patients 
with severe heart failure and delayed intraventricular 
conduction. 
The need for hospital care decreased significantly after cardiac resynchronisation. The 
total number of hospital days was reduced by 82%. 
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Author Typology of work and analysis Findings 
Bryan, Buxton and 
Brenna (2000) 
Analysis of changes in running costs and direct 
observation of resource use in a UK hospital 
following the introduction, in 1995, of a computer 
technology system in radiology (picture archiving 
and communication systems - PACS).  
PACS has added to hospital running costs by approximately 1.8%. Net additions to overall 
costs crowded out the expected efficiency and cost gains. Key additional cost sources include 
maintenance of the PACS technology, dedicated onsite maintenance staff. Among the savings: 
reduced expenditure on film and chemicals, clinician time. No significant reduction in average 
length of hospitalisation.  
Chernew, Hirth, Sonnad 
(1998) 
Extensive review of the literature on the impact on 
new medical technology on cost growth. 
“…Medical technology appears to be a prime driver of healthcare costs…”. 
Cromwell and Butrica 
(1995) 
Descriptive analysis of cost components for a large 
database of US hospitals (1980-92). 
The dramatic growth in the operating room, catheter lab, and other technologically driven 
cost centres is accompanied by a growth in hospital costs for the period of investigation, 
well in excess of inflation. 
Curnis (2003)  Analysis of hospital costs and clinical effectiveness 
of cardiac resynchronisation in heart failure. 
In the 12 months following the implant, overall costs were reduced by 24%. Cardiac 
resynchronisation in heart failure patients represents an efficient approach in the hospital 
perspective and allows a less intensive use of clinical resources. 
Cutler, McClellan and 
Newhouse (1999) 
Analysis and estimation of cost trends (based on 
various data sources and literature review) for the 
treatment of hearth attack (US, 1984-1991). 
The cost of heart attacks has increased by 50% in real terms between 1984 and 1991, due 
to more intense surgical therapies such as cardiac catheterisation, bypass surgery, 
angioplasty. (When also benefits are taken into account the value of improved health is greater 
than the increased cost). 
Cutler and Huckman 
(2003) 
Quantitative and econometric analysis of the long-
term diffusion of PTCA – a treatment for coronary 
artery disease – and of its impact on cost of care; 
data 1980-2000, for New York State. 
Growth in the use of PTCA led to higher costs, despite its lower unit cost compared to 
CABG, the previously dominant procedure. In particular the growth of PTCA in the 1980s 
occurred through treatment expansion and was accompanied by little offset in the use of CABG 
and thus by large increases in the overall cost of care. By the 90s however improved PTCA 
became a substitute for more expansive CABG, thus leading to an offset of the cost increases. 
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Author Typology of work and analysis Findings 
Dahler-Eriksen, 
Lauritzen, Lassen et al. 
(1999) 
Assessment of costs and savings associated with a 
trial (in Denmark, year 1996) where a sample of 
general practitioners were allowed to measure C-
reactive protein (CRP; test for the diagnosis and 
follow-up of infectious diseases) using a point-of-
care test (as an alternative to sending blood samples 
to hospital laboratory). 
The savings from decreased hospital laboratory testing resulted higher than the increased costs 
for the point-of-careCRP test.  
 
Di Matteo (2005) Econometric analysis of the impact of age 
distribution, income and time, the latter as a proxy 
for technological change; data for US States (1980-
1998) and Canadian Provinces (1975-2000). 
Time accounts for about two-thirds of health expenditure increases. Thus technological change 
explains the bulk of health expenditure increases (if one accepts that time is a good proxy 
for technological change). 
Feldstein (1977) Econometric analysis of the determinants of the 
increase of hospital costs over the period 1955-1975 
for the US. 
Hospital costs have risen sharply because insurance has increased the demand for hospital care. 
Hospitals have responded to this increased demand by raising their prices and providing more 
expensive technology-intense quality of care. Medical technologies have significantly 
contributed to increased hospital expenditures and costs through this “induced” effect. 
Feldstein (1995) Author’s perspective. The rising cost of hospital care – leading component of health expenditure in all systems – 
has been driven by changes in medical technology and style/quality of care (more inputs per 
patient day rather than higher prices for given inputs). 
Fuchs (1996) 
 
Survey: descriptive analysis of responses from 
questionnaire sent to health economists and 
practicing physicians. 
81% of health economists and 68% of practicing physicians gave a positive response to the 
question: “the primary reason for the increase in the health sector’s share of GDP over the 
past 30 years is technological change in medicine”. 
Fuchs (1999) Descriptive analysis of level of utilisation of seven 
frequently used procedures based on medical devices 
for the US, 1987-1995. 
The median rate of increase in utilisation was 11.1% per year. No substitution effect was noted 
between alternative technologies (CABG and angioplasty): increase in utilisation, though 
associated to cost-effective technologies, is a major expenditure driver.   
Ginsburg (2004) Author’s perspective. “..Over the long term, new medical technology has been the dominant driver of increases in 
healthcare costs and insurance premiums. ..”. 
 45
Author Typology of work and analysis Findings 
Ginzberg (1990) Author’s perspective. “…High-tech medicine is responsible for the severe cost escalation of the US medical care 
system…”.  
Goetghebeur, Forrest and 
Hay (2003) 
Extensive review of studies on the determinants of 
healthcare costs. 
A number of peer-reviewed studies report that new technology is a major determinant in 
the rise of healthcare expenditures; and although new technology exerts both upward and 
downward pressures on healthcare spending, overall new technology is estimated to represent 
22% of the increase in healthcare spending between 2001 and 2002. 
Hay (2003) Regression analysis of determinants of inpatient 
expenditures at State-level for the US (1998-2001).  
During 1998-2001 inpatient expenditure per member increased by an average of 5.9% annually. 
Hospital technology (proxied by variables such as percentage of hospitals with high-tech 
equipment) accounted for 19% of the increase and medical wages (reflecting in part higher 
skills necessary to operate new technologies) for 20%.  
Heymann, Brewer and 
Ettling (1997) 
Estimation of clinical and economic benefits 
associated to new (in vitro) diagnostic techniques, 
that on average reduce of two weeks the time to 
culture and identify tuberculosis.  
The reduction in cost of treatment of tuberculosis is estimated at 18%. 
 
Holahan, Dor and 
Zuckerman (1990) 
Descriptive and regression analysis of changes in 
Medicare expenditures for physician services per 
enrolee. (US, 1987-1992). 
Cost growth was greater in specialties likely to have experienced greater technical 
innovation. 
Ikegami and Creighton 
Campbell (2004) 
Decomposition of changes in national medical 
expenditure for Japan (1980-2002).  
For nearly every year in the period, spending attributable to technology grew at a rate lower 
than that of GDP growth. This finding for Japan – where strong pricing control measures on 
medical devices have been put into effect – lead the authors to conclude that “… evidently the 
key impact on spending is not technology itself but how it is priced…”. 
Katz, Welch and Verrilli 
(1997)  
Analysis of expenditure across different clinical 
categories for physician services (to the elderly) in 
US and Canada (1987-1992) on micro (claims) data. 
Cost growth was greatest for more technologically intensive clinical categories. 
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Author Typology of work and analysis Findings 
Koenig, Siegel, Dobson 
et al. (2003) 
Regression analysis on state-level physician cost data 
for the US (1990-2000). 
Over the investigated period, nominal physician expenditure per capita grew 4.7% annually. 
11% of this growth is attributed to technology, proxied mainly by percentage of beds 
offering technology intensive care (while 42% is attributed to general price inflation and 17% to 
general economic variables and demographics). 
Meara, White and Cutler 
(2004) 
Regression analysis on household expenditure for 
health in the US (1963; 1970; 1977; 1987; 2000); 
literature review and authors’ view. 
Population aging (focus of the study) accounts for only a small part of medical spending growth 
since 1970. The major driver of spending growth is technological change. 
Murphy (1998) Estimation of cost changes determined by the three 
major technology increases over time in the 
diagnosis and treatment of peptic ulceration (on cost 
data for the UK). 
The first two innovative phases generated increases in costs; the third has substantially 
decreased the cost of treatment. The evidence from this study is insufficient to support the 
assertion that new technology in general leads to either an increase or to a decrease in 
healthcare costs. 
Newhouse (1992) Descriptive analysis of figures and data for the US 
(1950-1989), based on the residual approach. 
Traditional factors – aging population, income growth, spread of insurance, physician-induced 
demand – can explain only less than one quarter of the recorded increased in health 
expenditure. The residual increase is attributable to technological change, as also confirmed 
by some data shown. 
Okunade and Murthy 
(2002) 
Regression analysis – for the US, 1960-1997 - of the 
relationship between health expenditure, income 
growth and technological change, proxied by health 
R&D expenditure. 
Changes in R&D spending, as a proxy for changes in technology, is a statistically 
significant long-run driver of the rising healthcare expenditure. 
Pammolli and Salerno 
(2004) 
Projection at 2050 of healthcare expenditure/GDP 
for EU Countries based on the extrapolation of past 
trends, and assessment of the discrepancy (residual) 
with the same projections based only on 
demographic changes and income growth. 
Health care expenditure/GDP ratio projected from past trends is 2-5.5% higher than that 
projected on the basis of income and demographics evolution only. Since past trends include, 
beside demographics and income changes, also changes in medical technology, the 
discrepancy (residual) can be interpreted as the significant projected impact of changes in 
medical technology. 
Peden and Freeland 
(1995) 
Regression analysis (US National Health Accounts, 
1960-1993) on the determinants of medical spending 
growth. Technological progress proxied by non-
commercial medical research.  
Non-commercial medical R&D spending generates about 1/4 of the 1960-1993 real per capita 
medical spending and 1/7 of that for 1983-1993. Since in the model growth in technology is 
greater when insurance coverage is wider, the set of variables that represent technical 
progress (R&D plus insurance coverage level) account for about 70% of the growth over 
the period. 
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Author Typology of work and analysis Findings 
Peden and Freeland 
(1998) 
Regression analysis (US National Health Accounts, 
1960-1993) on the determinants of medical spending 
growth. Technological progress is modelled as a 
function of insurance coverage and of R&D.  
About two-thirds of 1960-1993 spending growth came via cost-increasing advances in 
medical technology resulted from commercial R&D induced by coverage levels and non 
commercial medical research.  
PriceWaterhouseCooper 
(2002) 
Review of the literature, analysis of costs of 
healthcare providers, interviews with experts. 
Medical advances (defined as drugs, medical devices, treatments and testing) result as the 
major driver of healthcare costs, explaining 22%of the increase. 
Reinhard (2003) Survey of studies on the US on the impact of aging 
of the population on health costs. 
Most of the annual growth in national health spending has not been driven by the aging effect 
(focus of the analysis), rather than other factors that include new medical technology 
(together with rising per capita incomes, workforce shortages). 
Rettig (1994) Review of the literature; author’s view. There is a general consensus that a significant share of annual real healthcare cost growth 
is attributable to medical technology. 
Schumacher and Barr 
(1998) 
Review of clinical and economic studies pertaining 
to the use of therapeutic drug monitoring (TDM; 
through in vitro diagnostics).  
The studies that examined economic variables show TDM-influenced changes in therapies that 
resulted in significant savings in cost of care (and the few studies on cost-benefit analysis 
showed that TDM yielded a range from 4:1 to 52:1 in benefit-to-cost ratio). 
Schwartz (1987) Residual approach (assessment on the impact of non-
technology causes of cost growth and attribution of 
the unexplained residual to technology). 
Medical innovation is the primary factor contributing to the upward trend in healthcare 
expenditures. 
Scitovski (1985) Analysis of changes of treatment patterns for 
selected illnesses for a hospital (1971-1981, 
California-US). 
Breakthrough technologies (such as intensive care units, radiation therapy and chemotherapy 
and coronary bypass surgery) were found responsible for cost growth. 
Shactman, Altman, Eilat 
et al. (2003) 
Extrapolation of current (at 2003) trends in hospital 
spending to 2012 for the US. Decomposition of the 
projected increase and attribution to medical 
technology of the unexplained residual.  
Of the 4.8% annual real growth rate in hospital spending, 28% is attributable to demographics, 
29% to the excess of hospital inflation over the amount of inflation in the general economy and 
the remaining 43% represents the use of new technologies.  
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Author Typology of work and analysis Findings 
Shapiro, Shapiro and 
Wilcox (2001)  
Long-term (1960s -1990s) analysis of input and 
resources required for cataract surgery. 
The technique for extracting cataracts has improved substantially over the past 30 years, leading 
to a dramatic decrease in the resources required (length of hospital stay, surgeon/physician time, 
no need of post-operative spectacles and contact lenses). Even without accounting for quality 
improvements, the real cost of cataracts over time fell by a substantial amount.  
United States Congress 
Office of Technology 
Assessment (1984) 
Descriptive analysis and cost decomposition of data 
on hospital costs in the US and medical activity 
(1970s and beginning of 80s). 
“US healthcare costs have escalated rapidly over the past 15 years, and medical technology is 
the primary cause of the increase”. 
United States General 
Accounting Office (1992) 
Descriptive and regression analysis of hospitals’ cost 
structure, US (1980’s). 
Real hospital operating costs increased in the US by 63% during the 1980s. Descriptive analysis 
of hospital cost determinants and regression analysis (on cost structure changes) show that “the 
measured rise in costs largely results from innovations in medical technology intended to 
improve patient care”.  
Wilensky (1990) Author’s perspective. “…Medical technology has been responsible for rising medical care expenditures (as well as 
for improving health status and increasing life expectancy)…”.  
Zweifel, Felder and 
Meiers (1999) 
Regression analysis of healthcare expenditure 
determinants, on patient data from two Swiss sick 
funds (1983-1994). Technological change proxied by 
a time trend. 
“In 1992, real healthcare expenditure for patients was 2.1 times higher than in the benchmark 
year 1981, likely reflecting technological change in medicine”. 
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The literature review shows that although single new technologies may exert both upward and 
downward pressures on health costs and spending, the bulk of the empirical evidence is 
consistent in showing that a new technology is a major determinant in the rise of healthcare 
costs and expenditure. 
In a comprehensive survey of health economists and practicing physicians conducted by 
Fuchs (1996), 81 percent of health economists and 68 percent of the practicing physicians 
responded positive to the question “the primary reason for the increase in the health sector’s 
share of GDP over the past 30 years is technological change in medicine”. And this answer 
was given despite evidence showing the cost-reducing effect of some single technologies, as 
for instance in Curnis (2003), Bentkoven et al. (2003), Braunschweig (2000). In particular, a 
sizeable chunk of medical literature points to the cost-reducing effects of in vitro diagnostic 
tools and procedures that have proved to allow earlier treatment, to reduce costs of treatment 
of complications, and can reduce the spread of infectious diseases in the community (Dahler-
Eriksen et al., 1999; Binder et al., 1998; Schumacher and Barr, 1998; Heymann et al. 1997). 
But the overall impact appears positive and significant, ranging from 20 percent (Goetghebeur 
et al., 2003; PriceWaterhouseCoopers, 2002) to 70 percent (Peden and Freeland, 1995; 
Newhouse 1992), and averaging some 50 percent. Chapter 5 will provide some explanations 
that bridge the apparently contrasting findings of decreasing unit costs and increasing overall 
costs and expenditure. 
A large bulk of the evidence reviewed refers to hospital costs, which are adopting 
sophisticated technologies that have higher fixed and running costs, in order to accommodate 
patients demand, physician pressures and remain yet competitive (GAO, 1992; Cromwell and 
Butrica, 1995; Feldstein, 1995). X-ray machines are being replaced with computed 
tomography (CT) and magnetic resonance machines (MRI) and then by positron emission 
tomography imaging machines (PET) (Goetghebeur et al., 2003). In the US, the number of 
imaging procedures has been growing by 8-9 percent in recent years driven by the use of the 
more sophisticated and costly technologies, CT, MRI and PET (PriceWaterhouseCoopers, 
2002). Technology that introduces computer-based information networks for imaging 
archiving (PACS), are reported to increase annual hospital costs by 1.8 percent (Bryan et al., 
2000). New technologies produce impact on hospital costs also through the increase in 
medical wages, reflecting the higher skills necessary to operate new technology (Hay, 2003). 
Some studies have examined growth in physician expenditure. The two studies of this kind 
reviewed here (Katz, Welch and Verrilli, 1997; Holahan, Dor and Zuckerman, 1990) 
disaggregate the growth of expenditures by physician type and conclude both that cost growth 
was greatest in areas where technological change had been higher, such as cardiology, 
gastroenterology, orthopaedics. 
It is important to point out that the focus of the analysis here has been on the impact of 
technological change on health costs and expenditure; in other words, on the cost of 
technological change, which is, as we have seen, raising health expenditure. The side of the 
benefits of medical technology improvements – longer life, improved quality of life, 
prolonged working ability, and so on – is not considered in this literature. Consequently, no 
conclusions can be drawn on the issue of the value (or net value) that patients and society in 
general derive from innovations. 
This analysis has confirmed that technological change has accounted for a large part of 
medical care cost and expenditure increases over time. But, as Cutler and McClellan (2001) 
point out, “it does not necessarily follow that technological change is therefore bad. Costs of 
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technology need to be compared with benefits before welfare statements can be made. 
Technological change is bad only if the cost increases are greater than the benefits”. The 
critical policy questions are thus whether the benefits of such expenditure outweigh the costs 
and whether or not cost-benefit ratios can be improved. 
Chapter 4 will present a number of case-studies where such cost-benefit comparisons will be 
performed. But, as it will be pointed out there, despite the growing body of empirical work, 
summary conclusions on the net value and cost-effectiveness of technological change in 
medicine, cannot be drawn. In fact, net value and cost-effectiveness assessments need to be 
performed on a case-by-case basis (single technology of single condition), and the findings 
are difficult to generalise. 
As for the analysis here, we can conclude that the cost of technological change – rising health 
expenditure – is now well understood, if not well measured.  
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3.4 From cost-decreasing innovations to health expenditure increases: 
bridging the divide 
Despite the fact that in the two past decades several innovations have proved cost-decreasing 
per treatment, medical technology has not proved cost-decreasing in the aggregate, and 
instead, as seen in the review, has generated expenditure-increasing patterns on an overall 
level. This paragraph elaborates on this missing link, showing medical and economic 
mechanisms, as well as empirical evidence, that can help in explaining how innovations, often 
cost-decreasing in themselves might generate patterns that are cost and expenditure-increasing 
in the aggregate. Explanatory mechanisms have been identified in a) the increasing 
indications and applications of the innovations; b) the growing area of treatable conditions, 
whereby before the innovation some patients just went untreated; c) the increasing use of 
technologies for the same conditions, especially when they cause less discomfort to patients; 
d) the broadening definition of diseases; e) the life-extending effect of new technologies, for 
which each patient bears (or causes) “more years of yearly expenditures”. 
a. Increasing applications and indications 
Several new medical technologies, thought to be cost-reducing per patient treatment, have 
turned out to be expenditure-increasing in the aggregate due to their application to a wider set 
of indications and uses than originally anticipated. When the medical practice acquires a new 
technology and the skills to use it, it is able to shape these technologies further to expand their 
applications. The initial application of all imaging diagnostics (X-ray, ultrasound, computed 
tomography and magnetic resonance) was initially targeted to specific organs and functions; 
their application has since then extended to almost every organ of the human body (Blume, 
1992). 
b. Growing area of treatable conditions 
Several advances have created clinical ability to treat previously untreatable acute conditions. 
Organ transplant technology is an example of this. Before the establishment of this procedure, 
a person with serious liver malfunction simply died; now, with a total cost estimated at 
US$100,000 – 300,000 (National Kidney Foundation, 2005; Taylor at al., 2002) patients can 
undergo liver transplants. Other examples come from the cardiovascular field: the 
introduction of the coronary artery bypass graft allowed the treatment of acute conditions that 
previously went untreated or under-treated (Rettig, 1994); PTCA for instance was not 
originally applicable to patients with advanced and unstable medical conditions, but as result 
of refinement in PTCA catheters, the procedure was then applied to more complicated cases 
(Gelijns and Rosenberg, 1991). 
c. Increasing rate of use for the same conditions 
Several new technologies that for instance allow lower costs per unit, or cause less discomfort 
to patients, have decreased the threshold for performing procedures, and induced higher rates 
of use, a phenomenon sometimes addressed as treatment expansion (Cutler and McClellan, 
2001). Often new procedures that allow lower unit costs, reduced hospital stays and 
complication rates than the traditional procedures they replace, have the potential for 
significant cost savings. But the lower morbidity, risks and discomfort associated with these 
techniques may lead to increased provision of services to persons who, without the new 
technology, would have not undergone surgery. Therefore when the cost savings per case are 
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offset by the increased number of procedures, these techniques will lead to increased costs in 
the aggregate. 
Minimally invasive procedures – for example various types of endoscopic surgery in which 
access to the body is gained via incisions that are much smaller than those required by 
traditional techniques – allow the accomplishment of the same objectives as traditional 
techniques, but with much less morbidity. Several studies have shown that the introduction of 
minimally invasive techniques has led in many cases to an increase in the total number of 
procedures performed to patients. The evidence is particularly striking for procedures such as 
laparoscopic cholecystectomy, where for instance Chernew et al (1997) find for the US an 
increase of 20-30 percent (depending on the State) in cholecystectomy rates following the 
introduction, and rapid diffusion, of laparoscopic techniques at the beginning of the 90s; and 
for a large HMO, Legorreta et al (1993) found that the number of gallbladder removals 
increased by no less than 60 percent. Thus, although laparoscopic cholecystectomies reduce 
unit costs by 25 percent (mostly because of shorter hospital stays), their introduction has 
resulted in an increase, not a decrease, in aggregate expenditure (Gelijns and Rosenberg, 
1991). Knee surgery is another example of this pattern, whereby the introduction of 
arthroscopic techniques have lead to a dramatic increase in the number of people treated so 
that total expenditures for treating knee problems in the US rose even though the cost of 
treating each case fell (Weisbrod and LaMay, 1999). Shapiro et al. (2003), illustrate the large 
increase in the rate of cataract extraction associated to the decrease in its cost and in the 
related risks and discomfort to patients. 
Cutler and McClellan (2001) assess another interesting case of treatment expansion, the 
introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late 1970s. 
This new technology provided an intermediate treatment with costs and intensity between 
those of the existing surgery technique on the one side – coronary artery bypass graft (CABG) 
– and of the medical treatment for patients with milder coronary artery disease (CAD). 
Treatment expansion, that occurred among those previously under medical treatment and that 
underwent PTCA, was large and led to significant increases in the cost of care for CAD; 
treatment substitution effects, that involved some patients receiving PTCA rather than CAD, 
were initially offset by treatment expansion. In general, due to the rapid evolution of the 
technology used for angioplasty, its use has increased dramatically in recent years. In 1998 in 
the US, the number of procedures performed for elderly patients was nearly four times that in 
1990 (Lubitz et al., 2002); and major changes, such as use of glycopotein IIb/IIIa together 
with drug-eluting stents are resulting in more such procedures being performed each year 
(Mayers et al., 2002).  
The magnitude of these mechanisms leads Gelijns and Rosenberg (1991) to conclude that 
“…when technological change not only reduces costs but also improves quality, expectations 
of reductions in aggregate expenditures are likely to be frustrated…”  
d. Broadening definition of “disease” 
Vast improvements in the ability to diagnose and treat illnesses are expanding the definition 
of what an illness is, and the opportunities to deal with problems not conventionally 
considered as “illnesses”. The areas of human conditions treated under “healthcare” are 
getting wider and wider. 
Infertility is now regarded by the medical and social community as a “disease” and, as such, 
treated and covered by an increasing number of health insurance systems and schemes; this 
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was not the case before infertility treatments and in vitro fertilisation became technically 
feasible. The introduction of implantable artificial joints, such as hands, arms and legs, that 
provide esthetical comfort and some functionality, immediately transformed the related 
condition into a treatable (to some extent) condition, deserving coverage. 
Another striking example of this process, derived from the pharmaceutical field, is that of the 
treatment of male impotence. With impotence, health status, as conventionally defined, is not 
at stake; but the advent in 1998 of an effective treatment, Viagra, has in few years expanded 
the comprehensiveness of what constitutes “healthcare”, as confirmed by the product’s 
reimbursement under several schemes and systems.  
e. The life-extending effect of new technologies 
Life-extending medical technologies deploy their impact on health expenditure also through a 
computational effect, for which each individual bears (or causes) “more years of yearly 
expenditure”. Through this way, the overall effect of prolonged life might be an increase in 
life-time health expenditure even in the presence of decreasing average costs and expenditure 
per year of life (Weisbrod, 1991). 
3.5 Medical devices and medical technology: too expensive to be sustainable 
in the future? 
As seen in the previous paragraphs, innovation in medical technology and devices is normally 
associated with increasing healthcare expenditure. More generally EU public expenditure on 
health is projected to increase its incidence on GDP by more than 2.5 percentage points in the 
next five decades.  
These key facts suggest a question: despite their proved benefits, are technical innovations in 
medical devices and in medicine financially sustainable? What kind of policy measures 
should be enacted to sustain these improvements without constraining the number of 
beneficiaries and the acquisition and access to significant technologies? 
The analysis of the composition and of the long-term sustainability of healthcare expenditure 
and the broader social expenditure can provide important elements to approach these issues. 
The following table describes the long-term projections of the main voices of public social 
expenditure produced by the Ageing Working Group of the Economic Policy Committee of 
Ecofin (AGW; European Union Economic Policy Committee, 2001 and 2003). Together with 
healthcare pensions, education and unemployment benefits are also projected. These, as 
outlined in Box 3, have been projected mainly on the basis of the evolution of the 
demographic structure. 
 54
Table 3. Public social expenditure, 2000 and projections at 2050 - % of GDP 
 Base year 2000 Projections at 2050 
 pensions health care educat. 
unempl. 
benefits total pensions ∆  
health 
care ∆  educat. ∆  
unempl. 
benefits ∆  total ∆  
Austria 14.5 5.8 6.0 0.7 27.0 17.0 2.5 8.6 2.8 5.4 -0.6 0.6 -0.1 31.6 4.6 
Belgium 10.0 6.1 5.7 2.1 23.9 13.3 3.3 8.2 2.1 5.3 -0.4 1.0 -1.1 27.8 3.9 
Denmark 10.5 8.0 8.6 1.4 28.5 13.3 2.8 10.7 2.7 7.7 -0.9 1.4 0.0 33.1 4.6 
Finland 11.3 6.2 6.1 1.7 25.3 15.9 4.6 9.0 2.8 6.4 0.3 1.4 -0.3 32.7 7.4 
France (1) 12.1 6.9 6.4 1.2 26.6 15.8 3.7 8.6 1.7 6.4 0.0 0.7 -0.5 31.5 4.9 
Germany 11.8  n.a. 5.4 1.1 18.3 16.9 5.1  n.a. n.a 5.6 0.2 0.7 -0.4 23.2 4.9 
Greece 12.6  n.a. 4.0 0.4 17.0 24.8 12.2  n.a. n.a 4.5 0.5 0.2 -0.2 29.5 12.5
Ireland 4.6 6.6 4.7 0.8 16.7 9.0 4.4 9.1 2.5 4.3 -0.4 1.0 0.2 23.4 6.7 
Italy 13.8 5.5 4.6 0.3 24.2 14.1 0.3 7.4 1.9 4.3 -0.3 0.2 -0.1 26.0 1.8 
Luxemb. 7.4  n.a. n.a.  0.2 7.6 9.3 1.9 n.a.  n.a n.a.  n.a.  0.2 0.0 9.5 1.9 
Netherlands 7.9 7.2 5.0 1.3 21.4 13.6 5.7 10.4 3.2 5.0 0.0 1.4 0.1 30.4 9.0 
Portugal 9.8 n.a.  5.6 0.7 16.1 13.2 3.4  n.a. n.a 5.3 -0.3 0.6 -0.1 19.1 3.0 
Spain 9.4  n.a. 5.0 1.4 15.8 17.3 7.9  n.a. n.a 3.7 -1.3 0.4 -1.0 21.4 5.6 
Sweden 9.0 8.8 7.8 1.4 27.0 10.7 1.7 11.8 3.0 6.7 -1.1 1.1 -0.3 30.3 3.3 
UK 5.5 6.3 5.3 0.3 17.4 4.4 -1.1 8.1 1.8 5.9 0.6 0.4 0.1 18.8 1.4 
UE-15 10.0 6.7 5.7 1.0 20.9 13.9 3.9 9.2 2.5 5.5 -0.3 0.8 -0.2 25.9 5.0 
(1) Pension spending is projected at 2040 rather than 2050. 
Source: European Union Economic Policy Committee (2001, 2003). 
The figures reveal that:  
 in 2000, almost half of the EU public social expenditure consisted of pensions; pensions 
are also projected to record the highest expenditure growth at 2050 (+3.9 percentage 
points vs. 2.5 of healthcare); 
 though not shown in the table (but see Union Economic Policy Committee, 2001 and 
2003), while the profile of the incidence of pensions is curbed over the period of 
projection and tends to stabilise in the long run, this does not happen for healthcare, 
where the profile is slowly but continuously rising. Moreover, the projected path is to be 
considered as the lower limit of the actual expected path: besides the effect of innovation, 
on which we elaborated in Box 3, also “demand effects” might lead to stronger pressures 
than those projected, since the base may contain some unexpressed or “truncated” 
demand. 
The considerations above suggest that, independently from technological innovation in 
medicine and medical devices, EU Members will be asked to adopt significant reforms of 
their social security systems, in order to ensure both their financial and social sustainability 
(the latter being the adequacy of benefits and services, in terms of their diffusion and 
modernization16). 
                                                 
16 The European Council of Barcelona (see Council of The European Union, 2003) designing the main lines of 
action in reforming European pension systems suggested pursuing three goals: long term financial sustainability, 
adequacy of benefits and modernisation, in a wide sense, of the system. These goals can be extended to the entire 
set of social expenditures. 
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The general framework of policy mix normally identified by theory and practice (see for 
example Diamond, 2000; Miles and Sefton, 2002; Pammolli, Oglialoro and Salerno, 2004) to 
reach these goals consists in the so called “triple diversification” of the expenditure:  
I. a rebalancing within the components of public social expenditure, in order to better 
encounter new needs and demand; in particular, in many EU Member States public 
expenditure is, and is projected to be, too concentrated on pensions; 
II. a rebalancing between public and private sources of financing through the adoption of 
co-payment schemes. This with the aim not only of reinforcing the equilibrium of 
public finances, but also of creating the right incentives for cost-effective consumption 
of public goods and services;  
III. a rebalancing within the composition of private social expenditure, in order to 
strengthen the organised institutional pillars of pension and healthcare funds (to be 
achieved also under the impulse of favourable taxation). 
These three aspects of diversification complement each other. Their achievement will 
preserve the fundamental goals of the social system and optimise the mix of its financing. 
As for the last point, a vast economic literature (Miles and Cerny, 2006; OECD, 1998, 2001, 
2005; Modigliani and Muralidhar, 2004; Boeri and Perotti, 2002; OECD, 1998, 2001, 2005; 
Feldstein and Liebman, 2001; Barr, 2001) has pointed out the benefits associated to a 
diversified – private and public – and well-balanced financing structure. These benefits 
emerge under a dynamic point of view, where the two financing channels, public and private, 
play a different role: public financing, based on taxation and social contributions, evolves 
mainly in line with labour productivity; private financing, managed by fund managers, is 
instead connected to capital productivity. A balanced combination of public and private 
financing allows more moderate taxation. In this it contributes to higher employment and to 
labour productivity as well as to higher investments and capital productivity through the more 
efficient allocation of resources on the financial markets. 
As can be seen from Figures 5 and 6, the complementarity between public and private funding 
for health has been so far scarcely exploited in Europe and Japan compared to the US. For 
EU-15, EU-19 and Japan, the historical evolution of health and pharmaceutical expenditure 
shows a growing spread and asynchronism between public and private components. On the 
contrary, a clear co-evolution appears for the US, where public and private expenditure appear 
as integrated. 
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Figure 5. Long-term trends of public and private healthcare expenditure (% of GDP) 
Source: OECD Health Data (2004). 
Figure 6. Comparison between public and private pharmaceutical expenditure – 1970-
2002, % of GDP 
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The breakdown of private healthcare expenditure in Table 4 shows the different relevance of 
the private institutional pillar in the EU and US. Private expenditure in Europe consists 
largely of out-of-pocket payments by patients: almost 70 percent in 2002, compared to about 
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25 percent for the US. In the US, the percentage covered by the private institutional pillars is 
over 65 percent, whereas in Europe it is approximately equal to 17 percent. 
Table 4. Composition of private healthcare expenditure – 1980, 2002, % of GDP 
 1980 2002 
 institutionalised institutionalised 
 
out of pocket 
by  
households 
insurance contracts 
and health funds 
mutual 
organiz. 
out of pocket 
by 
households 
insurance contracts 
and health funds 
mutual 
organiz. 
Canada 58.9 3.2 26.3 50.3 3.8 38.4 
France 64.0 17.4 28.5 40.9 19.9 35.0 
Germany 48.5 27.5   48.2 39.9   
Italy 64.5 3.0   83.3 3.7   
Japan 90.2   2.5 89.9   1.5 
Spain 83.2 15.9   82.5 14.5   
UK 80.8 12.3   64.4 19.2   
US 41.4 48.5   25.4 65.7   
EU-15 68.3 15.6   68.8 17.1   
Source: authors’ calculations from OECD Health Data (2004). 
Note: mutual organisations work as a pay-as-you go system in which, as in the public health systems, members’ 
contributions pay for those members who need healthcare; on the contrary, insurance contracts and health funds 
work on a insurance financial basis.  
 
From a policy point of view, the underdevelopment of the institutional pillars assigns the 
burden of financing healthcare directly to households, without the “screen” of any specific 
and organic tax relief scheme; when adverse events occur, households need to pay out of 
pocket at least part of the treatment; this prevents the establishment of a direct and long-term 
connection between the resources devoted to healthcare goals, efficient allocations on capital 
markets and investments that are a key driving force for economic growth. 
EU Member States appear to have margins to strengthen the diversification of the financing 
sources for the long-term sustainability of healthcare expenditures. With the appropriate use 
of market regulation and fiscal incentives and support to the disadvantaged categories of 
patients, this structural change can take place preserving the fundamental social choices. 
Treatments based on innovative medical devices can be interested by the diversification of 
financing for at least two aspects: 
 a diversified financial structure could partially loosen budget constraints as well as the 
focus on cost-containment. This would allow more room for high price-performance 
products both in the public and private markets;  
 the industry of medical devices and of high-tech medicine can be one of the investment 
targets for health funds and benefit from a significant financial source for R&D and 
innovation.  
To sum up, the debate on the impact and sustainability of medical device expenditures needs 
to be enriched in order to include elements related to social expenditure composition and 
overall sustainability. The best way to approach the problem is to consider it as part of the 
economic reforms that will regard welfare systems next years, attempting to combine together 
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the so-called gold quartet: welfare diffusion, long-term financial stability, competitiveness 
and growth.
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4. ECONOMIC EVALUATION OF MEDICAL DEVICES: SOME CASE 
STUDIES 
Summary of the chapter 
The objective of this chapter is to present some examples of the impact of medical device 
innovations on the whole health system. In particular, we are interested in the evaluation of 
economic implications deriving from the adoption of innovations in medicine. 
Far from being an exhaustive review of all the possible innovative technologies, we focus 
here on four specific situations: the interventional market for cardiology, diabetes mellitus 
and blood glucose control, osteoarthritis and the prevention of breast cancer.  
Besides their relevance in terms of population affected by those pathologies, each of these 
cases witnessed the (relatively) recent introduction of highly innovative devices, which 
somehow produced a massive change in the way that the pathology is treated, both on a 
clinical and on an economic level. 
A common feature of all the case studies presented here is that, although these innovations 
typically proved a certain degree of clinical effectiveness improvement, economic evaluations 
led to more controversy. As a matter of fact, the short-term analysis almost always suggests 
that moving from standard (previous) treatments towards innovative ones can produce a 
significant increase in the overall costs associated to that pathology. 
However, despite these cases being characterised by different levels of heterogeneity, in all 
the situations that we considered here, when evaluated in the long-term, all the new devices 
are likely to be associated with some cost-effectiveness results. In particular, a proper 
economic analysis also allows to take into account relevant subpopulations (i.e. the high risk 
patients, however defined), among which the use of the innovative device becomes extremely 
cost-effective. A more rational allocation of resources is warranted in this way, as suggested 
by some of the evidence we presented here. 
4.1 Introduction 
The last twenty years have witnessed a massive interest in health technology assessment. The 
ageing of world population and the introduction of high-cost as well as high-performance 
innovations in medicine have increased the necessity of health services to monitor the 
financial impact of new technologies adopted, versus their therapeutic impact. This process 
has been initiated in the US system, during the late 1970s, but soon spread to European 
countries, and is now a widely accepted concept in all healthcare systems. 
At present, economic concepts are quite standard in this framework, thanks to the 
contributions of many scholars (e.g., Drummond et al, 1997, Donabedian, 1988 and Phelps, 
2003). For instance, classic analysis involves the evaluation of the costs associated with a 
given programme with respect to either the effectiveness (as measured by some suitable 
clinical proxies), or the benefits (in terms of utility, whatsoever specified) for society, derived 
by the utilisation of such innovations. Great care is needed in the definition of these concepts. 
As an example, costs involved could be only direct (i.e. that of acquisition and usage of the 
technology, as well as those derived by side effects), or could be extended to include also the 
indirect costs, associated with loss of work, home care and patients’ poor quality of life. 
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Recently, statistical research has focused massively on health economics topics, producing 
considerable advances in estimation techniques (see for example the works of O’Hagan and 
Stevens, 2001 and 2003, and that of Briggs, 1994). As a result, health economists are now 
equipped with tools that enable long-term evaluations that can jointly consider several 
parameters (such as the interaction of costs and clinical effectiveness). In addition, uncertainty 
derived by economic estimations can be taken into account properly (i.e. by means of 
probabilistic sensitivity analysis, Spiegelhalter et al., 2004). On the other hand, the need of 
systematic data collection, directly focusing on both cost and clinical effectiveness measures, 
is increasing in importance and massively advocated. 
In this section, we will illustrate some case studies of technological innovations in medicine, 
associated with medical devices. The objective of this section is to identify some archetypical 
examples of: 
a) The effectiveness of an innovation on health outcomes; 
b) The huge heterogeneity of the innovation process; 
c) The market structure. 
We will rely on methodology and findings of health technology assessment applied to the 
technology under examination. 
The case studies that we present in the following are representative of some areas of 
medicine, which for different reasons, play a major role in health systems. Our intention is by 
no means that of producing a comprehensive review of all the areas covered by innovation in 
medicine. The main criteria that guided our selection of cases are: a) the impact on the 
population, in terms of patients affected by a given pathology; b) the economic burden 
associated with the treatment of that pathology; and c) the innovative characteristics of the 
technology and associated product.  
The technologies illustrated here are: 
1. Interventional cardiology market: the case of drug eluting stents; 
2. Diabetes treatment and blood glucose control;  
3. Osteoarthritis and total hip replacement; 
4. Imaging devices for mammography. 
Of course, other areas could fit into the criteria that we defined in order to select the cases. 
However, we decided to concentrate on the ones described above because of the high 
relevance that is perceived. 
Each case study is presented as follows: 
a. Brief description of the pathology associated with the innovation, and its prevalent 
therapeutic protocols; 
b. Relevance of the pathology: population affected and costs associated; 
c. Background to innovation: history, previous standards and technologies; 
d. Innovation: description, impact on health and on costs. 
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4.2 Interventional Cardiology Market: the case of Drug Eluting Stents 
a. Brief description of the pathology associated with the innovation and prevalent 
therapeutic protocols 
Coronary artery disease (CAD) occurs when the arteries that supply blood to the heart muscle 
(coronary arteries) become hardened and narrowed, due to the build-up of plaques on the 
inner walls or lining of the arteries (atherosclerosis). Blood flow to the heart is reduced as 
plaques narrow the coronary arteries, leading to a decrease of the oxygen supply to the heart 
muscle (Figure 1).  
Figure 1. How Coronary Artery Disease develops  
 
Source: Mount Auburn Hospital Website (2005). 
CAD is the most common type of heart disease, and the leading cause of death in the US in 
both men and women.  
The set of available treatments comprises of three major programmes: 
• Medications, such as cholesterol lowering drugs, beta blockers, angiotensin converting 
enzyme, and other pharmaceutical treatments; 
• Open heart surgery, including bypass and laser revascularisation; 
• Minimally invasive surgery, such as angioplasty. 
Angioplasty, as a minimally invasive procedure, is performed under local anaesthesia. A 
balloon catheter (i.e. a small tubing system fitted with a deflated balloon at its extremity) is 
introduced in the arterial vasculature, through the groin and is guided to the coronary arteries 
via the aorta. The doctor visualises the balloon catheter navigating into the artery with an X-
Ray imaging system. 
The balloon catheter is then positioned at the site of the narrowing and the balloon is briefly 
inflated pushing and reorganising the plaque, i.e. the fatty deposit obstructing the arteries.  
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The balloon is then deflated and retrieved, leaving an enlarged artery and restoring normal 
blood flow.  The entire procedure may last up to an hour and the patient can be discharged 
from the hospital on the same day or the day after. 
b. Relevance of the pathology: population affected and costs associated 
An estimated 17 million people die of Cardiovascular Disease (CVD), particularly heart 
attacks and strokes, every year (WHO, 2004a). A substantial number of these deaths can be 
attributed to smoking, which increases the risk of dying from coronary heart disease and 
cerebrovascular disease by 2–3 fold. Physical inactivity and poor diet are other risk factor, 
which increase individual risks to cardiovascular diseases. 
Nearly half (49 percent) of all deaths are from CVD (55 percent of deaths in women and 43 
percent deaths in men). The main forms of CVD are CAD (also known as ‘ischemic 
diseases’) and stroke. About half of all deaths from CVD derive from CAD and nearly a third 
from stroke (see Tables A.4.1–A.4.3). CAD by itself is the most common cause of death in 
Europe: accounting for nearly two million deaths each year. Over one in five women (22 
percent) and men (21 percent) die from the disease. 
There are wide variations in mortality rates across Europe: eastern countries reach eight CVD 
related death per 1,000, while southern countries reach only three to four CVD-related deaths 
per 1,000. The picture is not that different for other major countries such as the US, or Japan. 
Tables A.4.1 to A.4.3 depict some information about prevalence and incidence of 
cardiovascular diseases, both in general and with specific focus on CAD. 
According to the American Heart Association and the National Heart, Lung, and Blood 
Institute the direct and indirect costs of cardiovascular diseases and stroke in the US for 2004 
are estimated at $368.4 billion. As for the EU, a recent Eurohealth report estimated the direct 
and indirect economic cost of CVD to be between €70 and €135 billion per year.17 More 
specifically, Shearer et al (2004) find that the total direct healthcare cost of CAD in the UK in 
2001 was estimated to be approximately £1,8 billion (about €2.64 billion). The largest cost 
components were drug treatment (70 percent) and hospital treatment (25 percent).  
c. Background to innovation: history, previous standards and technologies; 
The history of the treatment of CAD dates back at least to the nineteenth century. However, 
the latest 30 years have witnessed at least three blasting innovations, which determined a 
sensible change in the practice of the treatment of this pathology. 
The first one can be identified with the work of Dr. Andreas Greuntzig, a German physician 
working in Switzerland, who in 1977 inserted a balloon catheter into a patient’s coronary 
artery, successfully opened a blockage and restored blood flow to the heart. This was the first 
percutaneous transluminal coronary angioplasty (PTCA). A decade later, PTCA – a 
minimally invasive technique – took off in Europe, and rapidly established itself as one of the 
most common surgical procedures, all over the world.  
Although extremely successful, balloon angioplasty had limitations, mainly due to restenosis 
or re–narrowing of the treated lesions. Restenosis requires re–intervention, which usually 
occurs within nine months following the initial procedure. With PTCA, which is the standard 
                                                 
17 This figure includes both direct and indirect costs. Direct costs include the cost of physicians and other 
professionals, hospital and nursing home services, the cost of medications, home healthcare and other medical 
durables. Indirect costs include lost productivity that results from illness and death. 
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intervention, this side effect can occur in as many as 30 percent of the treated patients. 
Restenosis can be caused either by elastic recoil (75 percent), or neo-intimal proliferation (25 
percent). Elastic recoil is a mechanical reaction of the artery that springs back after it has been 
forced open during the PTCA procedure. Neo-intimal proliferation, which is similar to a scar 
tissue, is a biological response to the mechanical injury resulting from the procedure, or in 
other words, a healing process. 
In the first half of the 1990s, a second major innovation was introduced in the market. Stents 
were developed to try to solve the restenosis problem. A stent is a tiny metallic mesh with 
tubular shapes that is inserted into the artery using PTCA techniques, and acts like a 
mechanical scaffold that limits re-narrowing of the artery. Following the introduction of 
stents, restenosis rates dropped in the 15 percent – 20 percent range. 
Therefore, the stent market noticeably took off in Europe in the second half of the 1990’s, and 
landmark clinical trials established the superiority of stents over balloons. 
At the beginning of the new century, stents were able to cope brilliantly with all the 
mechanical issues. However, restenosis also involves a biological process during which scar 
tissues form inside the stent and reduce blood flow.  Hence, to address this biological process, 
drug–eluting stents were developed. 
d. Innovation: description, impact on health and on costs 
Drug eluting stents (DES) represent one of the most innovative developments in 
interventional cardiology. This device associates an anti-proliferate drug to prevent scar tissue 
formation, a drug delivery system to release the active drug at a specific rate and a stent to 
carry both the drug and the drug delivery system and to act as a mechanical scaffold. 
As a result, the risk of incurring in restenosis is highly reduced: the landmark trial RAVEL 
(Serruys et al, 2002) was the first one to compare conventional stents with DES and 
demonstrated an impressive 0 percent restenosis rate in the DES arm. Later, other studies 
were performed, which showed low (though not null) prevalence of restenosis in patients 
treated with DES; as compared to standard stent procedure, DES can reduce the risk of 
restenosis up to 75 percent. (Weaver et al, 2000; Rinfret et al, 2001; Leon et al, 2002).  
The expansion of the market for DES can be explained by the fact that, from the clinical point 
of view, the introduction of DES had the effect of allowing physicians to treat patients that 
present more complex conditions. These include diabetic patients, and individuals with 
smaller vessels and more extensive plaques in the artery, who were treated by means of 
invasive surgery, before the introduction of DES. This circumstance translated in a huge 
increase in the quality of life. 
However, although clinical benefits of DES are increasingly evident, important concerns 
about their costs have been raised in the medical community.  
The main issue is related to the fact that the clinical target of DES procedure – the reduction 
of restenosis – is mainly a secondary outcome. In fact, to date, no study has demonstrated a 
convincing link between restenosis and mortality. Consequently, despite the clear clinical 
benefits, concerns remain on whether the additional costs associated with the elimination of 
restenosis are worth paying. 
The unit cost of a DES was estimated as $2,700 per stent procedure, whereas standard balloon 
PCI only has an average cost of $700 (Greenberg et al, 2004). Lemos et al (2004) attribute 
this incremental costs to factors associated with the innovative process such as: 
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a) Higher R&D costs, as testified by the relatively high concentration of the market. In 
Europe, the main four companies account for more than 85 percent of total revenues; 
b) Acquisition of exclusive and valuable licenses from pharmaceutical companies; this 
factor has a huge impact in the strategic alliances of the companies, and determines a 
high level of competition among the main companies; 
c) New manufacturing facilities needed; as an example, Boston Scientific (market leader 
in Europe) has made an investment and exclusive option to purchase arrangement with 
REVA Medical, Inc. of San Diego, which is currently working on new generation 
DES; 
d) Low production levels; although increasing at relevant rates, as of 2003, DES only 
represent a limited share of total PCI procedures. 
As appears straightforward, the higher short-period costs associated with DES has major 
implications on the economic point of view. Greenberg et al (2004) estimate that uniform 
conversion of all current standard stent procedures to DES will result in a cost increase of 
about $2,800 per patient treated, whereas Lemos et al (2003) calculated that the unrestricted 
usage of DES in the patients that currently receive standard stents would cost the US system 
about $1.5 billion each year. 
However, several cost effectiveness analyses performed on sub-groups of patients with 
different initial clinical conditions demonstrated that DES could result in cost savings, when 
applied to medium-high risk patients. For instance, van Hout et al (2002) and Greenberg et al 
(2004) showed that treatment with DES could be cost effective for patients with estimated re-
intervention likelihood greater than 12 percent, and even result in cost savings for patients 
with estimated re-intervention likelihood greater than 20 percent (see Figure 2). Moreover, it 
has to be considered that the therapeutic alternative for these patients is surgery, which is an 
expensive procedure, besides being invasive. 
For this reason, other studies have focused on the comparison between DES and Coronary 
Artery Bypass Grafts (CABG) surgery. On the one hand, the effectiveness level of CABG is 
still superior, as compared to both standard and drug eluting stents (Hirshfeld and Wilensky, 
2004). However, on the other hand, DES have narrowed the efficacy gap, and in addition they 
also have improved significantly the quality of life of patients. Consequently, DES could turn 
to be cost saving, in case the expansion on the market is to the detriment of the highly 
expensive CABGs (Lemos et al, 2003). 
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Figure 2. Cost effectiveness of DES, as compared to standard stent procedure (a cost per 
event averted less than $10,000 is considered as indicative of cost effective procedure) 
 
Adapted from Greenberg et al. (2004) 
Yet, some analysists forecast that much of the DES market growth will occur at the expense 
of the BMS market. This circumstance inevitably leads to the necessity of re-designing the 
distribution of budgets and priority for the whole health system.  
A problem related to this issue is that suggested by O’Neill and Leon (2003), who reports 
some estimations made at the William Beaumont Hospital, MI (US). The penetration of DES 
in place of CABG would lead to a) fewer repeat procedures; b) fewer repeat bypasses; and c) 
higher total costs associated with DES procedure. This is perceived as a huge barrier to entry, 
and appears to generate noticeable problems with reimbursement activity. 
Furthermore, the decreased demand of standard stents will intensify price erosion among 
manufacturers competing for shares in a declining market.   
Conclusions 
Drug eluting stents proved to be a highly effective device in reducing the risk of restenosis. 
This feature is highly valuable, especially for patients who present complex conditions, such 
as diabetes, or particularly extensive lesions. 
The positive results in clinical trials will help DES establish in the market and in fact the 
penetration rate is estimated on 60.5 percent of all stented procedures by the year 2008. 
Market profitability is high, due to premium prices, which are associated with DES, since 
their clear innovativeness. However, this also leads to high prices, which, in conjunction with 
the poor reimbursement regulation, generate a barrier to the diffusion of DES.  
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From the perspective of healthcare providers, the available evidence suggests so far that DES 
are in fact a cost effective procedure for high risk patients, although unrestricted access to this 
new technology can generate increases in healthcare costs, in the short-term. 
4.3 Diabetes Mellitus and glucose control 
a. Brief description of the pathology associated with the innovation and prevalent 
therapeutic protocols 
Diabetes mellitus is a medical disorder characterised by varying or persistent hyperglycaemia 
(elevated blood sugar levels), especially after eating. While there are different types of 
diabetes mellitus, most are asymptomatic for a (variable) time after onset, but all share similar 
symptomatology and complications at advanced stages. This disease involves multiple casual 
factors and clinical aspects, all of which should be well understood for better management.  
Hyperglycaemia itself can lead to two severe complications, such as dehydration and 
ketoacidosis, which is a deficiency in insulin. Before the introduction of clinical insulin, back 
in 1922, the mortality rate for ketoacidosis was 100 percent; nowadays, it is only about 2 
percent (Bell and Alele, 1997).  
Longer-term complications include cardiovascular disease (doubled risk – equal rates to those 
with heart attacks from advanced atherosclerotic disease), renal failure (worldwide, diabetes 
mellitus is the most common cause of chronic renal failure requiring renal dialysis), retinal 
damage with eventual blindness, nerve damage and eventual gangrene with probable loss of 
toes, feet, and even legs. 
Historically, physicians have focused on the following factors that are characteristic of 
diabetes mellitus: a) decreased production of insulin, b) decreased sensitivity of body tissues 
to insulin (the most common), or c) a combination of both. The distinction between these 
circumstances remains important, and characterises the two main forms of diabetes: 
• Type 1 diabetes: (formerly known as ‘insulin-dependent’) in which the 
pancreas fails to produce the insulin, which is essential for survival. This form 
develops most frequently in children and adolescents, but is being 
increasingly noted later in life. 
• Type 2 diabetes: (formerly named ‘non-insulin-dependent’), which results 
from the body’s inability to respond properly to the action of insulin produced 
by the pancreas. Type 2 diabetes is much more common and accounts for 
around 90 percent of all diabetes cases worldwide. It occurs most frequently 
in adults, but is being noted increasingly in adolescents as well. 
Even in terms of therapeutic standards, the two forms of diabetes, though sharing some 
common features, are characterised by different procedures. 
Type 1 patients were the first to be identified, and the treatment is insulin supply, e.g. by 
means of injections. Additional drugs can be used by those patients to cope with concomitant 
conditions, even if these further treatments are not directly related to glucose control.  
Besides the use of insulin and testing, which are common features with Type 1 patients, 
individuals suffering from Type 2 diabetes are also treated with hypoglycaemic drugs. Testing 
procedures involve specific devices, along with particular diet regimes and physical activity. 
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b. Relevance of the pathology: population affected and costs associated 
According to the World Health Organisation (2004b), in the year 2004, more than 150 million 
people worldwide suffer from diabetes. The incidence of the pathology is increasing rapidly, 
and it is estimated that by the year 2030 this number will double (see Figure 3).  
Diabetes mellitus occurs throughout the world, but is more common (especially Type 2) in the 
more developed countries (see Figure 4). In 2002, there were about 18.2 million diabetics in 
the United States alone (WHO, 2004b), and for at least 20 years, diabetes rates in North 
America have been increasing substantially.  
Figure 3. Diabetes mellitus prevalence. Data observed in 2000 and forecasts for 2030.  
 
Source: WHO (2004b). 
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Figure 4. Prevalence estimates of diabetes mellitus, 2003 
 
Source: International Diabetes Federation (2004). 
Mortality rates in patients with diabetes mellitus are higher than those in the general 
population, and life expectancy in both type 1 and type 2 diabetes are reduced by 25 percent, 
as reported by the International Diabetes Federation (IDF, 2004). Currently, the number of 
deaths related to the disease has been estimated at just over 800,000 a year, worldwide, but 
the real figure is thought to be more in the region of 4 million a year. In contrast to the general 
population, the mortality rate among female diabetic patients is almost identical to that of 
males, and the increased mortality is mainly attributable to cardiovascular disease and renal 
failure. 
As for the economic burden of the disease, the American Diabetes Association (2003) 
estimate that diabetes costs $132 billion in the United States alone every year. IDF (2004) 
reports the annual cost for diabetic patients in some selected European Countries (see Figure 
5). Combining their estimation with the figures for the diabetic population (WHO, 2004b), we 
calculated a total estimated burden for Europe of $84 billion. 
While increasing in incidence, Type 1 diabetes already represents a substantial burden to 
health systems: Evans et al (2000) report that this disease accounts for over £ 35 million in the 
UK drug budget. 
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Figure 5. Annual costs of diabetes in Europe, 2000 
 
Source: International Diabetes Federation (2000). 
Garattini et al (2004) estimated the total direct cost associated with patients with type 1 and 
type 2 diabetes, from a multi-centres study. Patients on type 1 diabetes were associated with a 
cost of €136, whereas the cost for patients on type 2 diabetes was estimated at €123, 
suggesting that, although being less frequent, type 1 diabetes can lead to higher direct 
consumption of health resources. 
c. Background to innovation: history, previous standards and technologies 
Although diabetes has been known since antiquity, and treatments were known since the 
Middle Ages, the elucidation of the pathogenesis of diabetes occurred mainly in the 20th 
century. 
Despite this, diabetes remains a chronic disease with no standard pharmacological cure 
(except experimentally in Type 1 diabetics) as of 2004, even if some procedures exist, which 
usually to manage it effectively.  
In the last fifteen years, two clinical studies have produced major insights on diabetes 
management.  
The Diabetes Control and Complications Trial (DCCT, 1993) is a clinical study conducted 
from 1983 to 1993 by the National Institute of Diabetes and Digestive and Kidney Diseases. 
The study showed that keeping blood glucose levels as close to normal as possible slows the 
onset and progression of eye, kidney, and nerve diseases caused by diabetes. 
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The study compared the effects of two treatment regimens – standard therapy and intensive 
control – on the complications of diabetes. Volunteers were randomly assigned to each 
treatment group, showing the following results: 
• A reduction in new eye disease risk of about 76 percent; 
• Worsening of existing eye disease risk reduction of 54 percent; 
• Early kidney disease risk reduced by 54 percent; 
• More serious kidney problems reduce by 39 percent, and 
• Nerve damage risk reduction of 60 percent. 
The second important study was the UK Prospective Diabetes Study (UKPDS, 1998), the 
largest trial ever done on Type 2 diabetics, a very complicated trial lasting over 20 years, with 
multiple sub–studies. Its major contribution was to highlight the importance of tight control of 
both blood pressure and glucose levels, in order to reduce long-term complications of Type 2 
diabetes, showing: 
• Heart disease risk reduced by 56 percent; 
• Stroke risk reduced by 44 percent; 
• Kidney disease risk reduced by up to 33 percent, and 
• Eye disease risk reduction of 33 percent. 
Insulin pump therapy 
As Type 1 patients lack insulin, their therapy consists in insulin replacement. Initially, enough 
insulin to prevent ketoacidosis and minimise symptoms was thought to be an adequate 
treatment.  
Unlike other medicines, insulin cannot be taken orally, since in the gastrointestinal tract it is 
treated precisely as any other protein, i.e. it is reduced to its amino acid components, 
whereupon all ‘insulin activity’ is lost. There are research efforts underway to develop 
methods of protecting insulin from the digestive tract so that it can be taken orally, but none 
has yet reached clinical use. Given these circumstances, different routes of administrations 
had to be used.  
Until the 1970s, insulin was usually taken as subcutaneous injections by single-use syringes 
with needles, and patients needed to inject insulin several times a day (at least two), every day 
of their life. This was obviously perceived as a demanding treatment, contributing to a poor 
quality of life. 
Efforts were done, in order to light the load of patients, in terms of the number of injections, 
and to increase the effectiveness: a typical example is the introduction of pen injectors in the 
early 1980s. These are rather like ink cartridge pens in design, and contain a cartridge of 
insulin. Pens are the predominant insulin delivery system in most parts of the world, except 
the United States where syringes still dominate. 
In 1993, the DCCT trial showed that giving insulin was not enough, but mimicking the 
normal insulin secretion pattern of non–diabetic individuals was the real target. The trial 
compared conventional insulin injections to Multiple Daily Injection (MDI), and showed that 
the former had superior clinical benefits. After that, MDI became a very popular medication, 
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even if in the US market more than 50 percent of Type 1 patients still use one to two 
injections per day. This therapy has been classified as sub-optimal (DeWitt and Hirsh, 2003).  
A further innovation in the field is represented by Continuous Subcutaneous Insulin Infusion 
(CSII), which recent studies (cfr. Lenhard and Reeves, 2001 and Pickup et al., 2002) proved 
to provide superior glycaemic control, as compared to MDI.  
Self Management of Blood Glucose 
Based on the available literature, a recent guideline (Goldstein et al., 2004) reported that all 
treatment programs should encourage Self management of Blood Glucose (SMBG), as this 
strategy can help most patients with type 1 diabetes achieve the goal of maintaining blood 
glucose levels as close to normal as is safely possible. For this reason, SMGB is considered an 
integrated part of disease management in diabetes treatment, and specific devices have been 
introduced in the market to this aim. 
Glucose self-monitoring began in 1941 with the introduction of urine testing. In the 1950s, 
Ames Company, a division of Miles Laboratories in Elkhart, Indiana, introduced strips to test 
for glucose in the urine, with the result being determined by comparing the colour change 
generated on the strip with colour patches.  
Urine testing was the standard of care for many years, until 1965, when blood glucose testing 
began using the Ames Dextrostix system, a visually read paper strip. Accurate assessment of 
the resulting colour change by purely visual analysis was found to be a problem and, 
therefore, the company introduced a meter to read the strip, for use in doctors’ practices. This 
meter – the Ames Reflectance Meter – was first used by a patient at home in 1970. The result 
was given as a numerical outcome, via a swinging needle.  
The first widely available meter, the Eyetone, manufactured in Japan by Kyoto Daiichi 
Kagaku (KDK), was sold by Ames from 1972. As self-monitoring became more popular, 
more companies began to produce progressively more and more advanced meters. Boehringer 
Mannheim developed the Chemstrip strips, and later the first Accu-Chek meter to read those 
strips. LifeScan produced its first meter in 1980.  
Until the late 1980s, reflectance photometry was the only technology used for blood glucose 
monitoring. This technique worked by quantifying the intensity of a coloured product 
generated by the conversion of glucose via an enzyme catalyst, the amount of coloured 
product produced being directly related to the amount of glucose in the sample.  
MediSense laboratories were the first company to introduce a system based on 
Electrochemistry, a technique that quantifies the number of electrons generated by the 
reaction of glucose with a mediator via an enzyme catalyst. The number of electrons captured 
by the mediator is directly proportional to the amount of glucose present in the sample. A 
voltage is applied to the mediator, which transfers the electrons to the electrode, where they 
are counted. All major companies in the sector have adopted this technology, and it is slowly 
replacing reflectance technology as the preferred method of measurement.  
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d. Innovation: description, impact on health and on costs 
Insulin pump therapy 
CSII is provided by an insulin pump, made up of a pump reservoir filled with insulin, a small 
battery-operated pump and a computer chip that allows the user to control exactly how much 
insulin the pump delivers. It is all contained in a plastic case about the size of a beeper. 
The pump reservoir delivers insulin to the body by a thin plastic tube called ‘infusion set’. 
Infusion sets come in 24 inch and 42 inch (respectively, 60 and 106 cm) lengths and have a 
needle or soft cannula at the end, through which the insulin flows. Most people prefer the soft 
cannula, especially since insertion is virtually painless with the automatic inserter. The 
cannula is inserted just under the skin, usually into the abdomen. The process of putting the 
infusion set in place is called ‘insertion’, and is very much like giving a standard insulin 
injection. The infusion set is changed approximately every two to three days. As a result, as 
compared to injections, patients need only a single operation in three days, instead of six in 
the same period. 
The pump is used continuously and delivers insulin 24 hours a day according to a 
programmed plan, which is uniquely defined for each pump user. A small amount of insulin is 
given continually (the ‘basal rate’). This insulin keeps blood glucose in the desired range 
between meals and over night. When food is eaten, the user programs the pump to deliver a 
‘bolus dose’ of insulin matched to the amount of food that will be consumed, as depicted in 
Figure 6. 
Figure 6. How insulin pump infusion matches physiologic insulin secretion 
Bolus 
Basal
 
 
From the clinical point of view, CSII proved to significantly decrease the level of glycaeted 
haemoglobins, resulting in higher effectiveness (Pickup et al., 2002). Weissberg et al (2003) 
performed a meta analysis on 52 studies, and show that CSII decreased significantly more 
glycaeted haemoglobins level than MDI, with a difference of 0,95. Linkeshova et al. (2002) 
performed a long-term prospective study, and found out that CSII has a significantly positive 
impact on quality of life parameters, as depicted in Table A.4.5. Moreover, CSII proves 
important in the control of hypoglycaemia. Recent works (Linkeshova et al., 2002; 
Weissberg–Benchell et al., 2003) suggest in fact a substantial decreased frequency of 
hypoglycaemic episodes in patients associated with CSII therapy. 
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From the economic point of view, not many studies allow a direct comparison between MDI 
and CSII. In fact, none of the most important trials – the DCCT and the UKPDS – are directly 
focused on economic evaluation. Roze et al (2005) estimated a total annual cost of £ 2,641 for 
CSII therapy, as compared to £ 1,482 for MDI. However, given the estimated increase in the 
effectiveness measure analysed (quality adjusted life expectancy, QALE) of about 0.76 
(±0.19) years, the incremental cost effectiveness ratio (ICER) for CSII vs MDI was calculated 
at £ 25,648/ QALEs. This value is slightly above the current threshold defined by NICE to 
assess the cost effectiveness of an intervention (ICER < £ 20.000). Therefore, besides being a 
clinically effective intervention, CSII therapy can be considered to represent good value for 
money. 
Self-Management of Blood Glucose 
The principle of all blood glucose monitoring devices is virtually the same: a small blood 
sample is collected to a test strip by the patient, using a lancing device (a sterile pointed 
needle). This test strip contains various chemicals that, when the blood is applied, create a 
small electrical charge between two contacts. This charge will vary depending on the glucose 
levels within the blood and its effect on the chemicals contained within the strip. In older 
glucose meters, the drop of blood is placed on top of a strip. A chemical reaction occurs and 
the strip changes colour. The meter then measures the colour of the strip optically. 
However, not every meter suits all patients, and moreover, the last technological advances 
allowed meters to become progressively smaller, faster and easier to use, with smaller blood 
volumes being one of the greatest advances. Even over the last 5 years, test times have 
reduced from 45 seconds to only 5 seconds, and sample size from 10µl to less than 1µl.  
All of these advances have increased the acceptance of SMBG by patients and, as a result, its 
usage has grown enormously. This circumstance is highly relevant, both from the clinical and 
the economic point of view. 
At present, there are many (at least 20) different types of blood monitoring devices available 
on the market today. Competition between manufacturers is intense, with new offerings 
coming to the market on average every 6 months or so, and product life-cycles being 
relatively short (2-5 years depending on the product’s market acceptance).  
Despite the difficulty of doing so, investment in trying to find a device that is capable of being 
utilised by most types of patient is significant, with each manufacturer looking for the 
general-purpose device. Patients tend to replace their meter every 3-4 years, and therefore 
there are more than 2 million individuals looking to acquire a new device each year, so that 
the potential return on investment is significant for those devices that are accepted. However, 
the market entry criteria are becoming more challenging. 
In several EU countries blood glucose meters are not covered by reimbursement and their cost 
is transferred on the consumable component of the testing system, the test strip, which is 
reimbursed for most people with diabetes in the EU.  
With the complexity of devices increasing, as well as the cost of R&D, this barrier to market-
entry can represent a disincentive for some companies to participate in this area. However, 
there have been several recent entrants on the market, and in-licensing is also considered a 
good opportunity.  
As an alternative means of market access, companies are increasingly selling meters via retail 
pharmacies. Although more attractive in financial terms as compared to the provision of free 
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of charge meters, prices are low (around $10-20) and insufficient to cover the cost of 
manufacture.   
Both distribution channels can prove costly in terms of the necessary sales and marketing 
support needed to ensure awareness and advocacy. These costs are increasing as companies 
expand sales teams and expand marketing activities to cover direct to consumer promotion, 
including, in some EU countries, television advertising. An idea of the relevance of this 
market is given by the fact that the impact of the glucose monitoring market is estimated at 
around $3 billion.  
Convenience has been the major area of focus for product development over the last 5 years 
or so. There have been no significant improvements in the testing process, rather companies 
have concentrated on making the procedure faster and easier and less painful, with huge 
benefits for diabetic patients.  
A recent innovation, utilised only by two manufacturers so far, has been the incorporation of 
the test strips into a cartridge, which is then inserted into the device. Using this sort of 
mechanism eliminates the need to insert individual strips into the meter prior to testing, and to 
carry additional test strips around. Even though this advance appears to offer greater patient 
convenience, the mechanical reliability of these devices has been questioned and to date they 
have only achieved a relatively small combined market share (approximately 7 percent at the 
end of 2003). 
At the market level, the industry is characterised by a set of major companies, accounting for 
about 80 percent of the market. The rest can be seen as residual. Moreover, there is huge 
interaction with innovations in other areas (i.e. Electrochemistry).  
From the clinical point of view, the availability of medical treatments for diabetes means that 
excellent blood glucose control is achievable. This feature can also have a huge impact on the 
economic point of view, as long-term complications can take years to develop, so with 
excellent diabetes care it should be possible to avoid the great majority of these problems. 
The DCCT Trial (1993) involved two groups of patients with Type 1 diabetes, one of which 
was maintained on an intensive insulin regime aimed at keeping blood glucose at near normal 
levels with the other being treated conventionally. The standard measure of glucose control is 
the Glycated Haemoglobins (HbA1c) test, which shows how well the blood glucose levels 
were controlled during the previous 3-month period. Although the DCCT study did not 
analyse the direct effect of Self-Monitoring of Blood Glucose (SMBG) on patient outcomes, it 
seems that appropriate daily self monitoring of blood glucose levels did contribute to effective 
intensive insulin therapy and hence the HbA1c improvements reported. The study results 
demonstrated that intensive therapy reduced the risk of eye disease, diabetic kidney disease 
and diabetic neuropathy. 
Following these findings, UKPDS (1998) studied more than 5.000 people with Type 2 
diabetes and aimed at maintaining a group of patients on a similarly intensive therapy 
designed to maintain near normal blood glucose levels. The study also showed that intensive 
glucose control could reduce the risk of both diabetic retinopathy and diabetic neuropathy. 
Table A.4.6 summarises the results of these two studies, in terms of their effect on the rate of 
complications (notice that the former study was concerned with type 1 patients, whereas the 
latter was focused on type 2 patients, which explains the difference in the rates reported). 
Other studies have assessed the direct effect of SMBG on disease progression, such as that of 
Nyomba et al (2003), which looked at the effect of SMBG on glycaemic control. The main 
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finding was that when patients had unrestricted access to testing supplies, they were better 
able to control their glucose levels (as determined by measuring HbA1c levels) than were 
those patients who did not. Moreover, insulin dose did not change significantly in patients in 
the former group, whereas in the latter group the dose increased 1.5 fold over the duration of 
the study.  
Soumerai et al (2004) assessed the effect of SMBG on medication compliance. Initiating 
SMBG was associated with increased regularity in the use of medications and a reduction in 
high blood glucose levels that are associated with diabetes complications. 
The economic impact of SMBG has been investigated by UKPDS (2000). Their findings are 
that intensive glucose control increased trial treatment costs by £695 (95 percent confidence 
interval: £555 to £836) per patient. However, the costs of complications were reduced by 
£957 (£233 to £1,681), as compared with conventional management. 
Furthermore, UKPDS (2001) confirmed these results, reporting that intensive blood glucose 
control with metformin produced a net saving of £258 per patient, over the trial period (mean 
duration 19.7 years), again due to lower complication costs and increased life expectancy by 
0.4 years. 
Conclusions 
Diabetes mellitus is associated with various forms of heterogeneity, both in terms of patients’ 
characteristics, and of related treatments. Consequently, clinical and economic evaluations 
should be focused precisely on specific aspects. 
However, the evidence that we found in medical and economic literature tends to suggest the 
following conclusions: 
• Despite the high heterogeneity, a set of standard treatments can be identified for both 
type 1 and type 2 patients. These health programs are likely to involve continuous 
innovations, in order to meet the demand for better quality of life coming from 
diabetes patients. 
• This feature is quite important, since, on the one hand, the prevalence of diabetes is 
constantly increasing through the entire world, and, on the other hand, younger 
patients are being affected from this disease. Those individuals are likely to be in their 
full working and physical activity, generating a demand for minimally invasive 
procedures. 
• When measured in the long-term and considering patients’ quality of life as a relevant 
effectiveness measure, the introduction of different innovations in medicine and in-
vitro diagnostic can prove to be associated with lower costs. 
However, some concerns are increasingly arising with respect to reimbursement policies, 
which are substantially different in the US to other markets. This feature can possibly perturb 
the dynamics of diabetes markets, and need careful examinations by means of central 
authorities. 
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4.4 Osteoarthritis and Total Hip Replacement 
a. Brief description of the pathology associated with the innovation and prevalent 
therapeutic protocols 
Osteoarthritis (OA) is a major cause of pain and disability, particularly in older people, as 
worldwide it accounts for half of all chronic conditions in person aged 65 and older, and one 
in four people over the age of 60 have significant pain and disability from osteoarthritis.  
OA is a degenerative arthritis process, which determines the breakdown of the joints cartilage, 
the part of the joint that cushions the ends of bones. Cartilage breakdown causes bones to rub 
against each other, causing pain and loss of movement. OA can range from very mild to very 
severe, and it affects weight–bearing joints such as knees, hips, ankles, foot joints and the 
back. 
Many factors can cause OA: although age is a risk factor, research has shown that OA is not 
an inevitable part of aging: for instance, obesity may lead to osteoarthritis of the knees. In 
addition, people with joint injuries due to sports, work–related activity or accidents may be at 
increased risk of developing OA. Even genetics have a role in the development of this 
condition, i.e. some people may be born with defective cartilage or with slight defects in the 
way that joints fit together.  
As a person ages, these defects may cause early cartilage breakdown in the joint, and in the 
process of cartilage breakdown, there may be some inflammation, with enzymes released and 
more cartilage damage. 
The treatment of OA focuses on decreasing pain and improving joint movement, and may 
include: 
• Exercises to keep joints flexible and improve muscle strength; 
• Many different medications to control pain, including corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids injected into joints 
that are inflamed and not responsive to NSAIDs. For mild pain without inflammation, 
acetaminophen may be used; 
• Heat/cold therapy for temporary pain relief; 
• Joint protection to prevent strain or stress on painful joints; 
• Weight control to prevent extra stress on weight-bearing joints; 
• Surgery, to relieve chronic pain in damaged joints. 
Through pain, loss of sleep and decreased functional ability, osteoarthritis has a profound 
effect on the sufferer. The impairment in terms of global health and functional capacity of a 
patient with OA is equivalent to that of individuals with chronic renal failure on 
haemodialysis, or patients with intractable angina secondary to ischaemic heart disease 
(Canadian Erythropoetin Study Group, CESG, 1990). 
Once the patient’s condition has progressed beyond conservative management, joint 
replacement surgery is the treatment of choice. During the 1990s, increases in rates of Total 
Hip Replacements (THR) have been reported in Scandinavia (Lucht, 2000; Havelin et al, 
2000), Australia (Wells et al, 2002) and the United States (Dixon et al, 2004). 
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A hip replacement is a surgical procedure performed for the relief of pain and the restoration 
of function in patients with end-stage arthritis of the hip joint. This involves fitting patients 
with a hip prosthesis (see Figure 7). 
Figure 7. Cemented total hip replacement 
 
 
b. Relevance of the pathology: population affected and costs associated 
Currently, 103 million people are living with arthritis in Europe, the largest population living 
with this long-term medical condition in the world (World Health Organisation, WHO, 2000). 
By 2010, for the first time in Europe, there will be more people over 60 years of age than 
people less than 20, resulting in a huge escalation of treatment costs, which presents an 
enormous challenge to health services across all Member States. 
Osteoarthritis affects an estimated 20.7 million people in the US, mostly over the age of 45, 
and is responsible for more than 7 million physician visits per year. Figure 8 shows how 
arthritis is the leading cause of disability among American adults. 
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Figure 8. Leading causes of disability among US adults, 1999  
 
Source: MMWR (2001). 
Musculoskeletal conditions such as OA cost the US economy nearly $125 billion per year in 
direct expenses and lost wages and production, as reported by The Arthritis Foundation. In the 
United States, OA is rated the highest cause of work loss, despite being a condition that 
causes most problems to populations after retirement age, indicating a wider impact over the 
population.  
An important issue to bear in mind with conditions such as OA is the indirect impact on 
health status, e.g. the inability to enjoy leisure activities or a reduction in ability to work and 
activities of daily living. The impact of arthritis is often underestimated because of the 
difficulties in quantifying many of these consequences. 
c. Background to innovation: history, previous standards and technologies 
The first devices implanted to replace the arthritic hip were made of a variety of materials that 
were placed between the degenerated joint surfaces. In 1923, Dr. Marius Smith-Peterson, of 
Massachusetts General Hospital, used a glass cup to cover and reshape an arthritic femoral 
head. Although the original glass cup design failed, it led to the development of similarly 
shaped implants of strong and durable plastic and then metal materials. The next stage was the 
development of subsequent metallic femoral devices with anatomically sized heads and 
variable femoral stems. 
While many surgeons and bioengineers contributed to the concepts, techniques and designs of 
implants for total hip replacement, one pioneer stands out, Sir John Charnley, who reported 
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his experience with a steel femoral component and a plastic socket cup in 1961. He also 
revolutionised the field with the use of the self-curing acrylic cement used to fix the implants 
into the bone. These advances greatly improved the success rate of total hip replacement, and 
the Charnley concepts of hip implants are still in use today. 
Charnley’s innovative procedure was immediately successful, and rapidly disseminated into 
routine practice. Consequently, there has been a steady increase in the numbers of patients 
undergoing total hip replacement in Europe (see for instance Figure 9). As a result, death rates 
after hip replacement dramatically decreased, from the 1970s, to the 1980s and 1990s (Figure 
10). In the 1990s, the mortality rate was 0.15 percent, about 1 in 700 operations. 
Figure 9. Trend in the number of THRs in NHS hospitals, England 1967/2001 
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Figure 10. Total hip replacement – 30 days mortality from the 1970s to the 1990s 
 
 
However, a major problem with cemented hips was aseptic loosening, which was recognised 
as a long–term issue, related to the generation of polyethylene wear particles, especially in 
more active males and younger patients. Besides a decrease in prosthesis functionality, this 
problem can also cause a foreign body reaction with osteolysis (i.e. bone dissolving). Aseptic 
loosening is a cause of pain and bone loss with the result that the patient needs to undergo 
revision surgery to fit another prosthesis. 
d. Innovation: description, impact on health and on costs 
The industry activity and innovation can be summarised by means of the following two areas. 
1) Innovations as incremental activity on traditional surgery;  
2) Production of lesser and lesser invasive surgery. 
As for the first area, in the 1980s cementless hip prostheses, fixed by bony ingrowth were 
firstly developed in the US, in order to address the loosening issue, which at the time was 
thought to be caused by cement breakdown.  
In Europe, an innovative approach was the development of hydroxypatite (HA)–coated 
cementless implants. HA is a mineral, present in healthy bones and that can stimulate the 
formation of new bone. 
As reported by Furnes et al (2005), HA–coated device copes with the problem of avoiding 
stem loosening, compared to cemented hip replacement. However, the issue of polyethylene 
cup wear and subsequent cup loosening remains as a major problem. 
One solution has been developed, which represents a further step ahead in the innovative 
process: the development of newer low–wear bearing surfaces, which are based on using 
tougher polyethylene, or hard–on–hard materials, such as ceramic–on–ceramic or metal–on–
metal. 
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Moreover, the latest development is the use of low–wear–metal–on–metal bearing technology 
with the introduction of resurfacing hips, which are devices that simply resurface the head of 
the femur, rather than invasively replacing it with a long–stemmed device. 
Of course, this new device is associated with less invasive procedures, as only a part of the 
bone is resected. This aspect is crucial, and represents the second major area of interest. 
Furthermore, the level of clinician expertise required to obtain reproducible good outcomes 
has become higher, with hip replacement surgery being more and more diffused in clinical 
practice. The introduction of Computer Assisted Surgery (CAS) also led to an increase in the 
cost-effectiveness of the procedure, after a set up period by improving the precision of the 
surgery and reducing complications such as dislocation. 
Several studies have analysed the economic implications of the development of innovations in 
THR. For example, Fitzpatrick et al (1998) compared the new cementless prosthesis to the 
standard Charnley cemented hip. They considered two different scenarios: in the first one, 
they assumed that innovation is 300 percent more costly than standard, whereas in the second 
one, the acquisition cost of new technology is to be assumed just 150 percent higher than the 
older device. 
As a result, new procedures did not turn out to be cost-reducing in general. However, if 
reductions in the revision rate are greater than 50 percent of the baseline, then assuming a 
threshold cost per quality adjusted life year (QALY) of £6,500, cementless hips produce 
savings in the medium-long term (see Figure 11). 
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Figure 11. Two–way threshold analysis to indicate how more effective (in terms of 
revision rates) a new prosthesis has to be to justify its additional acquisition cost (––: 
cost neutral threshold; …: £6.500 per QALY threshold; – – –: £10.000 per QALY 
threshold) 
 
Source: Fitzpatrick et al (1998). 
On the other hand, Chang et al (1998) found that cost-effectiveness ratio increases with age, 
and is higher for men. In a base case scenario for a 60-year-old woman, they predicted that 
THR is cost saving, because of the high costs of custodial care associated with dependency 
due to worsening hip osteoarthritis. The procedure would lead to a quality-adjusted life 
expectancy (QALE) of about 7 additional years. 
O’Shea et al (2002) assessed the cost profile of THR in Ireland. The average unit cost was 
divided into 10 categories, and was estimated at £6,472 per THR performed (see Table 
A.4.7). Moreover, they used the SF 36 questionnaire (SF 36 Health Survey, 1994) to 
investigate the utility of THR, in terms of QALYs. The domains showing greatest 
improvement were a) physical functioning; b) physical role limitations; c) bodily pain; and d) 
social functioning.  
One year after intervention, a 10 points increase in the SF 36 scale costs £1,310 for physical 
functioning, and produces savings of £855 for physical role limitations, of £1,150 for bodily 
pain, and of £1,245 for social functioning. However, THR did not prove to greatly alter 
patients’ overall health perception, as measured by the SF 36 scale. 
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Conclusions 
It is plausible to assume that on the one hand, THR is an effective procedure, which can be 
used to treat severe osteoarthritis for all patients. Patients’ quality of life of is much increased, 
and from the clinical point of view, the additional costs related to innovations in the 
orthopaedic industry are worth paying for. 
From the economic point of view, in the case of older patients, the advantages can be found in 
the reduction of the costs related to disability, such as those of home care. Younger 
individuals, on the other hand, are mostly associated with indirect benefits, as they are 
allowed to maintain their physical activity, and keep working. Nevertheless, the cost of 
intervening on young people has historically been higher, as their higher level of physical 
activities has led to an increased need for revision (repeat) procedures. 
However, the use of the new wear-prevention technologies and more bone-conserving 
prostheses outlined above should minimise the need for revision surgery for young and old 
patients alike, reduce its complexity improving patient outcomes and thus lower service costs 
overall. 
4.5 The prevention of breast cancer: mammography 
a. Brief description of the pathology associated with the innovation and prevalent 
therapeutic protocols 
Breast cancer (BC) is the most common form of cancer in females worldwide, and in the 
Western world, it affects approximately 10 percent of all women at some stage of their life. 
Although significant efforts are made to achieve early detection and effective treatment, about 
20 percent of all women with breast cancer will die from the disease, and BC is the second 
most common cause of cancer deaths in women.  
Like all parts of the body, the cells in breasts usually grow and then rest in cycles. The periods 
of growth and rest in each cell are controlled by genes in the cell’s nucleus. When genes are in 
good working order, they keep cell growth under control. Conversely, when genes develop an 
abnormality, they sometimes lose their ability to control the cycle of cell growth and rest, 
leading to cancer. 
Cancer has the potential to break through normal breast tissue barriers and spread to other 
parts of the body. While cancer is always caused by a genetic ‘abnormality’ (a ‘mistake’ in 
the genetic material), only 5-10 percent of cancers are inherited from parents. Instead, 90 
percent of breast cancers are due to genetic abnormalities that happen because of the aging 
process and life in general. 
The risk of getting breast cancer increases with age. For a woman who lives to the age of 90 
the odds of getting breast cancer her entire lifetime is more than 12.5 percent or 1 in 8 (see 
Table A.4.8). Men can also develop breast cancer, although their risk is less than 1 in 1000. 
This risk is modified by many different factors; for instance, in some families, there is a 
strong inherited familial risk of breast cancer. 
Some racial groups have a higher risk of developing breast cancer – notably, women of 
European and African descent have been noted to have a higher rate of breast cancer than 
women of Asian origin, as reported by BreastCancer.org (2004). Other established risk factors 
include having no children, delaying first childbirth, not breastfeeding, early menarche, late 
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menopause and taking hormone replacement therapy. The probability of breast cancer rises 
with age but breast cancer tends to be more aggressive when it occurs in younger women.  
Two genes, BRCA1 and BRCA2, have been linked to the familial form of breast cancer. 
Women in families expressing mutations in these genes have a much higher risk of 
developing breast cancer than women who do not. Together with Li-Fraumeni syndrome (p53 
mutations), these genetic aberrations determine around 5 percent of all breast cancer cases, 
suggesting that the remainder is sporadic. 
Depending on the stage at which cancer is detected, standard treatments may vary from 
surgery to radiation therapy, chemotherapy and immunotherapy. However, the importance of 
prevention is now well established, and screening is now recommended in many countries as 
a best practice. Suggested screening methods include Breast Self-Examination (BSE) and 
mammography. Only mammography has been proven to reduce mortality from breast cancer.  
For this reason, mammography is still the modality of choice for screening of early breast 
cancer. It is the gold standard for other imaging methods such as ultrasound, Magnetic 
Resonance Imaging (MRI) and Computerised Tomography (CT), which are less useful due to 
their lower spatial resolution. CT by itself is nearly useless for breast cancer screening as MRI 
provides better resolution and quality (although it costs much more). 
b. Relevance of the pathology: population affected and costs associated 
Breast cancer has a huge impact on society, due to its high prevalence. In the US, BC is the 
most common malignancy in women. Mammography & Beyond (Institute of Medicine – 
National Research Council, 2001) suggests that each year, more than 180,000 new invasive 
cases are diagnosed in the United States. Jemal et al (2003) forecasted an even higher 
incidence of more than 216,000 new cases for the year 2003. 
The Surveillance, Epidemiology and End Result Group (SEER, 2004) produced an age-
adjusted analysis for incidence and mortality rates in the US; as depicted in Figure 12 and 13, 
in the year 2001, they estimated an incidence rate of about 135,000 cases and about 26,000 
deaths. Moreover, significant differences were suggested with respect to women of race: the 
incidence rates for black women were lower than those for white women, whereas mortality 
rates were increasingly higher for black women, starting from the 1980s. 
These figures are consistent with those produced by Ferlay et al (2001), which are 
summarised in Table A.4.9. As it is possible to see, Europe presents high incidence rates 
(even higher than those for Northern America). However, the deaths to new cases ratio is 
about 45 percent for Africa, about 38 percent for Asia, about 37 percent for Europe, and just 
around 25 percent for Northern America (including US and Canada), suggesting high 
differences with respect to the availability of treatments and prevention tools. 
The American Cancer Society (2005) estimates about 211,240 women in the United States 
will be found to have invasive breast cancer in 2005. About 40,410 women will die from the 
disease this year. 
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Figure 12. Age-adjusted incidence rates of breast cancer in US – all ages, 1973–2001 
 
Source: SEER (2004). 
Figure 13. Age-adjusted mortality rates for breast cancer in US – all ages, 1969–2001  
 
Source: SEER (2004). 
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As for the economic burden, Wendy (2003) performed a study focusing on the total cost of 
breast cancer in California. Preliminary estimates of the annual direct costs of breast cancer 
have been completed for 2000: 12,579 women were discharged from California hospitals with 
a principal diagnosis of breast cancer, and hospitalisation costs were estimated around $80 
million, or an average of $6,346 per discharge.  
One third of the hospitalised women were aged 50-64, and 41 percent were over 65. 
Hospitalisation costs associated with a secondary diagnosis of breast cancer added $28 
million in cost. Total healthcare costs, including hospitalisations, physician services, 
medications, nursing home care, home healthcare, and emergency department visits were then 
estimated as $284 million.  
In Italy, the social cost of BC has been estimated to be over €1 million a year (Italian Society 
for Cancer Research, AIRC, 2004), whereas Remak and Brazil (2004) estimated the total 
population cost of metastatic breast cancer around £26 million. 
 
Figure 14. Use of mammography for women older than 40 years and death rates for 
malignant neoplasm of breasts (US population) 
 
Source: our elaborations of data from Center for Disease Control (CDC, 2004). 
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c. Background to innovation: history, previous standards and technologies 
Only fifty years ago, no established tool was available for the detection of breast cancer at an 
early stage. However, a singular combination of advances in technology, policy 
recommendations and legal mandates has fostered massive changes in this situation. 
Table A.4.10 presents a summary of the main historical changes in breast screening in the last 
century. The first attempts to produce a methodology for breast screening date back to the 
beginning of the 1900s. However, mammography did not begin to emerge until the 1960s, 
when higher quality image producing methods were made available. 
Screening techniques (up to date X-ray mammography is the most used), are based on three 
distinct stages. The first one is the identification of abnormalities in breast tissue. This can be 
achieved either by physical examination, or by imaging technique. In general, physical 
examination is perceived as a less effective method; however, even the most advanced 
imaging devices are not error free, as will be discussed in the following. 
The second stage is that of diagnosis of the identified abnormality, as benign or malignant, by 
using either other imaging devices, or biopsy procedures. The choice is highly dependent on 
the conditions of the abnormality, as biopsy is a highly invasive operation. 
Finally, abnormalities labelled as malignant must be further investigated, by means of 
biochemical procedures, and staged according to tumour size and the extent of invasion, and 
metastasis to determine a prognosis and an appropriate treatment. 
X-ray mammographies have produced great advances in the detection of BC: in randomised 
clinical trials, it has been proved that screening reduced BC mortality by about 25-30 percent 
in women aged 50 to 70, and about 18 percent in women aged 40-50. However, some 
concerns remain about standard mammography procedures. 
The main inefficiencies of mammography are related to the specificity and sensitivity18 of the 
device. In fact, the level of false positive and false negative19 does represent a major issue, 
especially in a complicated area such as cancer.  
False positive results have an impact both on the clinical and the economic point of view. In 
fact, in case of a positive test, a woman is typically further investigated, possibly by means of 
invasive procedures, which lead to a) impairment in the patient’s quality of life (Lerman et al, 
1991), and b) additional costs for second stage investigations and overtreatments that could be 
avoided. 
As for false negatives, their impact is clearly huge, and affects mostly the clinical level. 
Moreover, because of the potential dire consequences associated with false negative findings, 
the number of lawsuits for medical malpractice stemming from missed cancer diagnoses 
considerably increased, since the massive introduction of screening programs. 
d. Innovation: description, impact on health and on costs 
Conventional X-ray mammography is nowadays a mature technology, widely used. However, 
as reported above, standard film-based mammography can be associated with bias in results, 
                                                 
18 The sensitivity of a device is defined as the ability of a test to correctly identify patients with the investigated 
disease, whereas by the term specificity we refer to the ability of a test to correctly identify patients without the 
investigated disease.  
19 A false positive is a patient who has not the disease, but is positively diagnosed by the test, whereas a false 
negative is a patient for which the test does not identify the presence of the disease, even if it is actually present. 
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and may not provide adequate diagnostic information for some categories of patients, i.e. 
women with radiosense breast tissue.  
The Institute of Medicine – National Research Council (2001) report standard mammography 
misses about 15 percent of breast cancer lesions, and that 60 to 85 percent of the lesions 
detected by mammography are benign, and thus many biopsies could be potentially avoided. 
The current limitations of mammography devices have been driving continuous innovation 
processes, aimed at developing new methods for the detection of BC. Among them, the most 
relevant are digital mammography, computer-aided detection and diagnosis (CAD) devices, 
ultrasound devices, and Magnetic Resonance Imaging (MRI). 
Although different in nature and in the technologies used (see Table A.4.1), these new tools 
share some common features. In fact, all of them derive from the need of reducing the biases 
of standard mammography devices, in terms of specificity and sensitivity. In addition, all of 
these devices can be used jointly with mammography, in order to provide a better estimation 
and to avoid useless interventions. 
Several economic evaluations have been performed recently. Gold et al (1996) report that the 
cost per years of life gained using mammography is within the threshold of $50,000/QALY, 
which is perceived as a reasonable range. However, other studies, such as that of Rosenquist 
and Lindfors (1998) suggest high variability in the results, depending on age, screening 
interval, and the assumed effectiveness or benefit measure, typically a given percentage 
decrease in BC mortality. 
Other comparisons have been performed between standard mammography and the newer 
technologies: for instance, digital mammography was compared to film screen devices; so far, 
the cost of new machines is significantly higher (about $450,000 per unit, as compared with 
about $70,000 per standard mammography device). In addition, the real improvements in 
specificity and sensitivity have not been fully explored. A simulation study conducted by 
Nields and Galaty (1998) showed that even a low increase of the devices predictive capability 
(number of BC accurately detected) of about 2 percent could turn to produce savings, due to 
the reduced number of unnecessary follow-up biopsies. 
Due to the lack of substantial data sets linking the newer BC detection devices and the alleged 
reduction in BC mortality rates (Institute of Medicine – National Research Council, 2001), 
some simulation studies have also analysed the economic impacts of MRI. A major result was 
that this technology could turn out to be to be particularly effective, and cost-effective 
especially within young women (Plevritis, 2000). However, although these results can provide 
useful information for policy makers, they suffer from being inadequate in terms of coverage 
perspective, not being based on clinical trials. 
Conclusions 
Breast cancer screening is somehow an archetypical topic in the health technology assessment 
field. In fact, several pieces of evidence show that the patients can benefit from these 
procedures, although concerns remain due to: a) the fact that screening is not per se a life 
saving procedure; and b) the high costs associated. 
The potentiality of BC screening devices has always been high, as this industry is linked to 
high-tech counterparts (i.e. some newly researched devices are partly funded by institutions 
such as Military Departments). 
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However, further and more up-to-date investigations are needed in order to assess the actual 
effectiveness, and more specifically the actual cost-effectiveness of these innovations. The 
increase of the overall costs associated with the pathology can be attributed to the highly 
innovative nature of the industry, besides the high prevalence.
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5. COMPETITIVENESS, PRODUCTIVITY AND INDUSTRY STRUCTURE 
Summary of the chapter 
In this chapter we provide descriptive evidence of the level of competitiveness of the 
European medical device industry in comparison with the industry in the US and in Japan. 
Competitiveness is a complex concept and different indicators have been considered in this 
Study, ranging from measures of value added and productivity, to trade analysis and industry 
structure indicators.  
The data presented in this chapter show that the European industry is lagging behind the US 
industry, both in terms of production capabilities and international competitiveness. This 
result also holds when analysing the R&D side of the industry (see Chapter 6). 
The European medical device industry is extremely heterogeneous both across sub-markets 
and countries that show different levels of production, value added, and outcomes in terms of 
productivity and international trade.  
Even though the analysis of product flows between countries shows the leading role of the US 
on the international scene, European countries have a competitive position in most of the 
diagnostic equipment segment of the industry. 
The analysis of the structure of the industry reveals that European firms are smaller and less 
diversified than US counterparts, a pattern which is likely to have implications in terms of 
minor resources and funding for research activities.  
5.1 Introduction and methodology 
This chapter presents indicators of market structure and dynamics for the medical device 
sector. The analysis will be performed at two different levels of aggregation: 
 at a national level, an assessment of the performance and characteristics of the industry 
will be used to characterise the main worldwide producers, and to compare, at the macro 
level, the performance of different countries. Data for the analysis are drawn from 
different sources20. Different data sources employ different classifications and definitions; 
therefore particular care has to be paid in the international comparison of national trends 
and performances. 
 at a more disaggregated level, we have employed data from the US Food and Drug 
Administration (FDA), containing fine-grained information about registered companies 
and medical device products, to characterise the industry at the micro level. We focused 
on the structure of the industry, particularly in relation to the level of competition and 
corporate diversification, both across sub-markets and geographical boundaries. In order 
to get a comprehensive picture, the analysis in the next chapter will take into 
consideration the processes and characteristics of technological innovation in medical 
devices. 
                                                 
20 For the EU data are from Eurostat; for the US from: US Census, AdvaMed and the US International Trade 
Commission; for Japan from the Ministry of Health, Labor and Welfare of Japan. 
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It is important to point out that the extent of the analysis performed here has been determined 
by data availability and quality and international comparisons are severely undermined due to 
lack of data uniformity at an international level. 
5.2 Productivity indicators and snapshot of the industry 
In this Section, we perform a comparative analysis of trends and patterns of the EU medical 
device industry with respect to the industry in the US and in Japan. A number of indicators 
and variables will be reviewed. The medical device industry is highly heterogeneous both 
across countries and at the sub-market level. When data are available, we will perform the 
analysis at the sub-market level and at Member State level in order to account for this 
heterogeneity. 
Box 1: Data comparability issues – production, employment and value added 
The analysis presented in this section has been based on various sources. For EU Member States, data 
have been collected from the Eurostat NewCronos database (Eurostat, 2004a). We considered the 
NACE 33.1 category, which reports data regarding the “Manufacture of medical and surgical 
equipment and orthopaedic appliances”. This class includes the manufacture of instruments and 
appliances used for medical, surgical, dental or veterinary purposes, manufacture of syringes, needles 
used in medicine, mirrors, reflectors, endoscopes, etc., manufacture of medical, surgical, dental or 
veterinary furniture, and manufacture of orthopaedic appliances.  
Data for Japan are based on data published by the Ministry of Health, Labour and Welfare (MHLW), 
and they have been obtained trough the Japanese Federation of Medical Device Associations 
(JFMDA).  
For the US, various data sources have been accessed, including AdvaMed and the US Census Bureau. 
For the US census data relevant NAICS sectors have been summed up: In-Vitro Diagnostic Substance 
Manufacturing (NAICS 325413); Laboratory Apparatus and Furniture Manufacturing (NAICS 
339111); Surgical and Medical Instrument Manufacturing  (NAICS 339112); Surgical Appliance and 
Supplies Manufacturing (NAICS 339113); Dental Equipment and Supplies Manufacturing (NAICS 
339114); Ophthalmic Goods Manufacturing (NAICS 339115); Electromedical and Electrotherapeutic 
Apparatus Manufacturing (NAICS 334510); Irradiation Apparatus Manufacturing (NAICS 334517). 
One major difference between the aggregate for the EU on the one side, and the US and Japan on the 
other is the inclusion in the latter two of in vitro diagnostics (IVD). NACE 33.1 does not include in 
vitro diagnostics, which are instead included in other classes (i.e. NACE 24.4 “Manufacture of 
pharmaceutical preparations” and 24.6 “Manufacture of other chemical products”). 
When data allows, we will present figures for the US both considering and excluding the NAICS 
325413 (IVD). 
Chapter 7 provides a more detailed description of available data sources and their shortcomings. 
a. Production, employment and productivity 
We start by exploring the macro-dynamics at work in this industry by looking at the value of 
production and value added in the EU, US and Japan.  
Tables 1 and 2 report, respectively, the value of production and value added together with the 
share in total manufacturing. 
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The US is the top producer in the medical device industry at a worldwide level. The 
production in the EU is roughly half21 that of the US. Japan is the third world producer. 
Medical device production is on the rise at the global and national level. In particular, 
production in the new Member States has increased steadily from 1999 to 2002. 
Table 1. Medical device real production value (constant 1995 € million), and share of 
production value in manufacturing total 
Country 1997 1998 1999 2000 2001 2002 2002 
 € € € € € € % 
US 48112 50220 52886 54698 55002 52100 2.0 
Japan 12368 12444 12363 12597 13057 13118 0.5 
EU-25 n.a. n.a. n.a. 29155 32139 33803 0.8 
EU-15 n.a. n.a. 29228 28212 31059 n.a. 1.1 
New Member States n.a. n.a. 510 561 614 705 0.3 
Source: AdvaMed (2004); MHLW (2004); Eurostat (2004a; see Table A.5.1 for details about data availability for 
EU Member States); OECD (2004; for total manufacturing in Japan and in the US). 
Note: for data and aggregates definition see Box 1. 
High heterogeneity exists across Member States (see Table A.5.1 in the Annex): for 2001, the 
share of medical device production over total manufacturing ranges from 0.1 percent 
(Portugal) to 3.8 percent (Ireland). As for Ireland, this figure has more than doubled from 
1997 to the year 2001 and it is still increasing in the year 2002 peaking 4.1 percent of total 
manufacturing production. Germany is the top medical device producer in Europe, followed 
by France, Italy, Ireland, and the UK.  
A similar pattern emerges from data on value added. 
                                                 
21 Aggregates for the EU have been obtained as the sum of available data; some data are missing for a few 
Member States, see Table A.5.1 in the Annex. 
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Table 2. Medical device value added at factor cost (constant 1995 € millions), and share 
of value added in manufacturing total 
Country 1997 1998 1999 2000 2001 2002 2002 
 € € € € € € % 
US 31778 33790 35257 36776 37625 38911 3.1 
US (excl. IVD) 27163 29201 30188 31590 32197 35246 2.8 
Japan 14729 14838 14467 14706 14779 n.a. 1.6 
EU-25 n.a. n.a. n.a. 13937 14709 n.a n.a 
EU-15 n.a. n.a. 14606 13527 14255 12739 1.5 
New Member States n.a. n.a. n.a. 228 271 305 0.6 
Source: US Census (2004); MHLW (2004); Eurostat (2004a; see Table A.5.2 for details about data availability 
for EU Member States); OECD (2004; for total manufacturing in Japan and in the US). 
Note: for data and aggregates definitions see Box 1. Data for Japan are for NACE 33 (“Medical, precision and 
optical instruments, watches and clocks”) 
Table 3 reports the number of employees, and share of employment with respect to the whole 
manufacturing sector. The number of employees in the industry is roughly the same for the 
EU and the US. 
Table 3. Number of employees (thousands) in medical devices and share medical device 
employment in total manufacturing  
Country 1997 1998 1999 2000 2001 2002 2002 
 n. n. n. n. n. n. % 
US 341 354 352 351 353 373 2.4 
US (excl. IVD) 302 314 311 311 312 346 2.2 
Japan 239 234 223 213 213 n.a. 1.9 
EU-25 n.a. n.a. 326 333 352 n.a. 1.2 
EU-15 n.a. n.a. 299 304 319 n.a. 1.3 
New Member States n.a. 27 27 28 32 35 1.1 
Source: US Census (2004); MHLW (2004); Eurostat (2004a; see Table A.5.3 for details about data availability 
for EU Member States); OECD (2004; for total manufacturing in Japan and in the US). 
Note: for data and aggregates definitions see Box 1. Data for Japan are for NACE 33 (“Medical, precision and 
optical instruments, watches and clocks”) 
Consistently with the findings about value added and production, the number of employees in 
Germany is the highest among EU Countries, and has increased over the period 1991-2001. 
However, in the year 2002, the number of employees in this country has significantly 
decreased (see Table A.5.3). Notwithstanding this slowdown in production, the share over the 
total employment is higher in this Country than the EU-15 average, which equals 1.6 percent 
in 2002. Ireland is the Country where the share of employment in manufacturing is the highest 
(6.3 percent) and the number of employees has significantly increased over the period. Where 
 94
available, the data for the share of employment over total manufacturing point to a share for 
the new Member States that is always lower than the EU-15 average. 
A similar number of employees together with large differences in value added between the 
EU and the US are reflected in different value added per employees, a proxy for labour 
productivity (see Table 4).  
Table 4. Medical device real gross value added per person employed (apparent labour 
productivity) (1995 € thousands) 
Country 1997 1998 1999 2000 2001 2002 
US 93,2 95,5 100,2 104,8 106,6 104,3 
Japan 61,6 63,4 64,9 69,0 69,4 n.a. 
EU-25 n.a. n.a. n.a. 36,8 36,6 n.a. 
EU-15 36,4 35,8 39,1 41,7 40,5 n.a. 
New Member States n.a. n.a. n.a. 9,1 5,5  
Source: Eurostat (2004a); US Census (2004); OECD (2003). 
Note: for data and aggregates definitions see Box 1. Data for Japan are for NACE 33 (“Medical, precision and 
optical instruments, watches and clocks”) 
Apparent labour productivity for the EU is significantly lower than for the US and Japan. The 
figures show an upward trend for all areas, but while for the EU (EU-15) between 1997 and 
2001 it has increased by 10 percent, in the US the increase has been 15 percent, and in Japan 
12 percent. 
 
Denmark, France, and Ireland represent exceptions to the general trend in Europe (see Table 
A.5.4). The Irish industry has witnessed a sharp increase in labour productivity over the 
period 1998-2002 (+73,2 percent), and, since 1999, it has registered the highest value added 
per person employed among the European countries. 
b. Trade flows 
Taking a different perspective, the assessment of the competitive position of the EU, Japan, 
and the US can be made by looking at the trade flows of medical device products. Here, the 
analysis focuses on the import and export of products. In the next chapter we will also take 
into consideration the international flow of technologies within the medical device industry. 
The analysis of these two patterns will allow for identifying the competitive position of the 
European countries, the US and Japan in the medical device industry both in terms of 
products and technologies. 
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Box 2: Data comparability issues – trade flows 
The analysis is based on the Eurostat ComExt Database and on the Trade Database of the US 
International Trade Commission, that record the amount, source, and destination of trade flows. 
The two data sources employ different classification systems. Eurostat uses the “Combined 
Nomenclature” (CN), while the US International Trade Commission database employs the 
“Harmonised Tariff Schedule” (HTS). However the two classification systems can be matched at 
the six-digit level that is the level of aggregation that is employed in this analysis.  
In order to be consistent with the analysis presented at the beginning of this section, the aggregate 
used for the analysis has been composed in harmony with the NACE 33.1 class (see Box 1 and 
Chapter 7 for details). The six-digit level of disaggregation has been considered in the analysis, as 
reported in the table. The table also reports the codes that will be employed in the figures that 
follow. The first digit of each code groups the products into product classes: diagnostic equipment 
(d), other electronic devices (e), disposables (x), dental devices (t), ophthalmic (o), mechano-
therapy (m); implantable high-tech devices (h), other implantables (i), furniture (f), apparatus for 
other uses (u).  
Sub-markets considered in the international trade flows analysis 
Code CN/HTS Description 
d0 902290 X-ray generators other than x-ray tubes, high tension generators, control panels and desks, 
screens, examination or treatment tables, chairs and the like, and general parts and accessories 
for apparatus of heading 9022, n.e.s. 
d1 901812 Ultrasonic scanning apparatus 
d2 901813 Magnetic resonance imaging apparatus 
d3 901814 Scintigraphic apparatus 
d4 901820 Ultra-violet or infra-red apparatus used in medical, surgical, dental or veterinary sciences 
d5 902212 Computer tomography apparatus 
d6 902213 Apparatus based on the use of x-rays for dental uses 
d7 902214 Apparatus based on the use of x-rays, for medical, surgical or veterinary uses (excluding for 
dental purposes and computer tomography apparatus) 
d8 902221 Apparatus based on the use of alpha, beta, or gamma radiation for medical, surgical, dental or 
veterinary uses 
d9 902230 X-ray tubes 
e1 901811 Electro-cardiographs 
e2 901819 Electro-diagnostic apparatus, including apparatus for functional exploratory examination or for 
checking physiological parameters (excluding electro-cardiographs) 
e3 901890 Instruments and appliances used in medical, surgical, dental or veterinary sciences n.e.s. 
f1 940210 Dentists’, barbers’ or similar chairs and parts thereof 
f2 940290 Other furniture 
h1 902111/ 
902131 
Artificial joints, for orthopaedic purposes  
h2 902150 Pacemakers for stimulating heart muscles (excluding parts and accessories) 
i1 902119/ 
902110 
Orthopaedic appliances and fracture appliances (excluding artificial joints) 
i2 902130/ 
902139 
Artificial parts of the body (excluding artificial teeth) 
i3 902140 Hearing aids (excluding parts and accessories) 
i4 902190 Articles and appliances, which are worn or carried, or implanted in the body, to compensate for 
a defect or disability (excluding artificial parts of the body, complete hearing aids and complete 
pacemakers for stimulating heart muscles) 
m1 901910 Mechano-therapy appliances, massage apparatus and psychological aptitude-testing apparatus 
m2 901920 Ozone therapy, oxygen therapy, aerosol therapy, artificial respiration or other therapeutic 
respiration apparatus 
o1 901850 Ophthalmic instruments and appliances n.e.s. 
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Code CN/HTS Description 
t1 901841 Dental drill engines, whether or not combined on a single base with other dental equipment 
t2 901849 Instruments and appliances used in dental sciences n.e.s. 
t3 902121 Artificial teeth 
t4 902129 Dental fittings (excluding artificial teeth) 
x1 901831 Syringes, whether or not with needles, used in medical, surgical, dental or veterinary sciences 
x2 901832 Tubular metal needles and needles for sutures, used in medical, surgical, dental or veterinary 
sciences 
x3 901839 Needles, catheters, cannulae and the like, used in medical, surgical, dental or veterinary sciences 
(excluding syringes, tubular metal needles and needles for sutures) 
u1 902219 Apparatus based on the use of x-rays for other uses 
u2 902229 Apparatus based on the use of alpha, beta, or gamma radiations, for other uses 
    
First, we considered the medical device aggregate obtained as the sum of the subclasses listed 
in the table in Box 1. Trends in the total exports, imports, and “trade balance” are presented in 
Figures 1-3.  
Figure 1. Total exports, medical devices, EU-15, US, Japan, 1988-2004, € billion 
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Source: Eurostat (2004b), US International Trade Commission (2004), MWLH (2003). 
 97
An upward trend characterises the total exports of the EU22 and of the US, while Japan is 
characterised by lower and stable dynamics. Total exports from the EU are higher than 
exports from the US. However, when considering only extra EU-15 exports, the value for the 
US and Europe are much more similar.  
On the other side, if we look at total imports, Japanese, extra EU-15 and US values are similar 
and show similar patterns (see Figure 2).  
Figure 2. Total Import, medical devices, EU-15, US, Japan, 1988-2004, € billion 
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Source: Eurostat (2004b), US International Trade Commission (2004), MWLH (2003). 
An important impetus to intra-EU trade is believed to have come from the 1993 European 
Directive on Medical Devices, which set out the classification criteria for medical devices and 
outlined the appropriate conformity assessment procedures for each class of device at a 
European level. 
In order to measure the trade balance, we computed the share of exports over the total trade 
(the sum of imports and exports). This index ranges from 0 (the country only imports) to 1 
                                                 
22 Total exports for the EU are the sum of intra and extra EU trade; Extra-EU figures do not include intra-EU 
trade. 
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(the country only exports) and it equals 0.5 in case the value of imports is the same of the 
value of exports23.  
Japan is the major net importer of medical devices, and its imports largely exceed exports. 
The US trade balance for medical devices has been deteriorating in recent years when the 
value of the index has decreased, pointing to a larger increase of imports with respect to 
exports. The trade balance for the EU does not show any particular trend, and the medical 
device industry gives a positive contribution to the European trade balance (see Figure 3). 
Figure 3. “Trade Balance” (ratio of export over total trade), EU-15, US, Japan, 1988-
2004  
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Source: Eurostat (2004b), US International Trade Commission (2004), MWLH (2003). 
Next, we move to a more disaggregated level, and consider data at the submarket level, 
following the classes presented in Box 2. The analysis can show in which sub-markets EU 
and US are net exporters or importers, and the magnitude of this phenomenon. Figure 4 gives 
a graphical representation of the index of “Trade Balance” in the years 1996 and 2003, while 
Table 5 summarises its magnitude and direction. 
                                                 
23 Trade balance is normally defined as the difference or the ratio of imports and exports. A different index was 
introduced here to be use in the following correspondence analysis. 
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Figure 4. “Trade Balance” (ratio of export over total trade), at the sub-market level, 
EU-15, US, 1996, 2003 
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Source: Eurostat (2004b), US International Trade Commission (2004). 
Note: see Box 2 for the correspondence of the abbreviations. 
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Table 5. Direction and magnitude of the “Trade Balance”, at the sub-market level, EU-
15, US, 1996, 2003 
EU-15 US 
Code Description 1996 2003 1996 2003
 diagnostic equipment     
d0 X-ray generators other than x-ray tubes, high tension generators, control panels 
and desks, screens, examination or treatment tables, chairs and the like, and 
general parts and accessories for apparatus of heading 9022, n.e.s. 
+ + + + 
d1 Ultrasonic scanning apparatus - - ++ + 
d2 Magnetic resonance imaging apparatus + + ++ - 
d3 Scintigraphic apparatus -- - ++ + 
d4 Ultra-violet or infra-red apparatus used in medical, surgical, dental or veterinary 
sciences 
+ - + - 
d5 Computer tomography apparatus + + -- - 
d6 Apparatus based on the use of x-rays for dental uses ++ ++ -- -- 
d7 Apparatus based on the use of x-rays, for medical, surgical or veterinary uses 
(excl. for dental purposes and computer tomography apparatus) 
+ + - - 
d8 Apparatus based on the use of alpha, beta, or gamma radiations, for medical, 
surgical, dental or veterinary uses 
+ + ++ - 
d9 X-ray tubes + + + + 
 other electronic device     
e1 Electro-cardiographs + + ++ + 
e2 Electro-diagnostic apparatus, incl. apparatus for functional exploratory 
examination or for checking physiological parameters (excl. electro-
cardiographs) 
+ + + + 
e3 Instruments and appliances used in medical, surgical, dental or veterinary 
sciences n.e.s. 
- + + + 
 forniture     
f1 Dentists',  barbers'  or  similar  chairs  and parts thereof + - + - 
f2 other + + ++ + 
 implantable high tech     
h1 Artificial joints, for orthopaedic purposes - - ++ + 
h2 Pacemakers for stimulating heart muscles (excl. parts and accessories) - + ++ -- 
 other implantable     
i1 Orthopaedic appliances and fracture appliances (excl. artificial joints) - - + + 
i2 Artificial parts of the body (excl. artificial teeth) - - ++ + 
i3 Hearing aids (excl. parts and accessories) + + - -- 
i4 Articles and appliances, which are worn or carried, or implanted in the body, to 
compensate for a defect or disability (excl. artificial parts of the body, complete 
hearing aids and complete pacemakers for stimulating heart muscles) 
- - ++ + 
 mechano-therapy     
m1 Mechano-therapy appliances, massage apparatus and psychological aptitude-
testing apparatus 
+ + - -- 
m2 Ozone therapy, oxygen therapy, aerosol therapy, artificial respiration or other 
therapeutic respiration apparatus 
+ + + - 
 ophthalmic     
o1 Ophthalmic instruments and appliances n.e.s. - + ++ + 
 dental     
t1 Dental drill engines, whether or not combined on a single base with other dental 
equipment 
++ + ++ + 
t2 Instruments and appliances used in dental sciences n.e.s. - + + - 
t3 Artificial teeth - - + + 
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EU-15 US 
Code Description 1996 2003 1996 2003
t4 Dental fittings (excl. artificial teeth) - - ++ + 
 disposable     
x1 Syringes, whether or not with needles, used in medical, surgical, dental or 
veterinary sciences 
+ + ++ + 
x2 Tubular metal needles and needles for sutures, used in medical, surgical, dental 
or veterinary sciences 
- + + - 
x3 Needles, catheters, cannulae and the like, used in medical, surgical, dental or 
veterinary sciences (excl. syringes, tubular metal needles and needles for 
sutures) 
+ + ++ + 
Legend: 
- value of the index <0.25 
-- value of the index  ≥0.25 and <0.50 
+ value of the index  >0.50 and <0.75 
++ value of the index ≥0.75 
 
Dental and high-tech implantable devices are sub-markets where the US is a major net 
exporter, while the global position of the EU countries is weaker. This is also the case of other 
implantable and electronic devices. As for the diagnostic equipment segment (d), with few 
exceptions (ultrasonic scanning apparatus and scintigraphic apparatus) the European countries 
are major net exporters. In the ultraviolet or infrared apparatus sub-market (d4) the EU has 
worsened its position becoming a net importer of this kind of devices in 2003. 
Figures 5 and 6 focus on the international trade flows between the EU on the one side, and the 
US and Japan on the other. These are represented for 1996 (Figure 5) and 2003 (Figure 6). EU 
Trade flows from/to the US and Japan have been calculated separately (and represented in the 
two axes in the Figures below).  
The EU appears as a major net exporter of diagnostic equipment, having a positive trade 
balance with both the US and Japan: most of the products within the diagnostic equipments 
category (whose first digit is “d” in the figure) are placed in the top right panel in Figures 5 
and 6 (i.e., our measure of “trade balance” is greater than 0.5 in both cases). The exceptions 
are the sub-market of the ultrasonic scanning apparatus, where the EU has a negative trade 
balance both with respect to the US and Japan, and scintigraphic apparatus, where the EU is a 
major importer from the US. In 2003, the EU has become a net exporter of pacemakers (h2) 
both with respect to the US and Japan. 
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Figure 5. “Trade Balance” (ratio of export over total trade), at the sub-market level, 
EU-15 with respect to US and Japan, 1996  
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Source: Eurostat (2004b). 
Figure 6. “Trade Balance” (ratio of export over total trade), at the sub-market level, 
EU-15 with respect to US and Japan, 2003  
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Source: Eurostat (2004b).
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Finally, correspondence analysis has been employed to study the pattern of specialisation of 
country’s flows of international trade (see Box 3). This technique has been applied to a matrix 
containing information about the “trade balance” of each country at the product level. Each 
row of the matrix is assigned to a product, and each column represents a country. The entries 
in the matrix report for each country, at the product level, the “trade balance” as measured by 
the ratio of exports over total trade (imports plus exports). 
Box 3: Correspondence Analysis 
Correspondence analysis is a statistical methodology that allows the graphic and synthetic analysis 
and description of large two-dimensional tables by finding the best simultaneous representation of the 
row and the columns in the table.  
It is often applied to contingency tables, i.e. tables in which you find at the intersection of a row and a 
column the number of units (which might be, for example, individuals or firms) that share the 
characteristic of the row and that of the column, but it can also be extended to other settings, as is the 
case in this Study. Only one restriction on the data is necessary for the analysis: the entries in the cells 
of the table must be non-negative numbers. 
The analysis highlights patterns of similarities among the rows and the columns of the table and 
allows identifying the existence of relationships between them.  
The main output of the analysis, the one that is mostly relevant for this Study, is a graphical 
representation on a two-dimensional plane, giving a synthetic representation of the structure of the 
data points, and allowing the comparison with the hypothetical situation of independence between the 
rows and the columns. 
The graph can be interpreted along two dimensions. First the positions relative to an axis of the points 
belonging to a same group (either row or column data points) give information about the similarities 
of profiles within each group. Two data points that are close on the graph also have a similar profile.  
For comparing data points belonging to different groups one can interpret at the angle between a row 
point and a column point (taking the origin as the summit). If the angle between the points is acute 
(<90º) the two characteristics for which the points stand for are correlated. On the contrary, if the 
angle is obtuse, the points are negatively correlated. Finally, if there is a right angle, the points do not 
interact. 
 104
Figure 7. Correspondence analysis: countries’ patterns of specialisation, 1996 
-1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1-0.8 
-0.6 
-0.4 
-0.2 
0 
0.2 
0.4 
0.6 
0.8 
 FR
 NL
 DE
 IT
 UK
 EI
 DK
 PT
 ES
 BL
 SE
 FI 
 AU
 US
e1
d1
d2 
d3
e2
d4
x1
x2
x3t1 
t2
o1
e3
m1
m2
h1
i1 t3
t4
i2
i3
h2
i4
d5
d6
d7
u1
d8
u2 
d9
d0
Correspondence analysis, 1996
 
Source: Eurostat (2004b). 
Figure 8. Correspondence analysis: countries’ patterns of specialisation, 2003 
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Source: Eurostat (2004b). 
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The analysis allows us to disentangle the similarities between countries and products in terms 
of “trade balance”, and to understand the competitive position of the countries across the 
different sub-markets. The analysis has been performed using data from the years 1996 
(Figure 7) and 2003 (Figure 8). 
The similarities between countries and their specialisation profile have changed over time. 
This happened particularly in the case of Ireland, where its “trade balance” profile was similar 
to those for the US and Germany in 1996, while it is placed quite far from these countries in 
2003.  
While in 1996 Germany and the US had very similar profiles (indeed the two countries are 
placed very close in the figure), in 2001 they have quite distinct profiles. In 2003, Germany, 
together with the Netherlands and Italy, has a profile that reflects specialisation in large 
diagnostic equipment (particularly ultraviolet and infrared apparatus, magnetic resonance 
imaging apparatus and apparatus based on the use of alpha, beta, or gamma radiation). 
In both years, Finland has quite specific features, being specialised in MRI (d2) and X-ray 
apparatus for dental uses (d6). Spain and Denmark show similar profiles in both years. 
Finally, in order to characterise the main partners of the EU countries and the US, we 
employed a network representation. Figure 9 visually represents the trade flows among the 
countries in the analysis.  
The network has been built considering the share of exports for European countries, the US 
and Japan. The existence of a tie between country X and Y (i.e. of an arrow starting from X 
and pointing towards Y) means that the share of exports for the country X to the country Y is 
greater than 15% (where shares have been computed over the total value of exports to the 
countries included in the analysis). The size of each country (node) in the drawing is 
proportional to the value of the exports of the countries to the other countries included in the 
analysis. 
Figure 9. Network representation of international trade flows, 2003 
 
 
Source: our elaborations on Eurostat (2004b), US International Trade Commission (2004). 
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The picture clearly shows the role of the US as the preferred partner of European countries 
and Japan. Germany is the European country with the largest export value and also the one 
with the most number of ties with other countries. Japan has ties with the US and Germany. 
Ireland has significant commercial ties with the US and the Netherlands. 
5.3 Market structure 
In this section we will develop indicators of market structure and dynamics, and we will 
present the results both at the aggregate level (for the whole medical device industry) and at 
the level of specific medical device sub-sectors.  
This section, more than the others, has been limited by poor data availability and quality.  
a. Number and size of firms  
A first account of the structure of the medical device industry can be obtained by the number 
of firms that are active in the countries taken into consideration. The US Census Bureau 
reports in the 2002 data for about 6,007 establishments24 operating in the medical device 
sector. Another useful source is given by the FDA establishment registry25. The FDA register 
11,409 US establishments involved in the manufacturing of medical devices owned by 10,027 
corporations (about 2 percent are non-US owner groups).  
For the European countries (EU-25), the NewCronos database (Eurostat, 2004a) reports about 
50,000 enterprises26 operating in the NACE 33.1. Eucomed (2004) reports about 8,500 
companies in Europe, while the European establishments registered with the FDA are 1,887, 
owned by 1,793 different groups (11.27 percent are US companies). 
A total of 5,040 companies are registered in Japan with the JFMDA, with 1,289 companies 
registered with the Japan Association of Health Industry Distributors. Japanese establishments 
registered with the FDA are 540 (457 owner groups). 
The composition, in terms of firm size, of the medical device industry in the US, the EU (both 
EU-15 and EU-25) and Japan is depicted in Figure 10, which reports the percentage of firms 
within classes defined according to the number of employees. The EU is characterised by a 
large share of small firms: more than 80 percent of the enterprises are small with less than 10 
employees. 
                                                 
24 “An establishment is a single physical location at which business is conducted and/or services are provided. It 
is not necessarily identical with a company or enterprise, which may consist of one establishment or more” (see 
http://www.census.gov/econ/census02/text/sector00/estab.htm).  
25 The registry lists all the “establishments engaged in the manufacture, preparation, propagation, compounding, 
assembly, or processing of medical devices intended for human use and commercial distribution. Foreign 
establishments that export to the U.S are also required to register” (see http://www.fda.gov/cdrh/databases.html). 
Detailed information about the operation activities of each registered establishment and its owner group are 
reported. Also the country of the establishment and of the owner group is reported. 
26 An enterprise is defined as “the smallest combination of legal units which constitutes an organisational unit for 
the production of goods and services enjoying certain decision-making autonomy, in particular for the allocation 
of its current resources. An enterprise carries out one or more activities in one or more places. An enterprise may 
correspond to a single legal unit” (Eurostat, 2003). 
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Figure 10. Size distribution of the firm in the medical device industry, EU (2001), US 
and Japan (2002) 
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Source: Eurostat (2004a); US Census (2004); MHLW (2003). 
As for Japan, data are based on a survey of about 2,800 medical device firms performed by 
the MHLW (MHLW, 2003). 1,574 companies participated in the survey, yielding a 56.2 
percent response rate. It is likely that no response firms are very small due to the lack of 
personal resources. However, if non-respondent firms were all in the 1-9 employees category, 
the share of those firms over the total would be roughly 65 percent, still lower than the share 
of small firms in the EU. 
Table 6 reports the distribution of the number of employees by firm size27 and, in the last 
column of the table, an index that compares the average number of employees per 
establishment/enterprise in the medical device industry and the same figure in the total 
manufacturing industry28. The interpretation of the size index is the following: it represents 
the average size of the enterprises/establishment in the medical device industry as a 
percentage of the average size of the enterprise/establishment in the manufacturing industry. 
                                                 
27 Analogously with Figure 10, firm size is measured in terms of the number of employees. The table differs 
from the graph since the share of the number of employees (rather than the share of the number of firms) is 
considered. 
28 The average size of the enterprise/establishment has been computed as the ratio of the total number of 
employees over the number of enterprises/establishments for each country. Then the size index has been 
obtained taking the ratio of the average size in the medical device industry and the average size in total 
manufacturing, multiplied by 100. 
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Table 6. Number of employees, by firm size (employees) 
  
Number 
of 
employees
1-19  
(%) 
20-49 
(%) 
50-99 
(%) 
100-249 
(%) 
250-499 
(%) 
500-999  
(%) 
more 
than 
1000  
(%) 
Size 
index 
US 361,384 5.78 7.87 9.61 20.48 18.13 18.32 19.81 142.41 
EU15 308,019 41.22 12.98 7.25 11.84 4.73 2.47 0.00 52.00 
NMS 409,67 37.16 8.08 6.55 7.87 1.89 9.86 0.03 10.66 
EU25 358,500 39.94 12.75 8.23 12.52 8.37 8.90 n.a. 41.77 
Germany 145,037 47.02 13.47 7.18 9.11 6.23 n.a. n.a. 39.24 
France 42,527 38.84 12.22 8.55 15.37 n.a. 4.91 n.a. 34.43 
UK 35,082 30.41 13.43 9.29 22.04 n.a. 8.50 n.a. 89.20 
Italy 25,692 43.45 15.89 8.50 16.05 6.25 9.86 0.00 20.22 
Poland 17,229 49.94 4.35 8.56 9.23 4.49 23.44 0.00 28.54 
Ireland 14,770 0.81 2.16 4.08 n.a. n.a. n.a. n.a. n.a. 
Spain 11,845 54.46 19.19 n.a. 11.71 0.00 n.a. 0.00 25.85 
Sweden 9,356 22.93 13.44 6.62 n.a. 28.89 n.a. n.a. 56.44 
Czech Rep. 8,649 35.69 14.29 12.79 8.02 n.a. n.a. 0.14 57.30 
Denmark 7,142 15.57 n.a. 7.62 21.06 17.08 n.a. 0.00 75.82 
other 31,657 44.62 12.42 3.74 9.18 0.00 0.00 0.00 -- 
Source: US Census (2004); Eurostat (2004a). 
The average size of the US establishment in the medical device industry is 142.41 percent the 
average size for the total manufacturing sector, pointing to a size of medical device 
establishments that are, on average, larger than the industry as a whole. The opposite is true 
for the European countries, where the average medical device enterprises are smaller than the 
average enterprise in the total manufacturing. Together with the size distribution depicted in 
figure 10, this result points to a different composition in terms of size of the firms operating in 
the medical device industry in the US with respect to the EU, where the industry is populated 
by small firms. This may have relevant implications in terms of available resources and 
funding of research activities. Another relevant aspect concerns the level of diversification 
both across sub-industries, and within each segment of the firms’ production. 
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b. Corporate ownership 
In order to characterise the medical device industry in terms of diversification of the actors 
involved, we employed FDA data. This data source allows an analysis at the sub-market level, 
since all products commercialised in the US are listed and classified according to their 
product class and medical specialty (see Table A.5.6 in Annex 5). The classification 
comprises 4,950 product classes, grouped into 19 medical specialties. In addition, for each 
product the database lists the establishment involved in the manufacturing activities and its 
owner group, providing a useful source of information for computing the share of ownership 
by home country corporations, European corporations (we considered EU-15 plus 
Switzerland and Norway), US and Japanese corporations, for each country (with at least one 
manufacturer registered with the FDA). Results are reported in Table 7. 
The fact that the database refers to the US could determine a bias towards US corporations; 
however, given that the US is the largest market in the world, and that it is targeted by most 
world producers, the following analysis has a good level of generalisation, and can provide 
relevant information about the structure and the characteristics of the medical device industry. 
Table 7. Share of corporate ownership, by establishment country 
Owner/Operator Group Country (%)  Establishment 
Country Europe Home Japan Other US N 
US 1.29 98.24 0.15 0.32 0.00 11,406 
Germany 92.94 91.07 0.21 0.21 6.65 963 
Canada 0.37 91.70 0.18 0.00 7.75 542 
UK 86.76 83.88 0.38 0.38 12.48 521 
Japan 0.60 97.82 0.00 0.00 1.59 504 
Italy 96.67 93.79 0.00 0.67 2.66 451 
France 88.54 84.72 0.35 1.04 10.07 288 
Switzerland 98.02 83.82 0.00 0.58 10.40 173 
Sweden 91.52 86.67 0.00 0.61 7.88 165 
Netherlands 88.51 81.61 0.00 0.00 11.49 87 
Denmark 91.77 90.59 0.00 1.18 7.06 85 
Ireland 38.56 31.33 0.00 1.20 60.24 83 
Spain 90.00 80.00 0.00 0.00 10.00 60 
Belgium 91.49 87.23 4.26 0.00 4.26 47 
Finland 82.61 78.26 0.00 0.00 17.39 46 
Austria 95.55 84.44 0.00 2.22 2.22 45 
Hungary 20.00 65.00 0.00 0.00 15.00 20 
Norway 90.00 85.00 0.00 0.00 10.00 20 
Poland 6.25 93.75 0.00 0.00 0.00 16 
Czech Republic 7.69 84.62 0.00 0.00 7.69 13 
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Owner/Operator Group Country (%)  Establishment 
Country Europe Home Japan Other US N 
Estonia 25.00 50.00 0.00 0.00 25.00 4 
Luxembourg 100.00 100.00 0.00 0.00 0.00 4 
Portugal 75.00 50.00 0.00 25.00 0.00 4 
Slovakia 33.33 0.00 0.00 0.00 66.67 3 
Ukraine 33.33 66.67 0.00 0.00 0.00 3 
Lithuania 0.00 100.00 0.00 0.00 0.00 2 
Malta 50.00 0.00 0.00 0.00 50.00 2 
Greece 100.00 100.00 0.00 0.00 0.00 1 
Slovenia 0.00 100.00 0.00 0.00 0.00 1 
Source: our elaborations on FDA (2004c). Europe is EU-15 plus Switzerland and Norway. 
European ownership of US establishments is not as strong as US ownership of European 
establishments. Indeed, while 1.29 percent of US establishments are owned by a European 
corporate group, US corporations own 6.65, 12.48 and 10.07 percent of respectively German, 
British and French establishments. The share is very large for Ireland: 60.24 percent of Irish 
establishments registered with the FDA are owned by a US corporation.  
The US ownership is reduced for the Japanese establishments where only 1.59 percent of 
Japanese establishments is owned by the US. On the reverse side, only 0.15 percent of US 
establishments is owned by a Japanese corporate group. 
The high ownership of European establishments by US corporations can be attributed to the 
large M&A activities that have involved US and European corporations during the 1990s (see 
the analysis in the next chapter). 
c. Specialisation and diversification of national production 
Using the information about the product commercialised by each establishment and the 
country of its corporate group, we have computed the level of specialisation of each country, 
as measured by a Herfindahl-type index of concentration and by the share of the top medical 
specialty. 
The Herfindahl index of concentration is computed as ∑
=
19
1
2
j
ijs  where sij is the share of 
products commercialised by corporations from country i in the medical specialty j. The shares 
have been summed over the total number of medical specialties (19), and the index has been 
computed separately for each country. 
Table 8 lists the total number of firms by nationality of the owner group, the share over the 
total and the Herfindahl and C1 indexes. 
The C1 index is the share of the largest medical specialty in each country, providing 
information about the level of specialisation of country’s activities. On average, European 
countries are more specialised than the US: the level of both the Herfindahl index and of the 
C1 index are higher. Also Japanese production is more specialised than the US production: 
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24.25 percent of the production by Japanese corporation is concentrated in one medical 
specialty. 
Table 8. Diversification of country products 
 N % Herfindahl C1 
US 10,976 46.64 0.0748 13.11 
Germany 1,756 7.46 0.0834 16.34 
China 1,727 7.34 0.1532 21.89 
Taiwan 1,205 5.12 0.1522 25.31 
Pakistan 1,166 4.95 0.1347 23.84 
South Korea 691 2.94 0.1926 35.75 
Canada 683 2.90 0.1024 21.23 
UK 657 2.79 0.0818 17.50 
Italy 553 2.35 0.2580 47.92 
Japan 544 2.31 0.1070 24.45 
Hong Kong 518 2.20 0.2397 40.93 
France 370 1.57 0.1057 22.97 
India 295 1.25 0.1324 21.69 
Israel 257 1.09 0.0840 14.01 
Switzerland 218 0.93 0.1064 20.64 
Sweden 215 0.91 0.0815 13.95 
Malaysia 172 0.73 0.3949 60.47 
Denmark 124 0.53 0.0748 12.90 
Australia 118 0.50 0.0975 18.64 
Mexico 104 0.44 0.1407 23.08 
Netherlands 100 0.42 0.0904 16.00 
Thailand 91 0.39 0.2424 40.66 
Brazil 90 0.38 0.1398 25.56 
Spain 79 0.34 0.1027 15.19 
Belgium 65 0.28 0.0845 13.85 
Russia 61 0.26 0.0922 13.11 
Austria 52 0.22 0.1213 23.08 
Indonesia 50 0.21 0.3032 52.00 
Source: our elaborations on FDA (2004c). Europe is EU-15 plus Switzerland and Norway. 
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To dig further into the patterns of specialisation in countries, we have applied the 
correspondence analysis to the matrix containing the number of products in each medical 
specialty by nationality of the owner corporate group (see Figure 11 – only countries in Table 
8 are considered).  
Figure 11. Correspondence analysis, all countries 
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Specialty codes: an: anesthesiology; cv: cardiovascular; ch: clinical chemistry; tx: clinical toxicology; de: 
dental; en: ear, nose, throat; su: general and plastic surgery; ho: general hospital; gu: gastroenterology/urology; 
he: haematology; im: immunology; mi: microbiology; ne: neurology; ob: obstetrics-gynecology; op: ophthalmic; 
or: orthopedic; pa: pathology; pm: physical medicine; ra: radiology. 
Source: our elaborations on FDA (2004c, 2004d). 
Japan, China, Taiwan, and Austria show a similar specialisation profile. The northern 
European countries (Denmark, Sweden, and the Netherlands, and to some extent the UK) 
show a specialisation profile that is similar to that of the US, structured around 
anaesthesiology, cardiovascular, and pathology devices. Belgium and Germany show a 
different profile and are specialised in obstetrics-gynaecology, general and plastic surgery, 
and orthopaedic. 
Due to the different classification systems employed, it is not possible to compare directly the 
trade data and the specialisation profile of the countries on the product side. 
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Finally, we analysed data at the manufacturer level and we consider an entropy-based 
measure of diversification (Berry, 1975). This index value is zero when the firm’s products 
are concentrated within a single medical specialty. At the other extreme, if the firm’s products 
are spread evenly across the K existing specialties, the firm’s entropy reaches its maximum 
equal to logK. Since the classification in the FDA listing is a hierarchical method of 
classification, and each product can be framed within a larger group defined by a higher level 
of aggregation (i.e. the medical specialty), we decomposed the firm’s total entropy into two 
components: the entropy that exists between and within product classes, providing 
respectively basic measures of ‘broad-spectrum’ and ‘narrow-spectrum’ diversification 
(Baldwin, Beckstead, Gellatly, and Peters, 2000). These measures are defined as follows. 
Let G be the number of sub-classes within each medical specialty and Sg the share of firms’ 
products within class g. We indicate with si the share of the sub-class i within class g. 
The entropy between groups is defined as: ∑
=
G
g
gg SS
1
)/1log( , while the entropy within a group 
is: ∑
∈ gSi
iggi sSSs )/log()/( . Those indexes allow us to evaluate separately the effect of the 
distribution of firm products across separate medical specialties and the distribution of firm 
products among different sub-classes within a medical specialty. 
Results are represented in Figure 12. The continuous and the dotted lines represent 
respectively the average index of total diversification and the average index of between-
entropy diversification.  
Germany is the country whose firms have a higher level of diversification and neither within 
nor between diversification plays a larger role in the level of diversification. Also Irish firms 
present a high degree of diversification, followed by Japan and the US. The Japanese firms 
have a diversification profile where the within diversification, i.e. the diversification of 
products within a medical specialty, plays a larger role (the index of between diversification 
account for about the 25 percent of the total). 
Italy is the country with the lowest level of diversification (among the countries considered) 
and its level of diversification is driven by the diversification within medical specialties. 
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Figure 12. Average entropy diversification index (within and between), by country of 
corporation 
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Source: our elaborations on FDA (2004c, 2004d). 
On the other side, grouping the firms according to the medical specialty they are active in, 
quite different diversification profiles emerge across medical device sub-markets. 
Firms operating in clinical toxicology and immunology show the larger level of 
diversification, whereas the larger role is played by a pattern of diversification into products 
belonging to the same medical specialty. The group with the highest relative contribution of 
the diversification across medical specialties (between-entropy) is given by obstetrics and 
gynaecology. This result confirms once again the high heterogeneity of the medical device 
industry, characterised by different sub-markets with different characteristics. 
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Figure 13 Entropy across medical specialties 
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Specialty codes: an: anaesthesiology; cv: cardiovascular; ch: clinical chemistry; tx: clinical toxicology; de: 
dental; en: ear, nose, throat; su: general and plastic surgery; ho: general hospital; gu: gastroenterology/urology; 
he: haematology; im: immunology; mi: microbiology; ne: neurology; ob: obstetrics-gynaecology; op: 
ophthalmic; or: orthopaedics; pa: pathology; pm: physical medicine; ra: radiology. 
Source: our elaborations on FDA (2004c, 2004d). 
 
 116
6. R&D AND INNOVATION 
Summary of the chapter 
In this chapter we take into account different aspects of the innovation process in the medical 
device sector from patents and scientific publications to the introduction of new devices on 
the market. This analysis is performed in order to assess the level of innovativeness of the 
European medical device industry and to compare it with the ability to innovate of firms and 
institutions operating in the US and Japan. 
First, in order to characterise the innovation process in medical devices, we present a set of 
indicators building upon patents and patent-based measures. The analysis of the information 
about the innovative activities contained in patents highlights the large role for small firms 
and individuals in the innovation process in this industry. Also the knowledge base of the 
medical device industry is more diversified in terms of technological classes, pointing to a 
higher level of interaction between areas in the sector. Here innovation is often related to the 
introduction of new materials or new technologies that have been developed outside the 
medical industry. This result is also confirmed by the diversification profiles of the firms 
innovating in the industry, being active on a more diverse portfolio of technological classes.  
The analysis of the R&D intensity of the sector and the comparison with the US and Japanese 
industries and within Europe across industries, is limited by the inadequacy of the data 
available. The results point to a lower level of R&D intensity of the European firms compared 
to the US. However, this result needs to be treated with caution. High heterogeneity in terms 
of R&D intensity exists across European Member States, and France and Germany are the top 
R&D spenders, followed by UK and Italy. High heterogeneity exists within the industry: 
different sub-markets are characterised by different level of R&D intensity, where high-tech 
segments (in-vitro diagnostics on top of all) present the highest R&D intensity, while 
traditional low-tech segments (laboratory apparatus and furniture, surgical appliance and 
supplies) are associated to the lowest. 
The analysis of the flow of R&D licensing agreements also reveals the role of the US firms as 
net exporter of technologies. Quite different patterns characterise the different segments, and 
the European countries appear to be net exporters of technologies related to implantable 
devices, and of therapeutic equipment and supplies, with respect to the US.  
As for collaborative agreements and licensing agreements for the sector, US show strong 
world dominance both as originator and as developer of licensing agreements. The analysis of 
the output side of the innovation process (number and quality of patents and publications, 
introduction of new devices on the US market) confirms to the leading role of the US, both in 
terms of numbers and “importance”. 
All in all, the analysis points to a lower level of innovativeness of the European industry as 
compared to the US industry. This result, coupled with the evidence presented in Chapter 5, 
presents a picture where the European industry is lagging behind the US industry along 
multiple dimensions taken as proxy for its level of competitiveness and innovativeness. 
6.1 Introduction and methodology 
The innovative activity of firms in the medical device industry has significantly contributed to 
enhance health conditions by helping patients to live longer and better-quality lives. A mail 
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survey was conducted in the US, where primary care physicians were asked to assess the 
relative importance of thirty medical innovations. (Fuchs and Fox, 2001). The ten surveyed 
medical innovations with the largest score and their country of origin are reported in Table 1. 
Table 1. Most important medical innovations and their country of origin 
Rank Technology Description Country of Origin 
1 Magnetic Resonance Imaging; 
Computed Tomography  
Non-invasive methods to view internal 
anatomy 
US; UK 
2 Angiotensin converting enzyme 
inhibitors 
Drugs for hypertension and heart failure 
(main indications) 
US 
3 Balloon angioplasty Minimally invasive surgery to treat 
blocked arteries 
Switzerland 
4 Statins Drugs lowering cholesterol synthesis US, Japan 
5 Mammography Radiographic examination of the breast 
(diagnostic tool to detect breast cancer) 
US 
6 Coronary artery bypass graft surgery Surgical therapy of ischaemic coronary 
artery disease 
US 
7 Proton pump inhibitors; H2-receptor 
antagonist 
Drugs reducing acid production in the 
stomach 
Sweden; UK 
8 Selective serotonin re-uptake 
inhibitors  
Antidepressant drugs US 
9 Cataract extraction and lens implant Eye surgery US, UK 
10 Hip replacement; Knee replacement Joint replacement with mechanical 
prosthesis 
UK; UK, US 
Source: Fuchs and Sox (2001), our search on the web. 
 
Besides assessing the importance of medical technologies, the table suggests the leading role 
of the US in the innovation process. The United States is the country of origin of eight out of 
ten of the medical innovations considered. Among the European countries, the UK and 
Sweden are the only countries appearing in the list.  
However, this is only part of the story. In this chapter, we attempt to characterise the 
innovation process in the medical device industry and to compare countries’ competitive 
advantages and R&D intensity. 
It is well known that measuring innovation is a difficult task and no single indicator can 
provide a satisfactory picture. We therefore take into consideration different aspects of the 
innovation process, looking both at the input and output sides of the research process, and 
different indicators are analysed to understand its characteristics.  
The medical device industry is highly heterogeneous. Different sub-markets coexist that are 
characterised by products at different stages of the product life-cycle and that require a 
different level of resources and investments. Medical device products range from lattice 
balloons to large equipment for therapeutic and diagnostic purposes, requiring considerable 
investment and trained personnel for their functioning. Whenever data at the sub-market level 
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are available, the analysis will attempt to unravel those differences and describe the main 
characteristics of each sub-market. However, different data sources classify medical device 
products according to different criteria, making it difficult to compare country performances 
across different sub-markets and indicators. This has severely limited the extent and 
implications of our analysis. 
In order to better understand the innovation process for the sector, we compared it with the 
pharmaceutical sector. It appears that many distinctive features characterise the nature of 
innovation in medical devices compared to innovation in pharmaceuticals. Using patent data 
from the NBER database29, we highlight the main differences between the two industries, 
with respect to the cumulativeness of knowledge, originality and generality of the knowledge 
base, and to the typology of firms involved in the innovation process (Trajtenberg, 
Henderson, and Jaffe, 1997; Hall, Jaffe, and Trajtenberg, 2001a; Hall, Jaffe, and Trajtenberg, 
2001b).  
The first input to the innovative activity is given by the expenditure in R&D. The analysis of 
Eurostat data (Eurostat, 2004a), measured at a national level, allows us to shape the broad 
picture of the R&D activities performed in Member States. Then, we also consider data at the 
firm level to gather information about the R&D intensity of the firms operating in this 
industry and in specific sub-markets. 
The analysis by firm size shows that smaller firms have a higher R&D intensity than the 
larger ones. This result suggests the existence of a division of innovative labour, where 
smaller firms are highly research intensive, while larger corporations have the resources and 
capabilities that are necessary for the development and commercialisation of new products. In 
order to shed light into this issue, we will analyse deals and collaboration agreements among 
medical device institutions, taking into consideration R&D collaboration and merger and 
acquisitions (M&A) as a means for appropriating knowledge originated outside the firm (and 
institution) boundaries. When compared to the pharmaceutical industry, mergers and 
acquisitions (M&A) have a higher incidence over the total number of deals. 
However, R&D expenditure and collaborations only provide a limited perspective to the study 
of innovativeness. In particular, they convey no information about the output side of the 
innovation process. We further analyse corporations working in the medical device sector on 
the basis of scientific publications and patents. When looking at those measures of the 
innovative activity of organisations, we provide a detailed analysis of industry dynamics and 
firm level strategies, distinguishing on the basis of the location of the organisation under 
study. Given the nature of the products in the medical device industry, a close link with the 
clinical scene is critical for companies that are trying to innovate in the medical fields (see 
references in Roberts, 1987). The world of physicians and public researchers and the one of 
firms are characterised by a different set of incentives for the disclosure of their innovations 
(Dasgupta and David, 1984). Therefore taking into account both patents and publications, we 
aim at providing a more complete picture of the innovative effort in R&D. 
The analysis of the number of patents published in the US30 reveals the dominance of the US 
in terms of innovation capabilities. Using data on citations received by each patent (a high 
number of citations received by a given firm or country can be interpreted as a measure of the 
quality and relevance of its innovative activities), US dominance in the medical device sector 
                                                 
29 See Hall, Jaffe, and Trajtenberg (2001b). 
30 Given the relevance of the US market, and the consequent fact that most innovations are also patented in the 
US, the picture from the patents in the US can provide relevant evidence on the general global patterns. 
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turns out to be even stronger than it appears from patent count data, also suggesting that, on 
average, patents assigned to US institutions have a relatively greater impact on future 
innovative activity. European countries and also Japan lag far behind, and overall those 
countries experience a decline in their relative position. 
A similar pattern emerges from the analysis of scientific publications. When the nationality of 
the main author is considered, the top patenting countries are ranked high also in terms of the 
number of publications. 
Finally, even though the analysis of the R&D side is important in gaining information about 
the most innovative countries in the medical device sector, the impact of new technology 
occurs at the diffusion stage, where clinicians play the most significant role (van Merode, 
Adang, Paulus, 2002). Even if a certain health technology is available in a country, its true 
impact can only be fully realised if there exists adequate dissemination of infrastructures in 
the healthcare industry. Among them, important factors determining diffusion are the 
availability of trained personnel and the attitude of the medical profession towards new 
technology, government pricing policies, technology assessment processes and the costs of 
common alternatives (see van Merode, Adang, Paulus, 2002). 
As an example of the phenomenon of “under-utilisation” of advanced medical technology in 
Europe, consider the case of implantable cardioverter-defibrillators (ICDs), an established, 
safe, proven, and cost-effective treatment for ventricular tachyarrhythmias and reduction in 
sudden cardiac death rates. Notwithstanding their characteristics, only 8 percent of the 
clinically eligible patients actually receive an ICD31. Unfortunately, such detailed data are not 
available for the industry as a whole. As a more reliable measure of inventive output, we take 
into consideration the introduction of medical devices into the US market. Again, we do not 
dispose of data about sales of medical device products, therefore we are not able to assess 
their diffusion and to analyse the pattern in life cycle of medical device products. 
6.2 The innovation process for medical devices 
This section aims at characterising the key feature of the innovation process in the medical 
device industry. Innovation in the medical device industry can take many different forms 
ranging from new products (both new devices and modifications of old devices), to new 
manufacturing processes, and new modes of practice (Robert, 1987). We will employ both 
patent data, a useful source of information to describe the key features of the innovations, and 
data from studies published in the empirical literature in order to describe the main 
characteristics and patterns of the innovation process in medical devices. 
The economic literature has long debated on the factors and incentives driving the rate and 
direction of the research effort undertaken by firms and institutions. The debate in the 
theoretical literature has focused the attention on “technology push” versus “demand pull” 
theories, the former considering the exogenous effect of science on technological change, 
while the latter regarding market growth and size as unique determinants of the decision to 
invest in R&D. Both theories only present a partial piece of the story. The decision to invest 
in R&D, and therefore the rate and direction of technological progress, is the result of the 
interplay between the advances spanning from basic science, institutional variables, and 
economic factors, namely market growth and size (Dosi, 1982, 1988). 
                                                 
31 Source: Guidant estimates. 
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Scientific opportunity, assessment of the market potential and of the resources needed for 
development, and medical needs have been identified in the pharmaceutical research as the 
major drivers of the pharmaceutical decisions to invest in R&D (Crogham and Pittman, 
2004). 
In the case of medical device innovation, the market for new devices is not always well 
defined. Consider the story of cardiac pacemakers (see Kahn, 1991). A market survey, at the 
time of their first introduction, estimated a total of 1,000 patients around the world needing 
the device, a tiny market of no interest to major corporations. Once developed and introduced 
(by a small companies – at that time), the market turned out to be 200,000 units a year. An 
evaluation of a device before its diffusion into clinical practice can grossly undervalue the 
technology to a degree that only a small company would find the prospects interesting. 
Medical imaging, where devices are costly and complex, is the exception to this “small-
company” rule (Kahn, 1991). 
Also, in the medical device industry, product development is inherently linked to product 
usage; therefore, users play a significant role in shaping the rate and direction of the 
innovative activities (Shaw, 1985). Many technologies need further improvements when first 
adopted, and feedback from clinical practice are important to disclose shortcomings and 
potentials that could not have been revealed in earlier, pre-market evaluations (The Lewin 
Group, 1999). Also, physicians are a source of ideas for alternative uses of existing 
technologies. For example, beyond their original uses in ophthalmology and dermatology, 
lasers are used in gynaecology, gastroenterology, oncology, thoracic surgery, and other 
specialties. Thus, widespread use of a product in one field can cause physicians to innovate 
and seek applications in other fields (The Lewin Group, 1999). 
In a pioneer study about the innovation process in the scientific instruments sector, Von 
Hippel (1975) found that 80 to 100 percent of the key innovations in technological categories 
related to scientific instruments were in fact invented, prototyped and first field-tested by 
users rather than by product manufacturers (see Table 2). The producers’ role in such cases 
was restricted to product engineering (work to improve prototype reliability, 
manufacturability and convenience of use, while leaving its principles of operation intact), 
manufacturing, marketing and selling. The user was also involved in the diffusion of detailed 
information, on the value of the innovation and how the prototype may be replicated, to other 
users, colleagues and scientific instrument companies alike.  
Table 2. User domination of instrument innovations 
Category of Instruments % user # user # mfg. 
Gas chromatography 82 9 2 
Nuclear Magnetic Resonance 79 11 3 
Ultraviolet spectrophotometry 100 4 0 
Transmission electron microscope 79 11 3 
Source: von Hippel (1976). 
This finding has been also confirmed by Shaw (1985), who proved that 18 out of 34 analysed 
innovations in the British medical equipment industry have been based on user prototype (see 
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also Roberts, 1987). In addition, he found that in his sample of 34 new products, 26 (76 
percent) had been developed through multiple and continuous interaction between the user 
and the manufacturer, resulting in 22 new devices successfully introduced on the market (see 
Conway, 1993 for a review). 
An alternative source of ideas is given by the academics, whether at universities or clinical 
settings. However, due to the different set of incentives at work in the “open science” (see 
Dasgupta and David, 1994), academics may be very productive in having ideas, but they only 
infrequently try to exploit them, regardless of potential personal and social gains. A closer 
interaction between the university and the industry would be beneficial to both worlds: on the 
one side, closeness to the clinical scene is beneficial for medical device innovation; on the 
other side, the industry is more apt at recognising potentially profitable ideas. 
A critical contribution to medical device innovation is given by small firms32. Much of the 
medical device industry comprises small entrepreneurial companies that have significant roles 
in medical devices and diagnostics innovation (see also the findings in Section 6). Start-up 
firms have been disproportionately responsible for the innovation and early development of 
truly novel devices, including angioplasty catheters, artificial joints, cardiac support devices, 
diagnostic ultrasound, diagnostic test kits, and vascular grafts. In contrast, larger firms are 
more likely to pursue next-generation or incremental improvements, for example, by refining 
or building on current product lines for familiar markets (The Lewin Group, 1999). 
In order to highlight this characteristic and compare the patterns in the pharmaceutical and 
biotechnology industry, we considered the size distribution of the firms and institutions 
involved in the innovation process, where we measured size in terms of the number of 
patents.  
                                                 
32 Although small companies may be responsible for early innovation, many will ultimately collaborate with 
larger partners to bring their products to market. Large corporations in this field are primarily acquirers of new 
technology emerging outside their organisational boundaries (often through the acquisition of young companies), 
and are effective in enhancing and commercialising existing technologies (Roberts, 1987; The Lewin Group, 
1999).  
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Box 1: Patents as a measure of innovative activities 
Patents have been extensively used in the empirical literature as a proxy for the output of innovative activities 
(see Griliches, 1984, 1990). They represent a unique source of information for studying innovation, since they 
provide detailed information about the (patented) inventions. In particular, each patent reports the technological 
area of the innovation, the name of the inventor(s) and of the institution(s) owing the patent right and their 
location. Also, the patent contains reference to previous patents and to the scientific literature, identifying the 
previous research upon which the patent builds. 
The main drawback of relying on patents as a means for measuring innovation is in the fact that not all 
inventions are patented. New inventions have to meet patentability criteria, i.e. the invention must be novel, non 
trivial, and with potential commercial application. Moreover, the propensity to patent varies over time and by 
technological field, making it difficult to compare patent counts across industries and over time. In addition, the 
firm owing the invention may strategically decide not to apply for a patent, preferring other means for protecting 
the intellectual property rights. For example trade secrets and lead times are considered to be effective in many 
industries. 
Surveys have been conducted to validate the use of patents as proxy for innovations (see Cohen, Nelson, Walsh, 
2000; Arundel and Kabla, 1998). All the studies have highlighted the existence of a marked difference among 
technological sectors. Among the others, Cohen, Nelson, Walsh (2000) investigate the “medical equipment” 
industry and highlight the importance of patents in this sector as a mean for appropriating returns from product 
and process innovation33.  
Driven by a different research question, the NBER/Case Western Reserve Survey of Patentees provided evidence 
of the validity of citations as a measure of the knowledge spillovers (see Jaffe, Trajtenberg, and Fogarty, 2000). 
Grounded in the view of technological change as a cumulative process, whereby each innovation build on the 
body of knowledge that preceded it and forms in turn the foundation for subsequent advances, citations in 
patents can be considered a good proxy for the evidence of a link between an innovation and its technological 
“antecedents” and “descendants”, therefore providing useful information for characterising the innovation 
process (Trajtenberg, Henderson, and Jaffe, 1997).  
 
The patent data employed in this section are extracted from the NBER database34 (Hall, Jaffe, 
Trajtenberg, 2001b), reporting data about the US patents granted between 1963 and 1999. For 
patents granted in the period 1975-1999, the database also reports information about the 
patents cited in each patent document and a series of indicators, computed on the basis of 
citations that describe the key characteristics of the innovation. We considered the patents 
classified within the “Drugs and Medical” category, further classified into Drugs, 
Biotechnology, Surgical and Medical Instruments (S&MI) and miscellaneous.  
We considered all assignees active in the categories considered, and counted their total 
number of patents. Then we measured the number of assignees with a given number of 
                                                 
33 Cohen, Nelson, Walsh (2000) report the results from a survey aimed at assessing the nature and the strength of 
appropriability conditions. The survey, the Carnegie Mellon Survey, was conducted in 1994 on more than 1000 
R&D laboratories in the US manufacturing sector. The “medical equipment” industry turns out to be the one 
where patents are considered most effective as a mechanism for appropriating returns from product innovation 
(the mean percentage of product innovation for which patents are considered effective is 54,70 against 50,20 in 
the drug industry). Also lead time is considered an effective appropriation mechanism (effective in 58,06 percent 
of product innovations). For process innovations, the score is reduced, but it is still one of the highest across 
industries. Secrecy and complementary manufacturing in this case turn out to be most effective (see Cohen, 
Nelson, Walsh, 2000, Table 1 and Table 2). 
34 The NBER database contains information about all US patents granted between January 1963 and December 
1999 and information about citations for patents granted in the period 1975-1999. Trends and country profiles 
will be analysed using ATAdb since this contains data up to the year 2003.  
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patents and used a Kernel technique to estimate the density function of the size distribution in 
terms of the number of patents35.  
Results are presented in Figure 1. 
Figure 1. Size distribution (log of the number of US patents) in Drugs & Medical 
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Source: NBER patent database. 
The S&MI category is populated by a large fraction of firms with a low number of patents. 
Indeed the share of assignees with only one patent is 35% in S&MI, while it is 28% in Drugs 
and 21% for biotechnology (see also the findings in Section 6). 
When comparing the distributions (using a Kolmogorov-Smirnov test), the size distribution in 
the S&MI is different from the distributions that characterise the pharmaceutical and 
biotechnology industries. Firms in the pharmaceutical and biotechnology industries are, on 
average, larger than those active in the S&MI sector. 
In addition, supporting a role for the user in the medical device innovation process, the share 
of patents assigned to individuals in this industry is larger than 2 percent, against 1,1 percent 
for the total database (see Hall, Jaffe, Trajtenberg, 2001b) and compared to 0.75 and 0.65 
percent respectively for Drugs and Biotechnology patents. 
                                                 
35 In order to enhance the graph’s readability, the logarithm of the number of patents has been considered. 
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Inter-relation in different areas is another key feature of the medical device industry. Many 
fields of science, including materials science, bio-engineering, molecular biology, computer 
sciences, management, and telecommunications significantly contribute to the medical device 
innovation process. Many healthcare technologies are adaptations from other fields, for 
example, lasers, ultrasound, magnetic resonance spectroscopy, and computing. Among the 
many technologies that were developed through the interdisciplinary work of clinicians and 
physicists, engineers, and other scientists are medical lasers, cardiac pacemakers and 
defibrillators, cochlear implants, endoscopies, catheters, and cardiac imaging (The Lewin 
Group, 1999).  
Citations in patents can be used to compute measures that capture different features of the 
(patented) innovation, and their links to other innovations. The NBER database reported the 
measures of generality and originality as defined in Trajtenberg, Jaffe and Henderson (1997). 
The measure of originality for a patent i is a Herfindahl type index of specialisation computed 
as: 
( )2
1
1 ∑
=
− i
n
j
ijs , 
where sij denotes the percentage of citations made by patent i to patents belonging to the 
patent class j, out of ni patent classes. Thus, if a patent cites previous patents belonging to a 
wide range of fields, the measure will be high, whereas if most citations are concentrated in a 
few fields it will be close to zero. Therefore, patents with a high value of originality are 
influenced by patents in different fields, pointing to inte-rrelation between areas of research, 
since it builds upon innovation in a variety of fields. 
The measure of generality is built in an analogous way, but it is computed using citations 
received by subsequent patents. Building on the presumption (widely accepted in the 
empirical literature in the economics of technical change) that subsequent citations are 
indicative of the impact of a patent, a high generality score suggests that the patent had a 
widespread impact. 
Table 3 reports the average values of the generality and originality indices for the categories 
we considered, and the average over the whole population of patents as a benchmark. 
Table 3. Index of Generality and Originality, Drugs and Medical 
Sub-category Generality Originality 
Drugs 0.265 0.326 
Biotechnology 0.271 0.274 
Surgery & Med Inst. 0.324 0.366 
Miscellaneous 0.252 0.266 
Overall 0.321 0.349 
Source: NBER patent database. 
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Compared with Drugs and Biotechnology, the S&MI category is characterised by a higher 
value of both the index of originality and generality. In particular, the value of the originality 
index suggests that patents in S&MI builds upon many different pieces of knowledge.  
Another important information from patent citations spans from the assignee of the cited 
patents36. Citations are informative of knowledge spillovers (Jaffe, Trajtenberg, and Fogarty, 
2000). Presumably, citations to patents that belong to the same assignee represent transfers of 
knowledge that are mostly internalised, whereas citations to patents of “others” are closer to 
the pure notion of (diffused) spillovers. 
The NBER database provides a lower and an upper bound for the share of self-citations 
computed on the basis of the citation made by each patent. To have a more reliable measure 
we only included patents granted from 1990 to 1999. 
The lower and upper bounds of the share of self-citations for the patents in the “Drugs and 
Medical” industry are reported in Table 4. Moreover, the average value computed over the 
whole sample (still for patents granted in the period 1990-1999) is also reported as a 
benchmark. Marked differences emerge between the drug and biotechnology industry and the 
medical device industry, as described by the S&MI category.  
Table 4. Self-citations (%), Drugs and Medical 
 Lower bound Upper bound 
Drugs 18.44 19.65 
Biotechnology 14.08 14.66 
Surgery & Med Inst.  7.42  9.47 
Miscellaneous  7.01  9.42 
Overall 11.68 13.22 
Source: NBER patent database. 
The difference in the share of self-citations between the various industries may well be the 
result of the size distribution of the firms. The pharmaceutical industry is indeed characterised 
by the presence of very large firms, and hence the likelihood that they will cite internally is 
higher. On the other side the S&MI category is populated by a large fraction of firms with a 
low number of patents (see Figure 1).  
This pattern has nonetheless implications for the cumulativeness of knowledge within the 
industry. Self-citations might be the result of the cumulative nature of innovation and the 
increasing returns property of knowledge accumulation. In particular, this happens within a 
narrow field or technology trajectory, suggesting that the firm has a strong competitive 
position in that particular technology and is able to capture some of the knowledge spillovers 
created by its previous research (Hall, Jaffe, Trajtenberg, 2001a). The analysis highlights the 
low cumulativeness of knowledge in the medical device industry with respect to the 
innovation process in pharmaceuticals and biotechnology. 
                                                 
36 Alternatively assignees in patents that subsequently cite the patent under analysis could be considered. 
However, since forward citations are affected from truncation, backward citations (i.e. citations made by the 
patent) are preferred since it is possible to get information over the whole distribution. 
 126
Under a complementary perspective, we take into consideration the backward citation lag, i.e. 
the time difference between the grant year of the citing patent and that of the cited patents. 
We preferred to use the backward citation lag rather than the forward citation lag. In fact, for 
patents granted from 1975, the NBER database reports the backward citation lag obtained 
from the complete list of citations made, while when looking at the time difference between 
the cited patent and the citation it receives (and therefore at forward citation lag), data are 
truncated since for more recent patents only a share of subsequent patents citing the patent 
under observation are observed. 
The average backward citation lag is shortening for more recent patents in S&MI and for the 
miscellaneous category, while it remains rather constant for Biotechnology and Drug patents. 
On the technological side37, the technology cycle in the S&MI is longer than Drugs and 
Biotechnology. In 1980, S&MI patents cited patents that were on average 14 years older, and 
this time lag has significantly shortened in recent years being 10 years for S&MI patents 
applied in 199838 (see Figure 2). This might be also the result of the higher inter-relation with 
other areas of the research in S&MI: more time may be needed to become aware of new 
material and improvements on the engineering side, and to introduce the innovations from 
other fields into medical technologies. 
Figure 2. Average backward citation lag (years), Drugs & Medical 
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Source: NBER patent database. 
                                                 
37 This must not be confused with the product life cycle, that we are not able to analyse given the lack of detailed 
data about sales of medical devices. 
38 Data for 1999 are not reported due to truncation in the patent series. 
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Finally, in order to characterise the activities of the firms involved in this industry, on a 
technological side, we considered all the patents assigned to non-government organisations 
with at least one patent classified into “Drugs and Medical”, and we computed the entropy 
index of diversification (see Baldwin et al, 2000; and the description of the index in Section 
5.3). 
Firms operating in the S&MI subcategory have on average a lower overall diversification 
index (see Table 5). 
Table 5. Entropy index of technological diversification 
 Average Median 
Drugs 0.72 0.64 
S&MI 0.60 0.00 
Biotechnology 0.94 0.90 
Source: NBER patent database. 
An interesting feature of this index is the possibility to decompose the firms’ total entropy 
(diversification) into two components: the entropy that exists between industry groups, and 
the entropy that exists within industry groups. We therefore computed both the within and 
between entropy and considered their respective contribution to the total entropy. 
Figure 3 reports the boxplots of the share of the within entropy index over the total index of 
diversification for all the firms active in the Drugs, S&MI, and Biotechnology technological 
categories. The median of the shares of within entropy diversification is lower for the firms 
operating in the S&MI category with respect to Drugs and particularly with respect to 
Biotechnology. This means that firms operating in the S&MI have a higher incidence of 
between groups (or “broad-spectrum”) diversification as compared to firms that are active in 
the Drug and Biotechnology sectors. 
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Figure 3. Share of Within Entropy over total diversification 
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Source: NBER patent database. 
6.3 R&D intensity of the medical device industry 
We start exploring the issue of R&D intensity of the medical device industry by comparing 
the share of R&D expenditure over turnover39 in the medical device industry and selected 
sectors within European boundaries. Figure 4 reports the share of intra-mural R&D 
expenditure over turnover for the following NACE in the years 1999 and 2001. 
 NACE 29.6: Manufacture of weapons and ammunition; 
 NACE 24.4: Manufacture of pharmaceuticals, medicinal chemicals and botanical 
products; 
 NACE 32: Manufacture of radio, television and communication equipment and apparatus; 
 NACE 35.3: Manufacture of aircraft and spacecraft; 
 NACE 34.1: Manufacture of motor vehicles; 
 NACE 33.1: Manufacture of medical and surgical equipment and orthopaedic appliances; 
 NACE 30: Manufacture of office machinery and computers; 
                                                 
39 Turnover is defined as the value of everything that is sold by the unit during the reference year, including 
goods sold from stocks and goods bought for resale (Eurostat, 2003). 
 129
 NACE 25.2: Manufacture of plastic products; 
 NACE D: Total Manufacturing; 
 
Data for the European countries are drawn from Eurostat, reporting information about the 
“Manufacture of medical and surgical equipment and orthopaedic appliances” sector 
(Eurostat, 2004a). 
Figure 4: R&D over turnover for selected economic activities (NACE), 1999, 2001 
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Source: our elaborations on Eurostat (2004a). 
The R&D intensity of the medical device industry is much lower than the R&D intensity of 
the pharmaceutical industry (NACE 24.4) and it has a similar level to that of the manufacture 
of motor vehicles (NACE 34.1) and office machinery and computers (NACE 30). Moreover, 
the R&D intensity of the sector has not changed substantially from 1999 to 2001 (see Table 
A.6.1 for details about data availability across the European countries). 
Here we need to mention the inadequacy of the NACE classification for identifying the whole 
medical sector. In particular, Eurostat data only take into consideration the low-tech sub-
markets of the sector, not including, among others, high-tech chemicals and biochemical-
based devices such as in vitro diagnostics. As a result, the R&D intensity of the sector is 
highly under-estimated. Indeed, the ranking of the industries in terms of R&D efforts does not 
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match with a similar ranking published by AdvaMed (2004). AdvaMed considered the share 
of R&D expenditure over sales of the companies listed in the Compustat North America 
database published by Standard and Poor’s. There the medical device industry ranked second 
in terms of R&D over sales, second only to the Drugs and Medicine industry.  
The comparison of these figures is not straightforward and also the availability of different 
measures limits the comparison of the R&D effort of the European countries with the US and 
Japan. For the US and Japan we have data about the share of R&D over sales, while time 
series spanning a few years report data on turnover for the European countries. In addition, as 
we have already pointed out, R&D data for the European countries are biased downward 
making it difficult to compare the R&D intensity in Europe with that of the US and Japan. 
Despite these limitations, the data reported in Table 6 can provide useful insights. Even 
though using these data it is not possible to compare US dynamics to the pattern in Europe, 
we can observe within-country variations in the R&D intensity of the medical device sector. 
The ratio of R&D over sales has increased in the US from 8.4 percent in 1995 to 11.4 percent 
in 2002, a figure which is more than double that of Japan, reporting a share of R&D over sales 
that equals 5.6 percent. 
On the other side, a different dynamic characterises the ratio of R&D over production, which 
is rather constant for the European countries.  
Table 6. R&D as a percentage of turnover/sales, European Countries, the US, and Japan 
Country 1995 1996 1997 1998 1999 2000 2001 2002 
US 8.4 9.6 11.1 12.9 10.1 10.9 12.3 11.4 
Japan n.a. n.a. n.a. n.a. n.a. n.a. n.a. 5.6 
EU15 n.a. n.a. 1.6 1.1 1.3 1.5 1.6 1.7 
NMS n.a. n.a. 0.5 0.6 0.4 0.5 0.5 0.5 
EU25 n.a. n.a. 1.3 0.9 1.1 1.1 1.0 0.9 
Source: AdvaMed (2004) for the US (data refer to publicly traded companies); Eurostat (2004a); MLHW (2003). 
See Table A.6.1 for details about the availability of EU Member States data. 
In order to compare the R&D intensity in Europe, the US and Japan, Table 7 reports data 
drawn from Eucomed publications reporting the level of R&D expenditure as a share of sales 
in various years ranging from 1999 to 2003 (see Eucomed, 2004 for details). 
Table 7. R&D expenditure as a % of sales, various years 
 R&D/Sales (%) Year 
United States 12.90 1999 
Japan 5.80 2000 
EU average 6.35 -- 
Denmark 6.00 2002 
France 3.00-5.00 2002 
Germany 10.00 2003 
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 R&D/Sales (%) Year 
Ireland 1.52 2003 
Portugal 0.05 2001 
Spain 5.00-10.00 2002 
Sweden 9.00 2001 
United Kingdom 5.00 2000 
Norway 0.00-8.00 2002 
Switzerland 10.00-15.00 2002 
Hungary 3.00-4.00 2001 
Poland (figures based on NACE 33) 0.90  2002 
Slovakia 0.50 2001 
Source: Eucomed (2004). 
The picture that emerges from the data reported in Table 7 is one where the R&D intensity of 
European firms is on average lower than that in the US, and slightly higher than the figure in 
Japan. High heterogeneity exists within European boundaries and the R&D intensity of 
Germany, Sweden and Switzerland is roughly equal to the ratio in the US. 
Also the level of intra-mural R&D expenditures is highly heterogeneous (see Table A.6.1).  
France and Germany are the top R&D spenders in Europe, followed by the UK and Italy. 
Different trends characterise these countries: France, Germany, and especially the UK are 
experiencing significant increases in the level of R&D expenditures in the medical device 
sector, while Italy presents a downward trend. The other European countries included in the 
analysis register a low level of R&D expenditures.  
Next we analyse the R&D intensity for selected sub-markets. As already pointed out, the 
medical device industry is highly heterogeneous and characterised by sub-markets at different 
stages in the product life cycle, and requiring a different amount of resources. 
The Compustat North America database (Standard & Poor’s Compustat®, 2004b) reports 
information about R&D, sales, and the number of employees for the American and Canadian 
public companies. In addition, firms are classified according to the North America Industry 
Classification System (NAICS) and are assigned a code on the basis of the principal line of 
activity40. 
We considered the eight sectors reported in Table 8. 
                                                 
40 R&D expenditure related to MD technologies by companies whose main line of activity is not classified in one 
of the NAICS included in the analysis is not considered. Also the R&D activity in sectors other than MD by 
large multinational companies with a main line of activity in one of the NAICS included are considered in the 
analysis. This is particularly relevant in the case of MD, where companies are characterised by “broad 
spectrum”, i.e. across sectors, diversification (see the results in the previous Section). 
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Table 8. Sub-markets considered in the analysis 
NAICS Description 
325413 In-Vitro Diagnostic Substance Manufacturing 
339111 Laboratory Apparatus and Furniture Manufacturing (pt) 
339112 Surgical and Medical Instrument Manufacturing (pt) 
339113 Surgical Appliance and Supplies Manufacturing 
339114 Dental Equipment and Supplies Manufacturing  
339115 Ophthalmic Goods Manufacturing (pt) 
334510 Electromedical and Electrotherapeutic Apparatus Manufacturing (pt) 
334517 Irradiation Apparatus Manufacturing (pt)  
 
For each firm in the sample41, we computed the share of R&D over sales and then considered 
the median value in three different points in time (1993, 1997, and 2002), which allows us to 
represent the patterns and trends of R&D intensity at the sub-market level. Results are 
summarised in figure 5 (see also Table A.6.3 for details).  
The figures show large heterogeneity in R&D intensity between the various sub-markets. The 
findings are in line with the expectations: high-tech segments (in-vitro diagnostics on top of 
all) present the highest R&D intensity, while traditional low-tech segments (laboratory 
apparatus and furniture, surgical appliance and supplies) the lowest. 
Trends appear clear for some sub-markets, mixed for most. As for the overall sector, the totals 
show an increase of the R&D intensity from in the early 1990s (when comparing 1993 to 
1997), while in more recent years (1997 versus 2002), we observe a decrease in the median 
R&D intensity of the medical device sector. 
                                                 
41 See Table A.7.2 for details about the size distribution of the firms included in the analysis. As expected, since 
the database cover public companies, small firms are under-represented in our sample (see Section 6).  
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Figure 5. Median R&D intensity at the sub-market level, Compustat Companies, 1993, 1997, 2002 
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Source: our elaborations on Standard and Poor’s Compustat® (2004b).
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We then compare R&D intensity by firm size42. Figure 6 and figure 7 clearly show that 
smaller firms have a higher R&D intensity than larger ones. This is consistent with the 
existence of the division of innovative labour, where smaller firms are highly R&D intense 
and specialised in innovative activities, while the larger firms are more involved in the 
marketing and commercialisation of the new devices. 
Figure 6. Distribution of R&D/Sales, by total sales ($ millions)  
 
Source: our elaborations on Standard and Poor’s Compustat® (2004b). 
                                                 
42 We first classified the companies according to their size, both on the basis of sales and of the number of 
employees, and then we considered the median (50% percentile) for each subgroup. 
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Figure 7. Distribution of R&D/Sales, by number of employees  
 
Source: our elaborations on Standard and Poor’s Compustat® (2004b). 
It is conventional wisdom that the division of innovative labour is at work in the 
pharmaceutical industry, where smaller firms are highly research intensive and have a 
competitive advantage in the early stage of the innovation process in drug development. 
Conversely, larger corporations have gained significant expertise in the later stages of the 
development of new innovations. It is argued in the literature that this organisation of the 
industry can be highly conducive to innovation performance, since it exploits the comparative 
advantages of larger and smaller firms in the different phases of the innovation process 
(Arrow, 1983). Evidence is also provided in the empirical literature supporting the existence 
of social advantages from this specialisation in innovative activities. The existence of a 
positive linkage between the probability of success of a research project and the existence of a 
license on the compound under development is shown in several contributions (see Arora, 
Gambardella, Pammolli, and Riccaboni, 2001; Danzon, Nicholson, and Pereira, 2003). 
Although we do not dispose of medical device research project level data, through a detailed 
description of the characteristics of the firms operating in the industry (mainly R&D intensity) 
and of the pattern of collaboration among them, we will try to understand the characteristics 
of the division of innovative labour, if any, in the medical device sector. 
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6.4 Deals and collaboration agreements 
In all high-tech industries innovation fuels economic success, and medical devices are not an 
exception. Knowledge, which lies at the heart of the success of firms operating in a dynamic 
environment, can be obtained through different sources. Besides formal R&D performed 
within the firms, knowledge can be obtained outside the firm boundaries, through formal 
collaboration agreements or through the interaction among economic agents, for example 
between firms and basic scientists. In this section we will focus on the relevance for the 
medical device industry of the appropriation of knowledge that was originated outside the 
boundaries of the firm, either through acquisition of an existing firm, or through formal 
collaboration agreements. In doing so, we aim at further exploring the division of innovative 
labour in the medical device industry.  
ATAdb (ATA, 2004), covering the most relevant deals on a worldwide level, reports a total of 
6,953 deals for medical devices from year 1991 to 2003. The organisations involved in the 
deals were classified into public/private and we distinguish biotech firms (considering first 
tier biotech separately), public research organisations, large pharmaceutical firms and other 
firms, according to their main technology.  
Figure 8 graphically depicts the evolution of the total number of deals among firms in the 
medical device industry over time and compares this dynamics with the evolution of the total 
number of deals in the pharmaceutical and biotechnology industry.  
The series describing the number of deals in the medical device and pharmaceutical industries 
proceed paired: the total number of deals in both industries decreased sharply starting from 
2000, after a steep rise. In 2003 the decline stops, and the figures are roughly equal to the 
ones in 2002. However, the number of deals is significantly lower in medical devices when 
compared to the pharmaceutical industry. 
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Figure 8. Total number of medical device and Pharmaceutical deals, 1991-2003 
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Source: ATA (2004). 
Table 9 distinguishes between acquisitions (total or partial), alliances (joint ventures, R&D 
and marketing agreements, product acquisitions), and financing types of collaboration. Quite 
different purposes and arrangements characterise the acquisition, licensing and financing 
agreements. Therefore, we will in turn analyse the dynamics of acquisitions, both in terms of 
numbers and value of the acquisitions, and the patterns of R&D licensing agreements. 
Table 9. Number of medical device and Pharmaceutical collaborations, by deal type 
  Medical Device Collaborations Pharmaceutical Collaborations 
Year Total Acquisition (%) 
Alliance 
(%) 
Financing 
(%) Total 
Acquisition 
(%) 
Alliance 
(%) 
Financing 
(%) 
1991 366 26.50 41.53 31.97 621 13.53 59.42 27.05 
1992 282 28.72 40.43 30.85 712 13.06 63.76 23.17 
1993 290 25.17 47.24 27.59 728 8.93 59.75 31.32 
1994 381 28.87 49.08 22.05 753 10.89 65.21 23.90 
1995 460 29.78 43.26 26.96 784 14.67 59.57 25.77 
1996 595 21.18 46.39 32.44 1,025 9.46 60.68 29.85 
1997 569 17.22 53.95 28.82 1,157 8.47 63.79 27.74 
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  Medical Device Collaborations Pharmaceutical Collaborations 
Year Total Acquisition (%) 
Alliance 
(%) 
Financing 
(%) Total 
Acquisition 
(%) 
Alliance 
(%) 
Financing 
(%) 
1998 637 19.94 51.02 29.04 1,190 8.57 66.97 24.45 
1999 605 19.34 51.24 29.42 1,143 10.67 63.52 25.81 
2000 866 18.59 42.96 38.45 1,662 10.53 54.09 35.38 
2001 731 15.46 50.34 34.20 1,464 10.31 60.45 29.23 
2002 598 18.06 46.66 35.28 1,415 8.76 64.45 26.78 
2003 573 21.47 37.52 41.01 1,421 9.50 55.45 35.05 
Source: ATA (2004). 
In relative terms, acquisitions play a larger role in medical devices as compared to 
pharmaceuticals, even though the share of medical device acquisitions has declined from 
26.50 percent in 1991 to 21.47 percent in 2003 (increasing from 18.06 percent in 2002). 
Figure 9 and figure 10 report the number and deal value of acquisitions respectively in the 
medical device and pharmaceutical industries over the period 1991-2003. A peak of 
acquisitions has been registered in 1997 and 1998 in the medical device industry, which 
however does not correspond to a peak in deal value. This circumstance means that the 
average value of acquisition has been reduced in these years.  
When compared to the acquisitions within the pharmaceutical industry, both the total value 
and the number of agreements in the medical device industry is significantly lower. Also, 
M&A are characterised by a lower average value in the medical device industry as compared 
to the pharmaceutical industry. 
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Figure 9 M&A number and value, medical devices 
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Source: ATA (2004). 
Figure 10. M&A number and value, Pharmaceuticals  
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Source: ATA (2004). 
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Table 10 analyses the nationality of the institutions involved in the medical device acquisition 
agreements, reporting the number and the average value of the acquisitions involving US, 
European, and Japanese institutions.  
It is interesting to note the low level of M&A within the European boundaries coupled with a 
high number of US-Europe acquisitions. Also, the average value of US-Europe acquisition is 
the largest for the medical device agreements.  
Table 10. Number and average value of acquisition agreements, medical devices, 1991-
2003 
 Number Avg. Value 
 US Europe Japan US Europe Japan 
US 835   125.10   
Europe 429 55  165.59 152.08  
Japan 16 2 0 46.52 85.00 -- 
Source: ATA (2004). 
Next, our interest is in the patterns and characteristics of the R&D alliances. 
We selected all the deals with R&D content where it was possible to distinguish the licensee 
from the licensor. In the case of one licensor and multiple licensees, we considered different 
deals for each licensee. The final sample of deals signed between 1991 and 2003 is composed 
of 2,112 licensing agreements. 
Figure 11 reports the evolution over time of the number of subscribed licensing agreements, 
comparing medical devices and pharmaceuticals. The pattern for both series is similar to that 
seen above, peaking in 2000 and then decreasing43.  
                                                 
43 The decrease in later years is contrasted to the sharp increase of patent co-assignment during the period 2000-
2003. However patent co-assignment is a particularly strong form of collaboration among firms, where they 
share the intellectual property right spanning from the research. In addition, licensing agreements are signed at 
different stages of the innovation process. 
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Figure 11. Evolution over time, R&D licensing agreements, medical devices and 
pharmaceuticals 
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Source: ATA (2004). 
Figure 12 graphically depicts the network of R&D licensing agreements classifying the 
originator and the developer (respectively the licensor and the licensee) according to the 
nationality of the organisations. From the figures, it is possible to understand the size of the 
R&D network of the institutions in each country and their preferred partners44. 
Only ties involving more than 3 deals between countries are reported and isolated nodes are 
deleted from the picture, after imposing this filter. The size of the lines connecting country X 
and Y is proportional to the total number of deals involving the two countries, and the size of 
each node is proportional to the number of out-licensing agreements it subscribed (within-
country licensing agreements are considered). 
The dominance of the US in this network is striking. The US has a strong world dominance 
both as originator and as developer of licensing agreements. US organisations originated 75 
percent of the deals in the network and developed 71 percent. Moreover, the picture reveals 
the presence of a large North American network. More than 80 percent of the licenses 
originated (developed) by US institutions are developed (originated) in US and Canada (see 
also Table A.6.4). 
On the contrary, Europe does not constitute a self-standing network: a large share of the 
projects originated/developed in Europe is then developed/originated by institutions in the 
                                                 
44 Detailed statistics are reported in Table A.7.4 in Annex 7. 
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US. Significant relationships are present between Germany and France on the one side and 
between the UK and Belgium on the other. However, the linkage with the US appears to be 
stronger than the linkages between European countries. 
As for Japan, the national Japanese network is almost non-existent (a low share of deals 
originated by a Japanese institution has a national partner). The preferred partner is usually 
the US, and no significant interaction takes place with Europe, the only exception being the 
UK. 
Moreover, Japan is the country with the largest negative difference between originated and 
developed projects, meaning that this country relies heavily on other countries (mainly the 
US) as a source of useful medical and in vitro technologies. On the other side, the US has 
always a large and positive difference. 
Overall, the centrality of the US network emerges both in terms of number of deals originated 
and developed, and as preferred partner of European and Japanese institutions. 
Figure 12. Network of medical device R&D licensing agreements 
 
Source: ATA (2004). 
It is interesting to compare the information about the flow of products (analysed in Section 6) 
with the information about the flow of technology as described by the R&D licensing 
agreements analysed in this section45. For each country in the analysis, we linked the indicator 
of “trade balance” (defined in section 5 as the ratio of medical device export to total medical 
device trade), to an analogous indicator of “R&D balance” computed as the ratio of R&D out-
licensing agreements over the total number of agreements (the sum of in-licensing and out-
licensing agreements). A value of the index higher (lower) than 0.5 indicates a positive 
                                                 
45 Since the in vitro diagnostics industry is not included in the international trade flow analysis, it will be 
excluded also in the analysis that follows. 
 143
(negative) R&D balance: countries with a value of the index lower than 0.5 are net importers 
of technology (i.e. the number of R&D in-licensing agreements is higher than the number of 
R&D out-licensing agreements), while the reverse is true if the index is higher than 0.5. 
In Figure 13 we represent the two indexes jointly (product and technology “trade balance”).  
The x-coordinate represents the technology “trade balance” computed on the basis of the 
licensing agreements, while the y-coordinate represents the product “trade balance” as 
computed in Section 6. The size of each country is proportional to its number of out-licensing 
agreements and to the value of its exports. 
The top left panel of the figure contains countries that are exporters of both products and 
technology, therefore in a strong competitive position on the international market, both on the 
R&D and on the product sides. These are the US and Ireland.  
The lower right panel contains countries that are importers of both technologies and products. 
This panel contains Japan and Italy. Japan is indeed a net importer of both technology and 
products: both the product and the R&D “trade balance” have a value which is lower than 0.5 
suggesting the fact that imports of both technology (through R&D alliances) and products are 
larger than the respective exports. 
The other quadrants contain countries that are importers in one dimension (product or 
technology) and exporters in the other one. 
Figure 13. R&D and product international “trade balance” 
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Given the high heterogeneity of the medical device industry, we also consider a more 
disaggregated level, and we analyse specific sub-markets comparing the in-licensing 
agreements to out-licensing agreements related to specific technologies. 
Unfortunately, the classification system employed in the ATAdb (ATA, 2004) for R&D deals 
is not easily reconciled with the classification systems employed for the classification of 
products. Therefore, extreme care is needed when comparing trade and technology flows at 
the sub-market level. 
Figure 14 reports the index previously described for Europe, US and Japanese firms. The 
diagram also considers the index computed for Europe taking into account the international 
technology flow from and to the US only. The European competitive position varies widely 
when considering specific sub-markets. 
European countries are net exporters of technology related to implantable devices, surgical 
equipment and devices (excluding minimally or less invasive surgical equipment and 
devices), and for drug delivery R&D alliances. When considering the therapeutic equipment 
and devices, Europe is a net importer. However, the technology balance with the US is 
positive (the index is higher than 0.5). The US has a technology trade balance always close to 
zero. Japan is the major net exporter of R&D alliances on biomaterials. 
Figure 14. Technology flows for selected sub-markets, medical device 
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6.5 Innovative output: patents, publications, and new product introductions 
In this section we analyse the output side of innovative activity looking both at patents and 
publications related to the medical device industry. In particular, by using the information on 
the location of the assignees (and inventors) in patents and on the affiliation in the 
publications, we will characterise the location of R&D activities within the industry.  
The nature of the innovation process in medical devices does not always lead to patentable 
claims. The basic principle behind innovation in medical devices can be patentable, but 
specific devices usually are not, since it is possible to design a device for a given application 
in a number of different ways (see Kahn, 1991). Therefore, taking into account both patents 
and publications, we aim at providing a more complete picture of the innovative effort in 
R&D. 
When using simple patent counts to measure the innovative performance of firms and 
institutions, the fact that “the quality of the underlying innovation varies widely from patent to 
patent” (Scherer, 1965) is not taken into account. For this reason, citations by subsequent 
patents, a piece of information nowadays easily available from patent documents, have been 
extensively used to proxy the impact of a patented innovation. Subsequent patent citations 
indicate that the cited patent has opened the way to a line of innovations, and it is therefore 
significant, at least in a technological sense. 
The first empirical work that assessed a linkage between the number of citations received by a 
patent and its economic significance analysed computed tomography scanners (CT). 
Trajtenberg (1990) provides evidence that the number of subsequent citations received by 
patents are positively correlated with their social surplus using information about citations to 
CT patents in the US and estimates of the associated social surplus46. It is also hinted that, 
since patents and patent citations are the result of the action of profit-seeking agents, citations 
can be informative also of the economic success of the innovations.  
This suggestion has been confirmed by surveys (Harhoff, Narin, Scherer, Vopel, 1999; Jaffe, 
Trajtenberg, Fogarty, 2000) and empirical work analysing the probability of renewal and of 
litigation of patents (see Lanjouw and Schankerman, 1999). Due to the high costs involved in 
litigation and renewal procedures, these events can be informative of the private value of the 
associated patented innovations. 
In our analysis, besides simple patent counts, we will also consider patent citations, in order to 
take into account the technological and economic impact of the patented innovations. 
Similarly, simple publication counts do not take into account that the quality of published 
research may vary widely. Therefore, we used the impact factor of journals to calculate a 
weighted count of publications. 
The first step in the analysis consisted in the identification of the patents and publications in 
the medical device sector. 
As for publications, we used the MeSH database from Pubmed to identify publications 
pertaining to the medical device sector. We considered the more than 600,000 publications 
                                                 
46 The author used information about sales to hospital, and attributes and prices of all CT scanners marketed in 
the US from 1973 (corresponding to the inception of CT) to 1982. He applied a multinomial logit model to data 
on sales per brand and on their attributes and prices to estimate the parameters of the demand function and, under 
some restrictions, of the corresponding utility function. The social gain in each year is obtained by comparing the 
consumer and producer surplus in two subsequent periods (see also Trajtenberg, 1989).  
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related to the equipment, supplies, apparatus, and instruments used in diagnostic, surgical, 
therapeutic, scientific, and experimental procedures (Equipment and Supplies). 
Figure 15 reports the evolution of publications over time. We also include the trends in the 
number of publications related to clinical laboratory techniques and surgical procedures. The 
number of publications in all the three categories considered has increased over time. 
Figure 15. Trends in the number of publications, medical devices 
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Source: Pubmed. 
ATA (2004) was employed to analyse the publication data at a more detailed level. 
In order to identify medical device patents, we selected patents classified into specific 
categories within the International Patent Classification (IPC) system and we searched 
specific words within the abstract of the patent (ATA, 2004).  
In particular, within the broad class A (Human Necessities), we focus on the class A6, i.e. 
Health, Amusement, looking more deeply at the patent classified within A61 (Medical or 
Veterinary Science; Hygiene). We considered the patents with main IPC in the following 
classes47: 
 A61B: Diagnosis; Surgery; Identification. 
                                                 
47 We did not consider the classes A61C (dentistry; oral or dental hygiene), and A61H (physical therapy 
apparatus), which are nonetheless a small share of the health patents (see Lichtenberg and Virabhak, 2003). 
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 A61F: filters implantable into blood vessels; Prostheses; Orthopaedic, nursing or 
contraceptive devices; Fomentation; Treatment or protection of eyes or ears; Bandages, 
dressings or absorbent pads; First-aid kits (excluding classes A61F 13, 15, and 17). 
 A61M: devices for introducing media into, or onto, the body; Devices for transducing 
body media or for taking media from the body; Devices for producing or ending sleep or 
stupor. 
 A61N: electrotherapy; Magnetotherapy; Radiation therapy; Ultrasound therapy.  
Finally, we included the devices for in vitro diagnostics in our sample. These have been 
selected using the information contained in the abstract of the patent and in the IPC that 
helped us in discarding the patent where “in vitro” technologies were applied to targets other 
than human/biological essays. 
In the analysis that follows we only considered the (about) 120,000 medical device patents 
registered in the US. 
We are confident that the analysis conducted here provides a satisfactory picture of the 
innovative activities in the medical device industry: given the size and the relevance of the US 
market, most innovations are also patented in the US. 
Figure 16 compares the evolution of the number of patents in the medical device industry (i.e. 
in the classes we considered) and the Pharmaceutical industry48 over time, from 1980 to 2003. 
The two series proceed paired: the number of medical device patents increased smoothly up to 
the mid-1990s; then we observe a few years where the number of granted patents stayed 
approximately constant, and then the number of granted patents increased sharply over the 
1990s. In recent years, the increase has slowed down and the number of both medical device 
and pharmaceutical patents remained approximately constant.  
In order to analyse the pattern of location of R&D activities around the world, we also 
considered the nationality of the assignee(s) owing the property right49 and the country of the 
affiliation in publications. 
Figure 17 reports the evolution of medical device patents, distinguishing US and non-US 
assignees. Both series increase over time, and a large share of patents is granted to US 
institutions. This share has remained approximately constant over the latest years (see the box 
in Figure 17)50. 
                                                 
48 Analogously to the MD patent selection, pharmaceutical patents have been selected according to the IPC 
classification. Particularly, we considered the patents with main IPC in the classes A61K and A01N (see 
Lanjouw and Cockburn, 2001). 
49 We also considered the nationality of the first inventor listed in the patent. Results do not change substantially 
(see Table A.7.5). When analysing the assignee, in order to consider the nationality of all the organizations 
involved in the invention process, we weighted the count of patents by the share of the assignees in the patent 
that were located in the country considered. For example, consider a patent with ten inventors, three of which 
from the US and seven from UK. When counting the patents for US, we considered this particular patent 
assigning 0.3 to the US and 0.7 to the UK. 
50 The analysis might be biased toward US corporations, due to the so called “home advantage bias”, i.e. the fact 
that companies first file a patent in their home country. The literature has proposed the use of the triadic patent 
families to overcome this bias (see Dernis and Kahn, 2004). however, it is a fact that US corporations have a 
stronger effort in health patents (Lichtenberg and Virabhak, 2003). 
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Figure 16. Evolution of publications and US patents, 1975-2003, medical devices and 
pharmaceuticals 
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Figure 17. Evolution of US patents (in the box: shares), 1975-2003, medical devices, by 
nationality of assignee  
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Source: ATA (2004). 
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Table 11 digs further into this issue and shows the number and the share of the patents 
classified according to the nationality of the assignee over the period 1974-200351.  
We consider the location of the assignee(s) in patents and the affiliation of the corresponding 
author in the case of publications, which indicates the location of the research laboratory that 
set forth the innovation. As already explained, we weighted the count of patent by the share of 
the assignees in the patent that were located in the country considered.  
Results do not change substantially looking at patents or at publications. In both cases, the 
data on the location of innovative activities shows the comparative advantage of the US over 
the European countries in attracting research in the medical device sector (see Table 11).  
Since the compared countries differ greatly in terms of size, we considered the number of 
patents/publication per 100,000 inhabitants, in order to control for bias due to country size. It 
would be preferable to standardise the patent and publication counts using the number of 
R&D personnel employed in the medical device industry. Unfortunately we have no such 
information available. 
Finally, our database reports the information about the number of forward citations received 
by each patent and the impact factor of each publication. Patent counts and publication counts 
are an imperfect measure of the innovative output, due to the fact that patents differ greatly in 
terms of value. Moreover, publications in different journals have in fact a different scientific 
content. Therefore, taking into consideration the number of forward citations and the impact 
factor of publications allow us to take into account the “importance” of the innovations. As 
already explained, the number of citations tends to be correlated with the technological and 
economic value of a patent: the higher the number of citations received, the higher the impact 
of the cited patent. Consequently, patent citations provide a better measure of the 
technological and economic potential value of innovative activities than patent counts. An 
analogous argument holds for the impact factor of publications, that can be interpreted as a 
measure of the quality and relevance of the firm or country innovative activities. Table 11 
reports the number of patent citations and the total impact factor, by nationality of patent 
assignee.  
US dominance in the medical device sector turns out to be even stronger than it appears from 
patent counts data. The share of citations to patents assigned to US institutions suggests that 
on average these have a relatively greater impact on future innovative activity. European 
countries and also Japan lag far behind, and overall those countries experience a decline in 
their relative position in terms of patenting activity. The reverse is true when looking at 
publications (see Table A.6.7). 
The result is also confirmed if we consider the average number of citations received and the 
average impact factor of publications, taken as a proxy for the “importance” of the research in 
the countries analysed (see Figure 18). 
 
                                                 
51 We also considered the patents classified according to the nationality of the first inventor. No significant 
difference emerges when considering assignees or inventors. Also when considering inventors, the dominance of 
US is striking. Patents from US inventors account for over 70 percent of the total over the entire period under 
analysis. The second Country is Japan, that had a share of 5.5 percent in 2003. The first four EU countries, 
Germany, France, UK and Sweden, account for 10 percent. No significant trend or pattern in the relative position 
of innovators is shown (see Table A.7.5 for detailed statistics).  
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Table 11. US Patents and Publications, by nationality of assignee, 1974-2003 
  Patents (1974-2003) Publications (1974-2003) 
  Count % Pat. per  100.000 ab Citations % 
Cit. per 
100.000 ab Count % 
Publ. per 
100.000 ab IF % 
IF per 
100.000 ab 
US 68389 74.60 27.80 1002484 81.43 407.53 99801 37.96 40.57 206604 44.77 83.99 
EU15 11340 12.37 3.13 111260 9.04 30.68 94182 35.83 25.97 154128 33.40 42.51 
NMS 125 0.14 0.17 1165 0.09 1.59 2311 0.88 3.14 2588 0.56 3.52 
EU25 11464 12.51 2.63 112425 9.13 25.78 96493 36.70 22.13 156715 33.96 35.94 
Japan 6323 6.90 5.23 63460 5.15 52.46 21352 8.12 17.65 31725 6.88 26.23 
Germany 4255 4.64 5.35 42796 3.48 53.77 21725 8.26 27.30 31389 6.80 39.44 
UK 1734 1.89 3.03 19028 1.55 33.23 22595 8.59 39.46 38822 8.41 67.80 
France 1691 1.84 3.03 18236 1.48 32.64 10811 4.11 19.35 19160 4.15 34.30 
Switzerland 1230 1.34 18.41 14112 1.15 211.24 4812 1.83 72.03 7549 1.64 113.00 
Canada 1132 1.23 4.20 12057 0.98 44.75 9344 3.55 34.68 18717 4.06 69.46 
Sweden 1119 1.22 13.15 9300 0.76 109.22 6016 2.29 70.66 9436 2.05 110.83 
Israel 812 0.89 17.42 7314 0.59 156.84 2685 1.02 57.58 4670 1.01 100.13 
Netherlands 828 0.90 5.61 6703 0.54 45.38 6803 2.59 46.06 13810 2.99 93.50 
Australia 550 0.60 3.35 6093 0.49 37.06 5913 2.25 35.96 9456 2.05 57.51 
Italy 612 0.67 1.08 6068 0.49 10.70 8264 3.14 14.57 13259 2.87 23.38 
Total 89901 98.06  1217945 98.93  240400 91.44  435436 94.37  
Total (a) 91675 100.00  1231154 100.00  549208 100.00  844627 100.00  
Unknown (b) 2691   47575   286314   383193   
Source: ATA (2004) 
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Figure 18: Average citations and average impact factor, by nationality of 
assignee/affiliation 
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Source: ATA (2004). 
The importance of patents, as measured by the number of citations received, and that of 
publications, as measured by the impact factor, is lower for the European countries and Japan 
with respect to the US.  
At a more disaggregated level, we take into account the city of the assignee in patents or of 
the affiliation in publications. Table 12 reports the number and importance of publications and 
patents of the most productive cities, where we only considered patents and publications 
published from 1980. In particular, we selected the set of cities that ranked among the top 15 
either in terms of the citations received by their patents, or in terms of the impact factor of 
their publication. Given the results of the analysis at a national level, it is not surprising that 
the large majority of the top cities are located in the US. To get a picture also of the position 
of European cities, we included in the table the main European cities. 
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Table 12. Top cities in terms of importance of patents and publications, 1980-2003 
Patents Publications 
City Rank Pat. 
Rank  
Publ. N % N Cit. % Cit N % N IF % IF 
Minneapolis, MN 1 19 2436 5.35 39882 6.60 1518 0.70 3419 0.89 
Tokyo 2 5 3087 6.78 30456 5.04 4793 2.23 6565 1.70 
Sunnyvale, CA 3 585 884 1.94 16957 2.80 42 0.02 65 0.02 
New York, NY 4 1 1046 2.30 15477 2.56 7971 3.70 16725 4.33 
Saint Paul, MN 5 137 1318 2.89 15597 2.58 304 0.14 514 0.13 
Palo Alto, CA 7 136 906 1.99 13988 2.31 236 0.11 526 0.14 
Norwalk, CT 8 1266 886 1.95 13516 2.24 6 0.00 14 0.00 
Mt. View, CA 9 601 710 1.56 12852 2.13 36 0.02 62 0.02 
Deerfield, IL 10 2165 679 1.49 12124 2.01 9 0.00 5 0.00 
Menlo Park, CA 11 313 534 1.17 11902 1.97 52 0.02 167 0.04 
Santa Clara, CA 12 561 778 1.71 11693 1.93 29 0.01 71 0.02 
Boston, MA 14 3 666 1.46 9886 1.63 5077 2.36 13891 3.60 
Murray Hill, NJ 15 427 393 0.86 9377 1.55 16 0.01 108 0.03 
London 34 2 433 0.95 4634 0.77 7359 3.42 14286 3.70 
Seattle, WA 39 12 271 0.60 3802 0.63 2093 0.97 5178 1.34 
Cleveland, OH 44 11 236 0.52 3488 0.58 2446 1.14 5228 1.35 
Los Angeles, CA 48 8 197 0.43 3213 0.53 3046 1.41 5983 1.55 
Philadelphia, PA 51 4 278 0.61 3277 0.54 3568 1.66 7389 1.91 
Houston, TX 54 6 207 0.45 3052 0.50 3160 1.47 6533 1.69 
Paris 64 9 296 0.65 2758 0.46 3482 1.62 5784 1.50 
Chicago, IL 65 10 168 0.37 2606 0.43 2861 1.33 5694 1.48 
Baltimore, MD 66 7 184 0.40 2572 0.43 2773 1.29 6301 1.63 
Munich 67 30 422 0.93 2460 0.41 996 0.46 2176 0.56 
San Francisco, CA 77 14 127 0.28 1991 0.33 2114 0.98 4971 1.29 
Atlanta, GA 90 16 115 0.25 1610 0.27 1793 0.83 4243 1.10 
Kyoto 95 25 229 0.50 1521 0.25 1307 0.61 2415 0.63 
Berlin 119 23 238 0.52 1185 0.20 2203 1.02 2859 0.74 
Stockholm 158 31 96 0.21 788 0.13 1234 0.57 2166 0.56 
Bethesda, MD 176 15 59 0.13 670 0.11 1306 0.61 4373 1.13 
Milan 213 26 55 0.12 529 0.09 1438 0.67 2323 0.60 
Vienna 216 22 25 0.05 521 0.09 1984 0.92 2903 0.75 
Toronto 242 13 49 0.11 454 0.08 2702 1.25 5072 1.31 
Oslo 324 59 84 0.18 310 0.05 781 0.36 1335 0.35 
Rome 339 28 27 0.06 279 0.05 1736 0.81 2269 0.59 
Amsterdam 410 275 36 0.08 219 0.04 57 0.03 223 0.06 
Dublin 469 88 34 0.07 183 0.03 619 0.29 958 0.25 
Brussels 538 45 18 0.04 155 0.03 1049 0.49 983 0.43 
Edinburgh 1096 44 2 0.00 54 0.01 837 0.39 1645 0.43 
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Patents Publications 
City Rank Pat. 
Rank  
Publ. N % N Cit. % Cit N % N IF % IF 
Barcelona 1209 42 8 0.02 46 0.01 1066 0.50 1660 0.44 
Innsbruck 2246 95 9 0.02 14 0.00 468 0.22 475 0.20 
Liverpool 2272 94 1 0.00 13 0.00 483 0.22 758 0.20 
Madrid 2412 27 6 0.01 11 0.00 1315 0.61 781 0.59 
Source: ATA (2004). 
Figure 19 reports the average number of citations and the average impact factors of 
respectively the patents and publications by the cities of the assignee/main author. 
The analysis confirms the results of performance on a national level, i.e. the importance of US 
research with respect to the research in European and Japanese cities. 
 
Figure 19: Average citations and average impact factor, by nationality of 
assignee/affiliation 
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Source: ATA (2004). 
Figure 19 also shows the existence of high heterogeneity within European boundaries and the 
ranking in terms of publications and of patents, suggesting the existence of different 
performance of academic and private research. This is true also for US cities. However, the 
case of Minneapolis is very interesting. This city ranks first in terms of the number of patents, 
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but it’s only 19th when we look at publications. This is due to the fact that this city is the head-
quarter of one important medical device firm. However, even though in terms of publications 
the city is not among the top 15, its research is highly important when we consider the 
average impact factor of its publications.  
On the other side, Sunnyvale is populated by a large number of small firms, and its ranking in 
terms of publications is very low, also in terms of importance. In Boston, where we have both 
companies and public research organisations innovating in the medical device field, the 
“importance” of both patents and publications is very high. 
Next, we consider the pattern and characteristics of co-assigned patents, i.e. the patents that 
are jointly owned by two or more institutions. Patent co-assignment represents a particularly 
strong form of collaboration among organisations. We considered the US patents with more 
than one assignee, totalling 13,028 patents.  
Figure 20. Share of co-assigned US patents, evolution over time  
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Source: ATA (2004). 
The evolution of the number of co-assigned US patents over the period 1980-2003 is reported 
in Figure 20. Patent co-assignment in the medical device industry is only a recent 
phenomenon: the number is very small up to the end of the 80s and increases slightly during 
the 1990s. We then register a sharp increase in later years from 2001 to 2003. It is interesting 
to notice that this is concomitant with the decrease in the number of R&D licensing 
agreements. Whether this is only a transient phenomenon or corresponds to a shift in the way 
innovative activities are organised within the medical device industry is a question that needs 
to be further investigated. 
Another interesting question is the following: do firms choose collaborators within the same 
country or is there a cross-national pattern of collaboration among medical device 
organisations? 
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Focusing on the patents in the US, we took into account the nationality of each assignee for 
the patent. Then we considered four broad categories: US, Europe, Japan, and “Others”, and 
analysed the patterns of collaborations among these groups. We only considered the more 
recent patents, i.e. the patents granted in the years 2002 and 2003. 
Table 13. Nationality of partners in co-assigned patents 
 US Europe Japan Other 
US 563 33 6 28 
Europe  102 0 5 
Japan   53 1 
Other    90 
Source: ATA (2004). 
The largest number of co-assignment takes place within the US, with almost 70 percent of co-
assigned patents involving only US institutions. Moreover, a significant amount of 
collaborations takes place within European boundaries, and among the patents involving at 
least one European organisation. About 20 percent also involves a US organisation. Finally, 
the number of collaborations between Japanese organisations and institutions outside Japan is 
fairly limited (see Table 13). 
The existence of a patent or a publication however does not ensure improvement to health 
conditions. The impact of new technology occurs at the diffusion stage, where clinicians and 
government policies influencing the pricing and reimbursement regime of the new device play 
an important role. Even if a certain health technology is available in a country, its true impact 
can only be fully realised if there exists adequate dissemination in the healthcare industry (van 
Merode, Adang, Paulus, 2002). 
As a more reliable measure of inventive output, we therefore take into consideration the 
introduction of medical devices into the US market. Unfortunately, we have no available data 
about sales of medical device products; therefore, we are not able to assess their diffusion. 
Data for the analysis presented here are drawn from the FDA web site52. We have extensively 
checked data sources and have not been able to access similar information for the European 
countries53. 
European regulation differs from the FDA regulation for marketing devices (Chai, 2000). 
However, both systems entail different rules according to the potential risk of injury of the 
new devices present to the users54 and accordingly assign different regulatory control 
mechanisms to each class. Moreover, both systems have similar post-market regulatory 
controls.  
                                                 
52 http://www.fda.gov/cdrh/consumer/mda/index.html#databases 
53 A European Database on Medical Devices (EUDAMED) is under development. However it will be only 
accessible to regulatory authorities. 
54 See OTA (1984); http://www.fda.gov/cdrh/manual/ireas.html#24; Eucomed (2004). 
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In Europe, devices are classified into four categories (Class I, IIa, IIb, and III), according to 
the risk associated with the device usage, the amount of time that the device is in contact with 
the human body, and the degree of invasiveness of the device. 
A set of essential requirements has been designed to ensure the highest level of patient and 
user security, besides the device performance. All medical devices must comply with these 
essential requirements, involving manufacturer registration, and administrative and safety 
requirements. In addition, all medical devices must comply with a set of conformity 
assessment procedures, i.e. a scheme designed to regulate the level of scrutiny required to 
deem a medical technology or device safe, based on the level of its inherent risk to the user, 
ranging from simple compliance with essential requirements for Class I devices to the 
Notified Body’s evaluation of full quality systems for Class III devices. 
If the product conforms to all the applicable community requirements and all the appropriate 
conformity assessment procedures have been completed, a CE marking is affixed on the 
product, and the Member States are not allowed to restrict usage of the product, unless 
evidence of non-compliance of the product is produced. 
Following recommendations from FDA classification panels, in the US devices are classified 
into three regulatory categories: 
 Class I contains devices for which general controls are sufficient to provide reasonable 
assurances of safety and effectiveness (for example: elastic bandages, examination 
gloves); 
 Class II encompasses devices which cannot be classified in Class I, and for which special 
controls, which might include special labelling requirements, mandatory and voluntary 
performance standards and post-market surveillance, are required (for example: X-ray 
devices, infusion pumps); 
 Class III applies to devices that cannot be classified in Class I or II and which support 
life, prevent health impairment, or present a potentially unreasonable risk of illness or 
injury, like cardiac pacemakers. 
Unless exempted55, manufacturers must register their devices with the FDA. The faster 
marketing process is the Pre-marketing Notification 510(k), under which the sponsor has to 
demonstrate that the device to be marketed is substantially equivalent to a legally marketed 
device that is not subject to PMA, in order to prove safety and efficacy. The notification has 
to be submitted to FDA at least 90 days before the marketing of the device. If FDA finds that 
the device is not substantially equivalent to one already in use, then the device must go 
through a Pre-market Approval (PMA) process56, which is the most stringent type of device 
marketing application required by FDA. As a result, the device is also automatically classified 
into Class III. PMA process requires valid scientific evidence to be provided by the 
manufacturer in order to prove safety and effectiveness for the device’s intended use(s). All 
clinical evaluations of investigational devices, unless exempt, must have an approved 
investigational device exemption (IDE) before the study is initiated. This allows the limited 
use of the investigational device in a clinical study in order to collect safety and effectiveness 
data required to support a PMA or a 510(k) submission to FDA57.  
                                                 
55 Given the low risk involved in their management, most Class I devices are exempted from the Pre-market 
Notification, while Class II devices usually are not. 
56 Only 1 percent of the medical devices in commercial distribution have gone through the PMA process. 
57 Clinical studies are most often conducted to support a PMA. Only a small percentage of 510(k)’s require 
clinical data to support the application. 
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We explored FDA databases containing information about IDE, Pre-marketing Notifications, 
and PMA. 
Figure 21 reports the evolution over time of IDE, 510(k), PMA, and PMA supplements 
distinguishing between the time of request (R) and of approval (A).  
The number of IDE has increased sharply from 1994 to 1998, and it is declining in the later 
years. The number of Pre-marketing Notifications, after a slight increase in the early 1990s, is 
decreasing over time, and it is been almost constant in the latest years. No clear trend emerges 
when we look at the number of PMA and PMA supplements. 
Notice the lower figures involved when dealing with PMA as compared to 510(k) 
notifications: the number of devices requiring clinical trials are a small percentage of the total 
number of devices in the market. Most devices are classified into the lower risk category. 
Figure 21. Evolution over time: PMA, PMA-S, IDE, 510(k) 
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Source: Our elaborations on FDA (2004a; 2004b). 
Table 14 reports the share of devices by class, classified according to their level of risk. 
We considered all the medical devices in commercial distribution in the US by both domestic 
and foreign manufacturers with a known owing corporation.  
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Table 14. Share of device by class 
 Share by Device Class (%) 
Country of corporation 
Number of  
products Unclassified Class 1 Class 2 Class 3 
US 265,078 2.33 45.82 48.58 3.27 
EU15 25,802 1.95 57.67 39.00 1.38 
NMS 219 0.46 76.71 22.37 0.46 
EU25 26,021 1.94 57.83 38.86 1.37 
Japan 3,713 1.45 38.81 58.69 1.05 
Germany 11,885 1.85 67.57 29.78 0.80 
UK 4,105 2.90 42.05 53.69 1.36 
France 2,532 2.09 57.98 37.20 2.73 
Sweden 2,223 1.71 43.95 52.27 2.07 
Denmark 2,073 1.50 48.91 48.09 1.50 
Switzerland 1,678 1.97 66.09 31.53 0.42 
Canada 1,381 4.13 59.23 35.41 1.23 
Italy 1,359 1.40 63.28 33.55 1.77 
Ireland 592 0.00 37.16 59.12 3.72 
Belgium 391 0.00 60.10 39.39 0.51 
Netherlands 265 4.53 50.19 43.77 1.51 
Spain 157 1.91 57.32 39.49 1.27 
Poland 110 0.91 80.91 18.18 0.00 
Austria 106 1.89 66.98 27.36 3.77 
Finland 106 5.66 47.17 47.17 0.00 
Norway 89 5.62 38.20 56.18 0.00 
Iceland 63 0.00 82.54 17.46 0.00 
Czech Republic 48 0.00 85.42 12.50 2.08 
Hungary 39 0.00 58.97 41.03 0.00 
Lithuania 16 0.00 81.25 18.75 0.00 
Total 316,674 2.28 48.93 45.90 2.90 
Source: our elaborations on FDA (2004d). 
Even though it is problematic to compare the number of products commercialised by US and 
European corporations, interesting information can be drawn from the table. Germany is the 
European country with the largest presence in the US with 11,885 products, followed by the 
UK with 4,105 products. Japan ranks only third with 3,173.  
Also, it is interesting to compare the share of devices classified in Class I, II, and III, 
identifying devices with a different level of potential risk for human health, and, due to the 
fact that they require closer inspection by the relevant authorities, with different levels of 
investments and complementary assets.  
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The share of Class I (low risk devices) is higher than 80 percent, pointing to an industry 
focused on low risk devices, in Poland, Czech Republic, Iceland and Switzerland. 
Austria and Ireland are the European countries with the largest share of products classified 
into Class III, the class with higher-risk devices requiring clinical trials. 
The result for Ireland is interesting when coupled with the large ownership of US-based 
corporations of Irish manufacturers (see Table 7 in Section 6). 
In fact, a large share of firms in the manufacturing sector in Ireland is owned by foreign 
corporations (see Barba Navaretti and Venables, 2004). Nowadays almost 50 percent of the 
Irish manufacturing employment is in foreign-owned firms (61 percent of them being US 
firms), as compared to an average for the other European countries (EU-15) of 19 percent. 
Despite this general pattern, medical and optical equipment are among the sectors where 
foreign industry predominates. 
Various factors have contributed to the strong increase in FDI inflows in Ireland. 
Starting from the late 1950s, the country introduced a zero tax rating on profits derived from 
manufactured exports, making Ireland a preferred exports platform for firms in Continental 
Europe and the US. By the 1980s, Ireland had become a well-established European 
production base for US multinationals, therefore being well positioned to capture the FDI 
inflows when US corporate strategy began to respond to the forthcoming Single European 
Market in the late 1980s-early 1990s. 
Besides the tax regime, other factors are likely to have been of importance. 
First of all, the role played by Ireland’s Industrial Development Agency (IDA), that was able 
to identify the sectors most suited for Ireland’s development aims, and that had an influence 
on successfully upgrading the human capital and physical infrastructure required to attract 
firms from these sectors. 
Moreover, the labour market conditions, the quality of public infrastructure (also enhanced by 
IDA), and the efficiency of the public administration system have also likely been of 
importance. 
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7. STATISTICAL SHORTCOMINGS FOR THE SECTOR: ANALYSIS AND 
PROPOSALS 
Summary of the chapter 
The lack of systematic effort at an international level to collect, integrate, update and diffuse 
primary data and information on the state and the evolution of the medical device industry 
represents a severe limitation to this study and to previous analytical efforts. This also 
dramatically reduces the possibility of formulating any reliable policy action to enhance the 
competitiveness and productivity of the EU medical device industry, limit the effect of market 
failures in healthcare systems and design and support the constitution of a European system of 
innovation.  
After describing the main characteristics and shortcomings of the data sources employed in 
the analysis, we propose a statistics framework for the creation of a data collection system 
targeted at the medical device industry.  
Firstly, single national statistical offices, regulatory authorities and international institutions 
urge the identification of a common definition for the medical device industry and a 
classification of relevant medical device sub-sectors based on both market and technological 
factors.  
Secondly, regulatory authorities and public institutions in general should provide incentives to 
private companies to communicate micro-level data on their activity. 
Thirdly, no efficient political action to support the competitiveness of the industry in Europe 
should be designed without the possibility to control the actual state of the industry and the 
effect of public intervention. 
Data and statistical information are the unique base upon which informed policy actions can 
be undertaken. 
7.1 Description of data sources 
Data used in this Study have been extracted by different sources. Both at the macro level, and 
even more so at the micro level, comparability of the figures across countries and sub-sectors 
is severely limited by non-homogeneous definitions and classifications employed by the 
different data sources.  
The analysis at the country level has been carried out regardless of the origin of the company 
and considering the medical device industry as a whole. The data for the analysis of the 
medical device industry competitiveness and innovativeness have been drawn from public 
sources, namely the Eurostat, the Japanese Ministry of Health, Labour and Welfare, and the 
data supplied by the US Census Bureau, briefly described in the following. In addition, 
market data for selected sub-markets have been obtained through Industry Trade 
Associations. 
For the European countries, data have been collected from the NewCronos database (Eurostat, 
2004a; 2004b). We considered the NACE 33.1, which reports data on “Manufacture of 
medical and surgical equipment and orthopaedic appliances”. 
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The data cover the period 1995-2002 and include58: 
 manufacture of instruments and appliances used for medical, surgical, dental or veterinary 
purposes (electro-diagnostic apparatus such as electrocardiographs, ultrasonic diagnostic 
equipment, scintillation scanners, nuclear magnetic resonance apparatus, dental drill 
engines, sterilisers, ophthalmic instruments); 
 manufacture of syringes, needles used in medicine, mirrors, reflectors, endoscopes, etc.; 
 manufacture of apparatus based on the use of X-rays or alpha, beta or gamma radiation, 
whether or not for use in human or animal medicine (X-ray tubes, high-tension 
generators, control panels, desks, screens, etc); 
 manufacture of medical, surgical, dental or veterinary furniture (operating tables, hospital 
beds with mechanical fittings, dentists' chairs); 
 manufacture of mechano-therapy appliances, massage apparatus, psychological testing 
apparatus, ozone therapy, oxygen therapy, artificial respiration apparatus, gas masks, etc.; 
 manufacture of orthopaedic appliances (crutches, surgical belts and trusses, splints, 
artificial teeth, artificial limbs and other artificial parts of the body, hearing aids, 
pacemakers, etc.). 
A major limitation of the NACE classification is the exclusion from the medical device 
aggregate of the high-tech chemical and biochemical-based devices such as in vitro 
diagnostics (that are classified under “chemicals”) and medical-impregnated products such as 
gauzes and bandages (that are grouped under “pharmaceutical preparations”). As a result, 
estimates of the R&D intensity of the sector for the European countries are biased 
downwards. 
Data for Japan are based on data published by the Ministry of Health, Labour and Welfare 
(MHLW), and they have been obtained through the Japanese Federation of Medical Device 
Associations (JFMDA). Data about the composition of the industry and R&D employment 
and expenditures are based on the results of a survey of a subset of the firms that are active in 
the industry. The data are likely to reflect the characteristics of the larger firms, since smaller 
firms are less likely to respond to the survey, due to the lack of personal resources. 
Unfortunately, it is not possible to assess the response rate on the basis of the firm size, since 
we do not have prior knowledge about the composition of the industry.  
For the US, we have not been able to find data related to the medical device industry as a 
whole. We therefore accessed different data sources, including data published by the US 
Census Bureau, and summed up the data of the following NAICS sector: 
 325413: In-Vitro Diagnostic Substance Manufacturing; 
 339111: Laboratory Apparatus and Furniture Manufacturing; 
 339112: Surgical and Medical Instrument Manufacturing; 
 339113: Surgical Appliance and Supplies Manufacturing; 
 339114: Dental Equipment and Supplies Manufacturing; 
 339115: Ophthalmic Goods Manufacturing; 
                                                 
58 A detailed description of the class is available through the European Commission web site 
http://europa.eu.int/. Data contain many missing value, therefore the computation of the European aggregates 
(both EU-15 and EU-25) is problematic, especially for the R&D data. 
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 334510: Electromedical and Electrotherapeutic Apparatus Manufacturing; 
 334517: Irradiation Apparatus Manufacturing. 
The analysis was based on various measures aimed at assessing the capabilities and 
competitiveness of European industry, especially in comparison with the US and Japan. 
As for the analysis at the sub-market level, we considered data from a proprietary database, 
Compustat North America (Standard and Poor’s Compustat®, 2004b), which reports data 
about public companies in the US and Canada. In this analysis larger firms are over-
represented. In addition, Compustat assigns each firm to a specific industry on the basis of its 
principal line of activity; therefore, it is not possible to distinguish the portion of R&D (and 
sales) that directly relate to the medical device industry for the large and diversified 
multinational companies. 
Data on international trade flows usually report information at the product level, allowing us 
to also perform analysis that considered well-defined product classes. 
Data have been extracted by two different sources: the Eurostat ComExt Database and the 
Trade Database of the US International Trade Commission. The data sources respectively 
classify imports and exports of European countries and the US, according to the sources and 
destinations of international flows. 
As for the classification of products, the two data sources employ two different systems for 
grouping the devices: the European data employs the Combined Nomenclature (CN), while 
the US International Trade Commission database is based upon the Harmonised Tariff 
Schedule (HTS). However, there exists full agreement between the two classification systems 
at six-digit level, i.e. the level of aggregation that we employ in the analysis.  
In order to be consistent with the analysis presented at the country level, we decided to 
resemble products by manufacturers classified in the NACE 33.1. Particularly, we considered 
the following classes (at the four-digit level): 
 9018: instruments and appliances used in medical, surgical, dental or veterinary sciences, 
including scintigraphic apparatus, other electro-medical apparatus and sight-testing 
instruments n.e.s.; 
 9019: mechano-therapy appliances; massage apparatus; psychological aptitude-testing 
apparatus; ozone therapy, oxygen therapy, aerosol therapy, artificial respiration or other 
therapeutic respiration apparatus; 
 9021: orthopaedic appliances, including crutches, surgical belts and trusses; splints and 
other fracture appliances; artificial parts of the body; hearing aids and other appliances 
which are worn or carried, or implanted in the body, to compensate for a defect or 
disability; 
 9022: apparatus based on the use of x-rays or of alpha, beta, or gamma radiation, whether 
or not for medical, surgical, dental or veterinary uses, including radiography or 
radiotherapy apparatus, x-ray tubes and x-ray generators, high-tension generators, control 
panels and desks, screens, examination or treatment tables; 
 9402: medical, surgical, dental or veterinary furniture, e.g. operating tables, examination 
tables, hospital beds with mechanical fittings and dentists' chairs; barbers' chairs and 
similar chairs having rotating as well as both reclining and elevating movement. 
At the micro-level, different sources have been considered to provide a comprehensive picture 
of the innovation process in medical devices. Most of the analysis is based upon the ATAdb 
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(ATA, 2004) providing detailed information, at the firm level, about various aspects of the 
innovation process in medical devices. In particular, we considered patents, publications, and 
deals among firms in the medical device industry. As for product introduction, we have been 
forced to use data about the US market, freely available on the FDA web site. We are not 
aware of data about the introduction of medical devices in Europe that are suited for statistical 
analysis. Patents and publications would be also available through public web sites, but in a 
form that needs processing before being suited for statistical purposes. 
Unfortunately, the comparison of the indicators devised for the description of the innovation 
process in different sub-markets is complicated by the different classification employed by 
each piece of information. Patent data employ a technology-based classification, which is 
different and not easily reconciled with the classification employed for publications and 
product introduction. 
The first step towards the development of a comprehensive statistical system for the analysis 
of the medical device industry a national level is certainly a clear definition of the industry 
and of the sub-markets involved.  
A definition is given in the European Union Medical Devices Directive (93/42/ECC), article 
1, which covers “any instrument, apparatus, appliance, material or other article, whether 
used alone or in combination, including the software necessary for its proper application 
intended by the manufacturer to be used for human beings for the purpose of: 
 diagnosis, prevention, monitoring, treatment or alleviation of disease; 
 diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap; 
 investigation, replacement or modification of the anatomy or of a physiological process; 
 control of conception; 
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its 
function by such means.” 
Against this background, the Directive has provided a common background for regulatory 
framework for market access, international trade relations and regulatory convergence of the 
industry. This is not yet reflected in the definitions and classifications in the data. 
In our Study, we have been forced to adopt broader or narrower definitions of medical 
devices, in order to address specific issues or, for the empirical analysis, to account for data 
availability.  
In addition, since the medical device industry is highly heterogeneous, a detailed 
classification of the industry is needed in order to compare sub-markets at the country level.  
Besides under-representing the high-tech part of the industry, the NACE classification does 
not allow to recover fine-grained information at the sub-market level, in order to assess the 
competitiveness of European countries in different sub-sectors. The current revision of the 
NACE classification should consider the provision of statistics at the sub-market level and 
should set a harmonised definition of these sub-markets across different countries. An effort 
should be made in order to isolate the in-vitro diagnostic industry from chemicals and 
pharmaceutical preparations, as to include this segment into the medical device aggregate 
statistics at the European level. 
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7.2 Towards a statistics framework for medical devices 
The definition of medical devices set forth in the Global Medical Device Nomenclature 
(GMDN) might be adopted for data collection purposes. The definition has been devised by 
the Global Harmonisation Task Force (GHTF), founded in 1993 by the governments and 
industry representatives of Australia, Canada, Japan, the European Union and the United 
States to encourage a convergence in standards and regulatory practices related to the safety, 
performance, and quality of medical devices (WHO, 2003). 
The GHTF has proposed the following definition of medical devices: 
“Medical device” means any instrument, apparatus, implement, machine, appliance, implant, 
in vitro reagent or calibrator, software, material or other similar or related article, intended by 
the manufacturer to be used, alone or in combination, for human beings for one or more of the 
specific purposes of: 
- diagnosis, prevention, monitoring, treatment or alleviation of disease 
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury 
- investigation, replacement, modification, or support of the anatomy or of a 
physiological process 
- supporting or sustaining life 
- control of conception 
- disinfection of medical devices 
- providing information for medical purposes by means of in vitro examination of 
specimens derived from the human body and which does not achieve its primary 
intended action in or on the human body by pharmacological, immunological, or 
metabolic means, but which may be assisted in its function by such means. 
We would therefore recommend the Commission to support the creation of a statistical data 
collection system targeted at the medical device industry as defined above. The importance of 
the industry in supporting health improvements and in increasing the quality of life is 
uncontroversial. However, informed policy actions can be only undertaken on the basis of 
data and statistical information. 
Against this background, we take on some of the issues identified in the Biotechnology 
Statistics Framework (OECD, 2001, 2004) and we try to set up a statistic framework for the 
medical device industry. 
We have identified a set of key indicators that are useful for describing various features of the 
industry and matched each indicator with a type of policy, trying to evaluate the usefulness of 
each indicator for different policy options. 
The results are summarised in Table 1 (adapted from Arundel 2003; OECD, 2004), where we 
also indicate the availability of data for the construction of the selected indicators among the 
EU-25 countries. Indicators with a “high” rating are available for 15 or more European 
countries, those with a “medium” rating are available for four to 15 countries, and those with 
a “low” rating are available for three or fewer countries.  
The last column of Table 1 provides information on the source of the original data for each 
indicator. Four main types of organisations collect data: government or international public 
organisations (GOV) such as the USPTO or EPO, national statistical offices (NSO), 
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academics, usually based at universities or semi-independent public research organisations 
(ACD), and private organisations, such as consultants or industry trade groups (PRI).  
In some cases, the indicator is collected by more than one type of organisation. If this is the 
case, the type of organisation providing more accurate data is listed first. 
We have tried to evaluate the usefulness of each indicator in terms of policy options. In 
particular, the indicators are divided into three main fields including those for (adapted from 
OECD, 2001, 2004; Arundel, 2003): 
1. The development of the medical device industry, which can be further classified into: 
(a) supporting research in medical devices; (b) fostering the diffusion of knowledge 
and expertise among different actors; (c) supporting the commercialisation of medical 
devices. 
2. The economic impacts and social issues, including the impact of medical devices on 
health, not directly relevant to a specific set of policies, but rather of vital importance 
and applicable to every policy areas. 
3. Industrial policy: a detailed description of the main feature of the industry is the 
necessary ground for guiding any policy aimed at fostering the competitiveness of the 
European medical device industry. 
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Table 1. Medical device indicators: relevance for main policy areas 
Indicator Supporting research 
Dissemination 
of knowledge 
Commercialisation 
and diffusion 
Impact and 
benefits 
Industrial 
policy 
Availability 
by country 
Main data 
source 
Patents granted 9 9  ?  High GOV/PRI 
Patent share of worldwide patents 9 9  ?  High GOV/PRI 
Patent growth rate 9 9  ?  High GOV/PRI 
Patent applications 9 9  ?  High GOV/PRI 
Scientific literature and impact 9 9  ?  High GOV/PRI 
International trade   9   High GOV 
Total R&D expenditures 9    9 Medium NSO 
Production     9 Medium NSO/PRI 
Value added     9 Medium NSO/PRI 
Number of employees     9 Medium NSO/PRI 
Number of firms    ?  9 Medium NSO 
Number of MD firms by size class   ?  9 Medium NSO/PRI 
Number of MD firms by area/field   ?  9 -- ??? 
MD alliances   9 ?   Medium PRI 
MD M&A  9 ?  9 Medium PRI 
Technology licensing  9 ?   Medium PRI 
Public R&D funding  9   ?  Low NSO 
Private R&D funding 9   ?  Low NSO 
Funding sources for SMEs 9   ?  -- NSO/GOV 
MD revenues/sales      9 Low PRI 
Market approval for MD   9  9 -- GOV 
Co-patenting or co-publishing  9  ?  Low PRI/ACD 
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As the medical device industry is highly research intensive, we first considered the information 
necessary for supporting research within this sector. There are two main ways in which government 
can support research: direct research activities by the public sector and direct and indirect 
government funding of the private sector research. Moreover, the public sector can sustain the 
private sector direct investment in medical device innovation by establishing a stable environment 
with respect to reimbursement, funding, and price mechanisms. 
Relevant indicators for the public funding of research for medical devices consist of both basic data 
on public R&D spending in medical devices and intermediate output measures of public research 
activities such as patenting by public research institutes. The availability of data about the sources 
of funding for the private R&D activity is limited within the medical device industry, and also we 
know very little about the funding sources for small and medium enterprises. 
Patents and scientific literature can be useful sources of information. Actually, these indicators have 
little or no direct relevance to the design of specific policies, but they provide useful insights into 
national capabilities. However, they can help governments decide if they need to introduce a range 
of policies to promote national capabilities in medical devices, and they can be employed as an 
output measure of the success of government actions undertaken to promote research in the field. 
An effort needs to be undertaken to classify patent information into public and private sources. In 
addition, academics are often involved in the research undertaken by large firms, but the public 
research organisation is not mentioned among the assignee(s) in the patent document. 
Another relevant aspect of patents and of the scientific literature is their contribution to the 
diffusion of knowledge within the industry. Many public policies provide incentives for 
collaboration in order to diffuse knowledge and expertise among different actors. These include 
subsidies to private firms to contract research out to public institutes, passive incentives to increase 
the number of contacts between public research and private firms, and research subsidies for private 
firms that require collaborative networks. Under this perspective, it is of interest to analyse the 
magnitude and direction of M&A and alliances, and of technology licensing. Moreover, data about 
co-patenting and co-licensing are useful sources of information for understanding the patterns of 
knowledge diffusion within the sector. Under this perspective, and given their different incentives 
for doing research, it is of interest to characterise the University-Industry linkage (if any) by 
analysing the patterns of co-patenting and co-publishing of private firms and public research 
organisations. 
A major limitation to the analysis of the medical device sector is the lack of detailed and 
comparable data on the state and evolution of products, firms, industries and markets. A first 
important step to partially overcome this problem at the EU level would be the completion of the 
European Database on Medical Devices (EUDAMED). EUDAMED is under development with the 
aim of helping European authorities to conduct market surveillance on medical devices through 
information exchange59. Since the first pilot study launched in 1997, some progress has been made; 
however, EUDAMED is not yet operational. In particular, the decision to use a common 
notification by National authorities and the adoption of the Global Medical Devices Nomenclature 
(GMDN) constitute two important steps toward the implementation of a European Database for 
medical devices. 
EUDAMED will be an information system for exchanging legal information between national 
competent Authorities and the Commission. Only these entities will have access to the database. 
Nevertheless, the “EUDAMED Global Implementation Plan” states that “a more widespread access 
to the system may be allowed following discussion, at a later stage”. Given the nature of the data 
that will be loaded in the database, we strongly recommend a wider access to the database, also for 
the purpose of statistical analysis. 
                                                 
59 Information about EUDAMED has been obtained at http://europa.eu.int/idabc/en/document/2256/16#what. 
 168
High quality operational data will be loaded in the database as specified in the medical devices 
Directives. These will include: 
y data related to registry of manufacturers, authorised representatives and devices;  
y data related to certificates issued, modified, supplemented, suspended, withdrawn or refused 
according to established procedures;  
y data obtained in accordance with the vigilance procedure on incidents or near-incidents which 
occur during the use of the medical device. 
Besides regulatory benefits, in terms of registration, vigilance and other investigations to the 
relevant national authorities, the availability of information about manufacturers and their products 
at a centralised place will greatly enhance the possibility of statistical analysis of the industry, 
allowing a deeper understanding of the characteristics of the medical device industry in Europe, and 
opening up the possibility for the suggestion of targeted policy actions. 
At a later stage, further information might be required from the companies, including product sales, 
R&D expenditures, patent applications, deal activities, in order to provide a database that is suited 
for the analysis of competitiveness and innovativeness of the medical device industry in Europe. 
This as a prerequisite for the suggestion of policies aimed at enhancing the competitiveness and 
innovativeness of the European medical device industry. 
 
 169
8. POLICY RECOMMENDATIONS  
This chapter proposes strategic recommendations to the European Commission and Member States 
on policy options for the medical devices sector, based on the analysis of previous chapters. As a 
starting point, policymakers must be aware of the inherent complexities of the medical device 
sector, whereby a heterogeneous and vital innovative medical devices industry is also a crucial 
component of European healthcare systems. This means that no easy-menu exists for policies aimed 
at controlling costs while enhancing the quality of health services, as well as innovation and 
competitiveness of the European medical device sector. The endorsement of these distinct 
objectives implies trade-offs and difficult resource allocation decisions. 
The following policy recommendations are based on another general principle: policy options need 
to rely mainly upon market incentives, rather than on administrative mechanisms of control. 
Generally speaking, administrative regulation applied to the markets for health services and 
products, as well as to other markets, has often proved distorsive, detrimental for innovation, and 
ineffective in the long-run. Commonly addressed options such as limiting the supply of medical 
technology, constraining investments in med-tech R&D and imposing administrative caps on the 
supply side of the market cannot be considered as viable options for Europe in the long-run. All the 
following policy options are directed at enhancing market signals and incentives in a coherent 
framework, and at lowering the adversity of the trade-offs by leveraging on the overall efficiency of 
the system. 
 
1. Member States and the European Commission should clearly state the key policy 
objectives and address the policy options in their full complexity and trade-offs 
The Study has revealed the existence of a common constraint – i.e. expenditure control – to three 
key policy objectives that are high on the agenda of the European Commission and all Member 
States: quality of health treatment, innovation and competitiveness of the medical device industry. 
As seen in the Study, the debate and literature on innovation in medical devices and technological 
progress in medicine has sometimes confounded the notions of quality and innovation. Innovation 
for instance has often been misconceived as a synonymous of improvement in medical practice. The 
Study has also assessed and highlighted that these objectives are of top-relevance for all European 
and Western countries, and are no longer deferrable. Governments need to take political choices on 
how to face the tension between their commitments to quality of care, medical innovation, and 
healthcare cost-containment needs. Nonetheless, for the most part, policies have been unwilling to 
acknowledge the inherent trade-offs between healthcare costs, people’s access to high quality care, 
and innovation. 
A preliminary exploration of the viable options and a better understanding of the interdependencies 
among policy objectives are strongly recommended. This prerequisite is vital to the development of 
coherent policy agendas and to the diffusion of consistent signals to the actors in the medical device 
sector.  
 
2. Member States should enhance their coordination to define concerted policies in 
order to send consistent signals to the market, reduce uncertainty, orient R&D and 
innovation toward cost-reducing or affordable technologies 
Both the theoretical and empirical analyses presented in the Study have shown that the diffusion of 
a number of existing technologies has been highly responsive to market signals and insurance-
related incentives. Decisions affecting the use of, and payments for, treatments based on medical 
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devices affect the expectations about profitability of various prospective products and the incentives 
to develop and produce them. In the past, the incentives injected in the market favoured the 
development of new medical technologies, regardless of their costs. The change in the incentives, 
marked by the move toward prospective-based insurance systems, altered the direction of medical 
innovation in favour of the development of cost-reducing and efficiency-enhancing medical devices 
and practices. 
Measures that affect the incentives to innovation, such as payment and reimbursement schemes, 
have proved to be policy tools for cost-conscious health insurers, capable of directing R&D 
incentives and innovation toward more “favourable” trajectories. Given the fact that medical device 
manufacturers operate under shorter R&D time horizons than, for instance, pharmaceutical 
manufacturers, the time for action of these incentives is of mid-to-short term. 
In order to turn this mechanism into an effective policy option, it is necessary that a) these 
incentives are operated consistently by a large “critical” mass of health schemes/systems; and b) a 
reference criteria for “efficiency-enhancing” is set and shared through technology assessment tools, 
since the key issue for health systems is not only how much costs are rising but also what is being 
achieved in terms of health benefits for the resources consumed (Recommendation 3).  
Medical R&D incentives are at present determined by the uncoordinated decisions of governments 
and private-sector insurers in each nation. The ambiguity of public policy on the issue of medical 
devices and healthcare cost-containment is generating economic uncertainty in the R&D 
environment. This is adding new uncertainties to the process by which innovator companies bring 
new products to the markets, to the detriment of the innovative process.  
Democratic societies find it difficult to resist incurring the costs of providing widespread access to 
new technologies and medical advances, regardless of their costs. A coordinated agenda for the 
Member States for the sector – oriented at maintaining the rate of innovation, but redirecting it 
toward cost-reducing technical change – could influence the multitude of new medical devices in 
their R&D investment decisions, rather than making the hard choices on utilisation only after 
products have been developed. 
 
3. Members States should enhance the use of evidence-based medicine and health 
technology assessment (HTA) analysis as an input to: a) their coverage policies; b) to 
their policies aimed at incentivating and strengthening research, development, and 
innovation in medical devices 
The policy trade-offs inherent to the medical device sector should be translated to a long-term cost-
effective equilibrium. Greater adherence to the practice of evidence-based medicine and greater 
assessment of technology before and once in use may all lead to gains in efficiency.  
The recognition that healthcare technology contributes to health spending growth has led to a recent 
expansion of the technology assessment focus, from “Is it safe?” and “Does it work?” to include 
considerations of cost-effectiveness, thus becoming “Is it worth it?”. This would move the present 
debate from how much costs are rising due to innovation in medical devices to what is being 
achieved in terms of health benefits for the resources consumed. Conducing cost-effectiveness 
analysis will not remove the need for difficult resource allocation decisions. But explicitly 
illuminating the trade-offs involved should help the process. 
Implementing an economic criterion will also create an incentive for producers to develop cost-
effective products in the first place (Recommendation 2).  
Despite the fact that the number of well-designed clinical trials have grown dramatically in the past 
few years, and that medical journals now routinely publish cost-effectiveness analysis, the use of 
 171
HTA by policymakers as an explicit part of the decisions on coverage, funding and clinical 
guidance, though increasing, is still limited, and confined to a minority of Member States. 
This Study recommends to all Member States the use of HTA methodologies as an input to rational 
choices. An extensive use of this tool would not only contribute to the efficiency of the national 
choices, but also to the broader system of consistent signals to the industry (Recommendation 2).  
Since the health impact of the devices cannot be isolated by the system where it is used the 
responsibilities for conducting HTA should stay at the level of a set of “centers of excellence” under 
the responsibility of Member States. The European Commission should favour the diffusion of 
information about medical technology innovations and best medical practices throughout Europe. 
Unlike the pharmaceutical sector, where new products go through a costly series of regulatory 
clinical trials during development and pre-launch, HTA applied to medical devices should be 
performed mainly at the post-market phase, due to: a) the fact that once a class of devices is 
established with accepted clinical data, pre-market clinical trials for incrementally improved devices 
are not required for CE Marking, so no clinical data is available for pre-marketing; b) many device-
based interventions are subject to a learning curve which improves outcomes after marketing; c) 
incremental post-launch product improvements d) the dependence of outcomes from system factors, 
that cannot be assessed a priori.  
HTA of medical devices can be seen and used not only to illuminate cost-containment decisions, 
but also to wise up industrial policy and promote innovation. Long-term evaluation of the benefits 
and costs (clinical, social, economic and system-wide) of a technology in a given system provides 
the “value” of the technology and of the innovation that introduced it into practice. 
The economic and medical evidence provided by HTA can therefore be used to set up innovation-
oriented pricing and reimbursement schemes.  
In this perspective HTA and the long-term evaluation of the benefits and costs are instruments to: 
 appreciate the application spectrum of innovative outcomes; 
 promote the uptake of valuable medical innovations; 
 ensure rapid and equal access to new medical devices and best practice throughout Europe; 
 provide incentives to innovative ventures; 
 promote the collaboration among institutions in order to identify unmet clinical needs. 
 
4. The Commission should reinvigorate the process of coordination and harmonisation 
of national HTA processes and experiences 
The process of implementation of HTA is at present progressing, with Member States adopting 
different metodologies and standards. Exchangeability and access to the evidence-based 
information for policy-making and practice obtained through HTA would instead be enhanced by 
the harmonisation of the methodologies and standards of data compilation. The processes and 
initiatives in place (the ECHTA/ECAHI project) have so far led to partial results. 
The Commission should reinvigorate this process of coordination through the enhancement and 
sponsorship of an effective and well-endorsed “European Network for Medical Technology 
Assessment”. The mission of the network should include the development of agreed harmonised EU 
standards for HTA in medical technologies, together with the collection and dissemination of the 
knowledge produced all along the diverse pipelines of R&D for medical devices: individual 
scientists, physicians, academic medical centers, small device companies and multinational 
corporations.  
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The objective of the network would be to assist the European Union, its Member States and the 
candidate countries to plan, deliver and monitor health services effectively. The network should 
involve those working actively on assessments in healthcare throughout the Europe Union, focusing 
on those in the public sector, but welcoming those working in other settings. The network should 
work closely with global collaborative efforts in the field, such as INAHTA (The International 
Network of Agencies for Health Technology Assessment) and the US Agency for Healthcare 
Research and Quality under the Department of Health and Social Services. As the Agency of 
Healthcare Research and Quality in the US and the INAHTA, the network will focus on the key 
technologies identifitied based on mission-oriented programmes.  
 
5. Member States should diversify the financial structure of medical expenditure as a 
mean to ease the policy trade-offs and to achieve financial and social sustainability 
Considerations in the Study suggest that the debate on the impact and sustainability of medical 
devices expenditures needs to be enriched in order to include elements related to social expenditure 
composition and overall sustainability. Projection of health and social expenditure for EU countries 
suggests in fact that, independently from the technological innovation in medicine and medical 
devices, EU Members will be asked to adopt significant reforms of their social security systems, in 
order to ensure their financial and social sustainability. 
To this regard, international experience as well as economic considerations on the efficiency of the 
financial structure of social expenditure, suggest the existence of benefits associated to a higher 
heterogeneity of the financial sources, through an increased role for private insurance-based funds 
(health funds, when applied to the health sector), the so-called “private institutional pillar”. 
Diversification should preserve the fundamental goals of the social system and, at the same time, 
enhance the efficiency of the healthcare system. 
The scenario, for the medical device sector would be among other things, a partial loosening of 
budget constraints as well as the focus on cost-containment. This would allow more room for high 
performance products both in the public and private markets. 
 
6. Member States and the European Commission should promote and establish a 
coherent statistical framework for the analysis of the competitiveness and 
innovativeness of the medical device sector in Europe 
The Study has revealed the inadequacy of the available statistical framework for the analysis of the 
medical device sector, both at the aggregate and at the disaggregate levels.  
The present lack of a systematic effort at the international level to collect, integrate, update and 
diffuse primary data and information on the state and the evolution of the medical device industry 
severely constrains the possibility to formulate reliable policy actions to enhance the 
competitiveness and innovativeness of the EU medical device industry. Moreover, data availability 
is a prerequisite to design and support the constitution of a unified European system of innovation. 
The first step toward the design of a statistical framework for the analysis of the medical device 
sector is the adoption of a common definition of the industry, agreed and accepted by all the actors 
involved in the data collection process such as the definition set forth by the Global Healthcare 
Unification Task Force. In addition, given the heterogeneity of the medical device sector, that is 
composed of a wide range of different products, the identification and adoption of a unified 
classification system at the international level is needed. 
In Chapter 6, we have proposed a set of indicators, that can illuminate policy decisions, and on 
which statistical collection should focus. Among these are data on the number of patents and 
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publications; on the introduction of new products in the marketplace; on the number, size and 
dynamics (birth and deceases) of companies, and on their R&D expenditures, sales, value added, 
number of employees, and collaborative ventures. 
Data gathering and management should be centralised at Eurostat.  
Appropriate market-based incentives should be devised to enhance: i) the transparency of the 
administrative procedure for determining the value of medical devices, ii) the transparency of the 
decision-making process for the review of new and existing procedures and technologies and iii) the 
participation of companies, hospitals, as well as local and national institutions in the provision and 
diffusion of medical data and information on the sector. This issue is linked with the 
recommendation of undertaking systematic assessments of the value and degree of innovativeness 
of medical devices on the market. The design of market mechanisms based on innovation-oriented 
premium price schemes will provide incentives for investments in R&D and for the disclosure of 
unbiased data and information. Data collected this way could then be used to inform, design and 
monitor policy choices and trade-offs (see Recommendation 1) and initiatives for the promotion and 
the support of competitiveness and innovation.  
Market-based incentives and HTA can provide incentives to companies and public institutions for a 
transparent and unbiased provision of information and data on the value of their innovation, on their 
innovative efforts as well as on market dynamics. Such information and data can be of use only 
through a systematic and unified statistical framework, that needs further development as the 
analysis has revealed. The establishment of a unified and leading European system of innovation in 
medical technologies need to be well-informed and supported by data at all stages of action.  
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Table A.4.1. DALY – disability adjusted lost year (x 100) by age, sex and cause, 2001 worldwide 
 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total 
Cardiovascular diseases 3,542,736.14 1,760,964.89 6,943,255.86 16,417,432.57 40,595,419.76 36,278,481.76 27,775,327.79 9,650,093.98 142,963,712.76 
Rheumatic heart disease 542,927.14 373,763.62 1,239,211.09 794,823.04 902,529.46 464,535.36 263,561.84 66,074.80 4,647,426.36 
Hypertensive heart disease 80,843.40 46,059.61 225,566.63 756,894.20 1,941,117.67 1,863,497.03 1,443,421.58 550,912.48 6,908,312.61 
Ischaemic heart disease (CAD) 272,727.84 294,919.40 1,586,902.03 7,056,466.43 21,062,210.22 17,550,509.96 12,466,654.17 3,840,041.42 64,130,431.48 
Cerebrovascular disease 644,956.68 329,178.88 1,298,341.58 3,746,393.10 11,687,904.36 12,557,953.90 10,017,540.13 3,161,146.75 43,443,415.37 
Inflammatory heart diseases 500,347.47 166,691.39 772,137.43 1,124,333.76 1,240,197.93 784,042.36 560,767.98 207,291.94 5,355,810.26 
M
a
l
e
 
Other cardiovascular diseases 1,500,933.62 550,351.99 1,821,097.09 2,938,522.03 3,761,460.14 3,057,943.15 3,023,382.08 1,824,626.58 18,478,316.68 
Cardiovascular diseases 4,322,292.12 2,043,699.48 6,515,640.21 10,578,754.65 27,406,391.57 31,842,342.77 35,168,560.99 18,227,567.25 136,105,249.03 
Rheumatic heart disease 603,195.43 687,304.58 1,341,074.46 1,086,931.75 1,289,672.30 799,746.60 534,464.20 167,365.44 6,509,754.77 
Hypertensive heart disease 81,822.97 59,077.08 183,292.28 534,181.73 1,727,068.64 1,909,272.08 1,990,450.24 1,125,682.68 7,610,847.69 
Ischaemic heart disease (CAD) 232,696.48 197,380.29 1,790,133.99 3,693,401.62 11,009,195.44 13,826,324.43 13,928,748.72 6,612,270.71 51,290,151.68 
Cerebrovascular disease 541,859.55 289,058.48 964,054.22 2,711,239.00 9,268,449.82 11,412,033.79 13,366,898.74 6,481,309.66 45,034,903.26 
Inflammatory heart diseases 494,725.30 199,525.67 568,768.30 593,270.57 765,102.32 647,069.47 699,404.34 354,334.21 4,322,200.19 
F
e
m
a
l
e
 
Other cardiovascular diseases 2,367,992.37 611,353.38 1,668,316.95 1,959,729.99 3,346,903.05 3,247,896.40 4,648,594.75 3,486,604.56 21,337,391.44 
Source: WHO (2002). 
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Table A.4.2. DALY – disability adjusted lost year (x1000s) by region, 2001 worldwide 
CAUSE OF DISEASE EASTERN MEDITERRANEAN EUROPE SOUTH–EAST ASIA 
WESTERN 
PACIFIC AFRICA THE AMERICAS 
  Mortality stratum Mortality stratum Mortality stratum Mortality stratum Mortality stratum Mortality stratum 
 
Low child, 
low adult 
High child,
high adult 
Very low 
child, 
very low 
adult 
Low child,
low adult
Low child,
high adult
Low child,
low adult 
High child, 
high adult 
Very low 
child, 
very low 
adult 
Low child,
low adult 
High child,
high adult 
High child,
very high 
adult 
Very low 
child, 
very low 
adult 
Low child,
low adult
High 
child, 
high adult 
Population (x 1000) 141,835 351,256 412,512 219,983 241,683 297,525 1,262,285 154,919 1,546,770 301,878 353,598 328,176 437,142 72,649 
 (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) (x 1000) 
Cardiovascular 
diseases   280   757  1,760  1,111  2,171   571  3,226   395  3,350  5,388  5,976  6,950  7,194  1,001 
Rheumatic heart 
disease   3   21   11   8   15   9   123   3   105   359   405   42   108   11 
Hypertensive heart 
disease   35   56   68   67   40   63   75   9   276   256   304   324   563   118 
Ischaemic heart 
disease (CAD)   147   376   738   500  1,185   232  1,740   136   827  1,614  1,644  3,523  2,688   295 
Cerebrovascular 
disease   47   171   456   296   728   193   877   163  1,763  1,508  1,810  1,448  2,332   277 
Inflammatory heart 
disease   6   23   29   27   31   12   66   8   74   358   414   400   418   24 
TOTAL DALYs   707  3,449  4,076  1,969  3,658  2,194  12,273  1,161  10,475  147,899  209,985 46,520 81,270 17,427 
Source: WHO (2002). 
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Table A.4.3. Incidence of cardiovascular disease on total deaths, worldwide, Estimates for 2001 
 
SEX 
CAUSE OF DEATH 
Both sexes Males Females 
Population (x 1000) 6,122,210 3,083,884 3,038,327 
 (x 1000) % total (x 1000) % total (x 1000) % total 
Cardiovascular diseases  16,585 29.3  7,962 26.9  8,623 32.0 
Rheumatic heart disease   338 0.6   140 0.5   197 0.7 
Hypertensive heart disease   874 1.5   397 1.3   477 1.8 
Ischaemic heart disease (CAD)  7,181 12.7  3,756 12.7  3,425 12.7 
Cerebrovascular disease  5,454 9.6  2,499 8.4  2,956 11.0 
Inflammatory heart disease   375 0.7   192 0.6   183 0.7 
TOTAL Deaths  56,554 100.0  29,628 100.0  26,926 100.0 
Source: WHO (2002).       
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Table A.4.4. Total direct cost profile for a diabetic patients in Europe (2000) 
Country 
General healthcare 
cost per patient (US$)
Additional cost due to 
presence of diabetes (US$)
Annual cost per patient with 
type 2 diabetes (US$) 
Belgium 1,495 1,647 3,142 
France 1,979 1,009 2,988 
Germany 2,146 1,330 3,476 
Italy 1,259 1,611 2,870 
Netherlands 1,634 180 1,814 
Spain 1,046 241 1,287 
Sweden 1,710 855 2,565 
United Kingdom 1,144 881 2,025 
Average 1,552 969 2,521 
Source: International Diabetes Federation (2004). 
 
Table A.4.5. CSII impact on Quality of Life parameters scale (0=poorest QoL, 100=highest 
QoL), as compared to MDI 
 MDI CSII p-value 
Social relations 79 85 0.025 
Time flexibility 71 82 0.001 
Physical complaints 68 81 0.000 
Worries about future 37 51 0.010 
Diet restrictions 60 77 0.001 
Daily hassles 54 66 0.003 
Fear of hypoglycaemia 54 68 0.000 
Burdens of hypoglycaemic events 50 69 0.000 
Blood glucose fluctuations 40 65 0.000 
Self efficacy 70 79 0.001 
Treatment satisfaction 51 71 0.000 
Adapted from Linkeschova et al (2002) 
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Table A.4.6. Comparison of the results of the DCCT (1993) and the UKPDS (1998) studies 
with respect to intensive control of blood glucose levels 
 
Risks (measures of outcome) DCCT (1993) UKPDS (1998) 
HbA1c 9  
Retinopathy Reduction of 63% Reduction of 17-21% 
Nephropathy Reduction of 54% Reduction of 24-33% 
Neuropathy Reduction of 60% – 
Macrovascular Disease Reduction of 41% Reduction of 16% 
 
Table A.4.7. Cost per unit THR in Ireland 
 Cost per unit THR 
Salaries (including medical, nursing, physiotherapy, administrative, etc.) £4,203.87 
Materials £641.19 
Implant (FC 2 femur, Charnley cup) £478.71 
Medical equipment £172.67 
Laboratory/Radiology costs £155.72 
Maintenance charges £207.56 
Provisions £114.37 
Housekeeping £214.72 
Administration £200.79 
Miscellaneous £82.46 
Total £6,472.06 
Adapted from O’Shea et al (2002)  
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Table A.4.8. Percentage probability of developing breast cancer from age on the rows to age on the columns, years 1991-2001, US female population 
 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 95+ 
0 0.00 0.00 0.00 0.00 0.01 0.05 0.18 0.48 1.05 1.93 3.09 4.54 6.18 7.90 9.57 11.10 12.24 12.97 13.27 13.39 
5  0.00 0.00 0.00 0.01 0.05 0.18 0.49 1.06 1.95 3.12 4.59 6.25 7.98 9.67 11.21 12.37 13.11 13.41 13.53 
10   0.00 0.00 0.01 0.05 0.18 0.49 1.06 1.95 3.12 4.59 6.25 7.99 9.68 11.22 12.38 13.12 13.42 13.54 
15    0.00 0.01 0.05 0.18 0.49 1.06 1.95 3.12 4.60 6.25 7.99 9.69 11.23 12.39 13.13 13.43 13.55 
20     0.01 0.05 0.18 0.49 1.06 1.95 3.13 4.60 6.26 8.00 9.70 11.25 12.41 13.14 13.45 13.57 
25      0.04 0.17 0.48 1.05 1.95 3.12 4.60 6.27 8.01 9.71 11.26 12.43 13.16 13.46 13.59 
30       0.13 0.44 1.01 1.91 3.09 4.57 6.24 7.99 9.69 11.25 12.42 13.16 13.46 13.59 
35        0.31 0.88 1.78 2.97 4.46 6.14 7.89 9.60 11.16 12.34 13.08 13.38 13.51 
40         0.58 1.49 2.68 4.18 5.87 7.64 9.37 10.94 12.12 12.87 13.18 13.31 
45          0.92 2.13 3.65 5.36 7.16 8.90 10.50 11.70 12.45 12.76 12.89 
50           1.24 2.79 4.53 6.36 8.14 9.77 10.99 11.76 12.08 12.21 
55            1.59 3.39 5.27 7.11 8.78 10.04 10.83 11.16 11.29 
60             1.87 3.84 5.75 7.49 8.80 9.63 9.97 10.11 
65              2.08 4.12 5.97 7.36 8.24 8.60 8.75 
70               2.22 4.24 5.77 6.73 7.12 7.29 
75                2.31 4.04 5.14 5.59 5.78 
80                 2.12 3.46 4.01 4.24 
85                  1.86 2.63 2.95 
90                   1.34 1.91 
95                    1.28 
Source: Fay (2003). 
 193
 
Table A.4.9. Estimated Breast Cancer Cases/Deaths Worldwide. Source Ferlay et al (2001) 
Region  New Cases (2000) Deaths (2000) 
Eastern Africa 13,615 6,119 
Middle Africa 3,902 1,775 
Northern Africa 18,724 8,388 
Southern Africa 5,537 2,504 
Western Africa 17,389 7,830 
Caribbean 6,210 2,310 
Central America 18,663 5,888 
South America 69,924 22,735 
Northern America 202,044 51,184 
Eastern Asia 142,656 38,826 
South–Eastern Asia 55,907 24,961 
South Central Asia 129,620 62,212 
Western Asia 20,155 8,459 
Eastern Europe 110,975 43,058 
Northern Europe 54,551 20,992 
Southern Europe 65,284 25,205 
Western Europe 115,308 40,443 
Australia/New Zealand 12,748 3,427 
Melanesia 470 209 
Micronesia 62 28 
Polynesia  127 58 
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Table A.4.10. A history of Breast Cancer screening  
 
William Roentgen discovered X-rays 1894 
Albert Salomon (pathologist in Berlin) produced images of 3.000 gross mastectomy 
specimens, observing black spots at the centres of breast carcinomas 
1913 
Jacob Gershon–Cohen (Jefferson Medical College, PA) thought studying the normal breast 
‘under all conditions of growth and physiology’ would improve understanding of the cancerous 
breast 
1930s 
Stafford Warren (Rochester Memorial Hospital, NY) developed a stereoscopic system for 
tumour identification 
1940s 
Raul Lebrogne (Uruguay) emphasised breast compression for identification of calcifications 1949 
Breast Self–Examination (BSE) advocated 1940s, 1950s 
Charles Gros (France) developed a radiological unit designed for breast examinations 1951 
Robert Egan (US) adapted high–resolution industrial film for mammography, allowing simple 
and reproducible mammograms. 
1960 
First randomised trial of screening by the Health Insurance Plan of New York (HIP Trial) 
found that mammography reduced the 5–year BC mortality by 30% 
1963 
Siemens, Philips and Picker began selling special mammography systems. Philips’ device set 
as new standard 
1970s 
Xerox technology was coupled with mammography, replacing traditional X-ray film with an 
electrically charged selenium–coated aluminium plate 
1971 
Breast Cancer Detection Demonstration Project (BCDDP) began in 29 US centres  1973 
Malmoe Trial on breast screening by mammography 1976 
NIH Consensus Conference on BC screening 1977 
Trial of Early Detection of Breast Cancer (TEDBC) in the U.K. 1979 
Canadian National Breast Cancer Studies (CNBCS) 1980 
Stockholm Trial on breast screening by mammography 1981 
Gothenburg Trial on breast screening by mammography 1983 
The American College of Radiology developed breast screening accreditation program for 
radiologists and technicians 
1986 
Joint Guidelines issued for mammography screening by American College of Radiology and 
NCI 
1988 
International Breast Cancer Screening Network (IBCSN) established to assess screening 
programs 
1990 
Mammography Quality Standards ACT passed 1992 
NCI International Workshop on mammography trials 1993 
Major improvements in mammography equipments include reduced radiation dosage, 
automatic exposure controls, better films, film emulsifiers, digital imaging, computer aided 
detection 
1980s, 
1990s 
Sources: Gold et al (1990), Institute of Medicine – National Research Council (2001), Lerner (2001) 
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Table A.4.11. Most recent developments in imaging devices 
Technology Description, mechanism Potential strengths Current limitations 
Digital Mammography 
Detector responds to X-ray 
exposure, sends electronic 
signal to computer to be 
digitised and processed. 
Separates detector and 
image display. 
Ability to manipulate 
contrast and magnification 
with one exposure. Ease of 
image storage & retrieval. 
Facilitates CAD, digital 
tomo-synthesis, and tele-
mammography 
Spatial resolution and 
luminance of digital display 
are lower than standard 
film–screen mammography. 
Old film–screen difficult to 
digitalise for comparison 
Computer Aided 
Detection and 
Diagnosis (CAD) 
Computer programs to aid 
in identification of 
suspicious mammograms 
and classification as benign 
or malignant. Serves as a 
second opinion to 
radiologists 
Retrospective studies show 
that CAD can improve 
radiologists’ readings and 
improve rate of false–
negative results 
CAD used alone has very 
low specificity. Sensitivity 
& specificity are 
undetermined for general 
screening population 
Ultrasound 
Use of high–frequency 
sound waves to generate an 
image 
Studies suggest potential for 
increased use in diagnosis 
and perhaps even screening, 
especially for women with 
dense breasts 
Poor ability to detect 
microcalcifications due to 
speckle. Compound 
imaging may help reduce 
speckle 
Magnetic Resonance 
Imaging (MRI) 
Image generated by signals 
from excitation of nuclear 
particles in magnetic field. 
Breast tumour show 
increased uptake of contrast 
agent 
Benefits in detection are 
detection of multiple 
malignancies; detection of 
invasive carcinoma; 
screening for high–risk 
women with dense breasts; 
detection of recurrent 
cancers  
Lack of uniform 
interpretation criteria. 
Cannot reliably detect 
microcalcifications and 
small tumours, especially if 
they do not pick up the 
contrast agent. Overlap in 
uptake time course of 
benign and malignant 
tumours 
Adapted from Institute of Medicine – National Research Council (2001) 
 
 
Table A.4.12. Screening tests for women at different ages, recommendations and benefits
Age Recommendation Benefit 
Age 40 to 49  Mammogram every 1 to 2 years, with or without clinical breast exam  
May reduce risk of dying from 
breast cancer by 17% 
Age 50 to 74  Mammogram every 1 to 2 years, with or without clinical breast exam  
May reduce risk of dying from 
breast cancer by 30% 
Source: USPSTF (2004). 
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ANNEX TO CHAPTER 5 
Table A.5.1. Production value (constant 1995 € millions), and share of production value 
in manufacturing total (%), MD (NACE 33.1), 1997-2002 
 1997 1998 1999 2000 2001 2002 
 € % € % € % € % € % € % 
Austria 586 0.7 660 0.7 655 0.7 421 0.4 464 0.5 459 0.4 
Belgium 543 0.4 574 0.4 370 0.3 481 0.3 422 0.2 n.a. n.a. 
Denmark 752 1.3 792 1.3 778 1.3 826 1.3 945 1.4 987 1.5 
Finland 522 0.7 579 0.8 595 0.7 663 0.7 757 0.8 773 0.9 
France 4355 0.6 4313 0.6 4616 0.6 4873 0.6 5364 0.7 5458 0.6 
Germany n.a. n.a. n.a. n.a. 14183 1.1 11847 0.9 12417 0.9 13048 1.0 
Ireland 988 n.a. 1032 n.a. 1394 2.2 1965 2.6 2755 3.8 2888 4.1 
Italy 2509 0.4 2784 0.5 2498 0.5 2916 0.5 3219 0.5 3238 0.5 
Luxembourg 13 0.2 11 0.2 14 n.a. 15 0.2 15 0.2 15 0.2 
Netherlands 1164 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Portugal 80 0.1 106 0.2 89 0.2 80 0.1 77 0.1 n.a. n.a. 
Spain 414 0.2 527 0.2 557 0.2 578 0.2 747 0.2 870 0.3 
Sweden 1032 0.9 1097 0.9 1062 0.8 1304 1.0 1461 1.1 n.a. n.a. 
UK 2194 0.5 2238 0.5 2418 0.5 2242 0.5 2416 0.5 n.a. n.a. 
Cyprus 4 0.2 3 0.2 n.a. n.a. 3 0.1 4 0.2 4 0.2 
Czech Rep. 127 0.3 186 0.5 158 0.5 132 0.3 145 n.a. 166 0.4 
Estonia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 9 0.4 11 0.5 
Hungary n.a. n.a. 85 0.3 125 0.5 80 0.2 111 0.3 119 0.3 
Latria 3 0.1 4 0.2 5 0.3 4 0.2 4 0.2 n.a. n.a. 
Lithuania n.a. n.a. n.a. n.a. n.a. n.a. 9 0.3 15 0.5 15 0.5 
Malta n.a. n.a. n.a. n.a. 20 1.0 23 0.9 n.a. n.a. n.a. n.a. 
Poland 183 0.3 186 0.3 238 0.3 253 0.3 258 0.3 301 0.4 
Slovak Rep. 37 0.4 30 0.3 n.a. n.a. 31 0.2 44 0.3 50 0.4 
Slovenia 18 0.2 17 0.1 16 0.1 18 0.1 23 0.2 38 0.3 
Bulgaria 8 0.1 9 0.1 8 0.2 8 0.1 8 0.1 8 0.1 
Norway 199 0.5 205 0.4 220 0.5 195 0.5 198 0.5 n.a. n.a. 
Romania n.a. n.a. n.a. n.a. n.a. n.a. 9 0.1 11 0.1 11 0.1 
Source: Eurostat (2004). 
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Table A.5.2. Value added at factor cost (constant 1995 € millions), and share of value 
added in manufacturing total (%), MD (NACE 33.1), 1997-2002 
 1997 1998 1999 2000 2001 2002 
 € % € % € % € % € % € % 
Austria 296 0.9 349 1.0 337 1.0 238 0.7 247 0.7 278 0.8 
Belgium 165 0.4 163 0.4 159 0.4 180 0.4 152 0.4 n.a. n.a. 
Denmark 344 1.6 397 1.8 369 1.7 390 1.7 443 1.9 467 2.1 
Finland 273 1.2 278 1.1 304 1.2 311 1.1 341 1.2 342 1.2 
France 1851 1.0 1781 1.0 1918 1.0 2013 1.0 2196 1.1 2119 1.1 
Germany n.a. n.a. n.a. n.a. 7793 1.8 6057 1.5 6415 1.6 6556 1.7 
Ireland 508 2.9 487 2.7 671 3.0 1050 4.0 1230 5.0 1246 4.9 
Italy 1175 0.8 1132 0.7 1126 0.7 1327 0.8 1224 0.8 1346 0.9 
Luxembourg 7 0.4 6 0.3 6 n.a. 10 0.5 6 0.3 7 0.4 
Netherlands 482 1.0 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Portugal 30 0.2 40 0.3 35 0.2 34 0.2 31 0.2 n.a. n.a. 
Spain 191 0.2 242 0.3 261 0.3 284 0.3 340 0.4 376 0.4 
Sweden 421 1.1 389 1.0 355 0.9 440 1.1 429 1.1 n.a. n.a. 
UK 1038 0.6 1128 0.7 1273 0.8 1192 0.8 1199 0.8 n.a. n.a. 
Cyprus 2 0.3 2 0.3 n.a. n.a. 2 0.3 2 0.3 2 0.3 
Czech Rep. n.a. n.a. n.a. n.a. n.a. n.a. 58 0.6 58 0.6 73 0.7 
Estonia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 3 0.6 4 0.6 
Hungary n.a. n.a. 33 0.5 41 0.6 9 0.1 44 0.6 50 0.6 
Latria 1 0.2 1 0.2 3 0.5 2 0.3 2 0.2 n.a. n.a. 
Lithuania n.a. n.a. n.a. n.a. n.a. n.a. 3 0.5 -5 -0.8 5 0.7 
Malta n.a. n.a. n.a. n.a. 12 2.1 14 2.0 n.a. n.a. n.a. n.a. 
Poland 98 0.4 103 0.4 130 0.5 121 0.5 139 0.5 138 0.5 
Slovak Rep. 12 0.6 12 0.5 n.a. n.a. 11 0.4 17 0.5 20 0.7 
Slovenia 7 0.2 7 0.2 6 0.2 7 0.2 9 0.2 13 0.3 
Bulgaria n.a. n.a. n.a. n.a. 3 0.2 3 0.2 3 0.3 3 0.3 
Norway 81 0.6 78 0.5 93 0.7 78 0.6 73 0.5 n.a. n.a. 
Romania n.a. n.a. n.a. n.a. n.a. n.a. 4 0.1 5 0.1 4 0.1 
Source: Eurostat (2004). 
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Table A.5.3. Number of employees, and share of employment in manufacturing total 
(%), MD (NACE 33.1), 1997-2002 
 1997 1998 1999 2000 2001 2002 
 n % n % n % n % n % n % 
Austria 7405 1.2 8054 1.3 7322 1.2 6081 1.0 6249 1.0 6335 1.0 
Belgium 3168 0.5 3311 0.5 3167 0.5 3005 0.5 2980 0.5 n.a. n.a. 
Denmark n.a. n.a. 7762 1.6 6466 1.4 6676 1.4 7142 1.5 7397 1.6 
Finland 4402 1.1 4734 1.1 5139 1.2 5377 1.3 5115 1.2 5156 1.2 
France 39155 1.0 40095 1.0 40611 1.0 39762 1.0 42527 1.1 43297 1.1 
Germany n.a. n.a. n.a. n.a. 140199 1.9 141022 1.9 145037 2.0 140328 2.0 
Ireland 9503 n.a. 10194 n.a. 11484 4.6 12936 5.1 14770 5.9 15093 6.3 
Italy 25624 0.6 25721 0.6 26080 0.7 28728 0.7 25692 0.6 26769 0.7 
Luxembourg 271 0.8 284 0.8 278 n.a. 288 0.9 290 0.9 301 0.9 
Netherlands 10228 n.a. 9949 n.a. 9890 1.2 10698 1.2 n.a. c n.a. 10742 1.3 
Portugal 1891 0.2 2670 0.3 2011 0.2 2005 0.2 2223 0.3 n.a. n.a. 
Spain 7488 0.3 8899 0.4 8154 0.4 8593 0.4 11845 0.5 13014 0.5 
Sweden 8330 1.1 8342 1.1 8268 1.1 9043 1.2 9356 1.2 n.a. n.a. 
UK 28247 0.7 31458 0.7 30092 0.7 29844 0.8 35082 0.9 n.a. n.a. 
Cyprus n.a. n.a. n.a. n.a. n.a. n.a. 112 0.3 n.a. n.a. n.a. n.a. 
Czech Rep. 7980 0.6 8924 0.7 8052 0.6 7168 0.6 8649 n.a. 8613 0.7 
Estonia n.a. n.a. n.a. n.a. n.a. n.a. n.a. c n.a. 528 0.4 685 0.5 
Hungary n.a. n.a. 4653 0.6 4775 0.6 4993 0.7 7019 0.8 7682 0.9 
Latria 503 0.3 449 0.3 530 0.4 568 0.4 564 0.4 n.a. n.a. 
Lithuania n.a. n.a. n.a. n.a. n.a. n.a. 1206 0.5 1415 0.6 1451 0.6 
Malta n.a. n.a. n.a. n.a. 484 1.7 502 1.7 n.a. c n.a. n.a. n.a. 
Poland 8573 0.3 9378 0.4 10368 0.4 10654 0.5 10621 0.5 12675 0.6 
Slovak Rep. 3616 0.8 2477 0.6 n.a. c n.a. 2139 0.5 2600 0.6 2764 0.7 
Slovenia 730 0.3 721 0.3 671 0.3 707 0.3 827 0.3 1010 0.4 
Bulgaria 2044 0.3 2181 0.3 2133 0.3 2342 0.4 1977 0.3 1996 0.3 
Norway 1851 0.6 1801 0.6 1927 0.7 1804 0.6 1750 0.6 n.a. n.a. 
Romania n.a. n.a. n.a. n.a. n.a. n.a. 2015 0.1 2008 0.1 2067 0.1 
Source: Eurostat (2004). 
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Table A.5.4. Gross value added per person employed (apparent labour productivity) 
Country 1997 1998 1999 2000 2001 2002 
Austria 37.2 40.9 43.0 35.7 36.3 40.1 
Belgium 37.3 35.2 35.6 40.5 36.5 n.a. 
Denmark 41.0 50.1 55.8 57.2 60.9 62.2 
Finland 59.7 57.2 57.8 56.6 65.2 64.0 
France 42.4 40.0 42.6 45.8 47.1 44.8 
Germany n.a. n.a. 55.2 42.7 41.7 43.7 
Ireland 53.4 47.7 58.4 81.1 83.3 82.6 
Italy 22.9 22.0 22.6 26.3 24.9 27.5 
Luxembourg 25.2 21.0 20.7 32.1 21.3 22.7 
Netherlands 38.9 n.a. n.a. n.a. n.a. n.a. 
Portugal 13.8 13.4 14.3 14.3 11.3 n.a. 
Spain 19.2 23.4 22.3 24.1 22.2 22.5 
Sweden 48.3 44.6 n.a. 46.1 43.5 n.a. 
UK 33.7 34.7 40.8 38.9 33.0 n.a. 
Cyprus n.a. n.a. n.a. 13.8 14.2 13.0 
Czech Rep. n.a. n.a. n.a. n.a. 5.6 6.8 
Estonia n.a. n.a. n.a. n.a. 6.5 5.6 
Hungary n.a. n.a. n.a. 1.8 5.4 5.2 
Latria n.a. n.a. 5.7 3.5 4.0 n.a. 
Lithuania n.a. n.a. n.a. 2.6 -3.4 3.1 
Malta n.a. n.a. 25.1 27.5 n.a. n.a. 
Poland n.a. n.a. n.a. n.a. n.a. 6.5 
Slovak Rep. n.a. n.a. n.a. 5.1 6.6 7.3 
Slovenia n.a. n.a. n.a. n.a. n.a. 12.4 
Albania n.a. n.a. n.a. n.a. n.a. n.a. 
Bulgaria n.a. n.a. n.a. n.a. 1.2 1.3 
Norway 42.1 41.7 47.1 42.4 41.4 n.a. 
Romania n.a. n.a. n.a. 2.0 2.3 2.0 
Source: Eurostat (2004). 
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Table A.5.5. International Trade, MD (CN 9018, 9019, 9021, 9022, 9402), 1988-2001, € mil 
 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 
EXPORTS FROM EU TO               
INTRA EU-15 2,903 3,304 3,656 4,170 4,672 4,727 5,187 7,165 8,341 8,809 9,604 10,866 12,345 13,296 
EXTRA EU-15 3,444 3,764 3,976 4,506 4,902 5,739 6,144 6,530 7,138 8,094 8,836 9,962 12,284 14,874 
Switzerland 202 230 244 257 261 264 288 332 345 366 402 505 560 678 
Norway 59 63 66 74 77 77 79 134 157 181 208 228 251 265 
Iceland 4 4 4 5 5 5 5 6 8 9 9 12 15 26 
New Member States60 108 132 137 194 241 293 367 450 504 563 586 604 769 860 
US 1,114 1,117 1,115 1,415 1,475 1,571 1,492 1,715 1,776 2,093 2,581 3,340 4,023 5,177 
Japan 268 306 322 340 376 467 490 709 761 927 890 1,111 1,385 1,448 
Rest of the world 1,689 1,913 2,088 2,220 2,467 3,061 3,423 3,183 3,586 3,956 4,159 4,162 5,281 6,421 
Extra/Intra EU-15 1.19 1.14 1.09 1.08 1.05 1.21 1.18 0.91 0.86 0.92 0.92 0.92 1.00 1.12 
IMPORTS TO EU FROM               
INTRA EU-15 3,009 3,433 3,926 4,451 4,937 4,581 5,088 6,820 7,863 8,298 9,396 10,140 11,685 12,233 
EXTRA EU-15 2,624 3,170 3,343 4,046 4,355 4,636 4,978 5,222 5,958 6,949 7,484 9,251 11,143 12,936 
Switzerland 378 384 429 507 551 561 617 752 780 781 910 1,147 1,400 1,706 
Norway 21 24 26 30 33 38 41 52 53 61 64 70 68 71 
Iceland 0,4 0,1 0,1 0,3 0,5 0,7 1,3 2,1 2,8 3,8 5 6 9 10 
New Member States 61 8 8 10 20 32 34 50 87 106 116 191 224 226 312 
US  1,213 1,584 1,640 2,027 2,146 2,354 2,579 2,979 3,537 4,307 4,399 5,347 6,639 7,881 
Japan 530 618 619 708 735 723 676 738 725 737 833 1,073 1,077 1,130 
                                                 
60 Time series start from 1992 for Slovenia, Estonia, and Lithuania, and from 1993 for Latvia and Poland. 
61 Data for Czech Republic are missing for the time period 1988-1990. Time series start from 1992 for Slovenia (the year in which its independence was recognised), from 
1994 for Cyprus, from 1995 for Estonia, from 1996 for Lithuania, and from 1997 for Latvia. Data for Malta are missing in 2000. 
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 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 
Rest of the world 473 552 619 754 859 925 1,014 611 754 943 1,083 1,385 1,724 1,826 
Extra/Intra EU-15 0.87 0.92 0.85 0.91 0.88 1.01 0.98 0.77 0.76 0.84 0.80 0.91 0.95 1.06 
TRADE BALANCE               
EXTRA EU-15 821 594 633 461 546 1,103 1,167 1,308 1,180 1,146 1,352 711 1,141 1,938 
EXTRA EU-15 
Export/Import ratio 
1.31 1.19 1.19 1.11 1.13 1.24 1.23 1.25 1.20 1.16 1.18 1.08 1.10 1.15 
Source: Eurostat (2005). 
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Table A.5.6. Medical Specialty in the FDA product listing 
Medical Specialty Code Medical Specialty Code 
Anaesthesiology an Immunology  im 
Cardiovascular  cv Microbiology  mi 
Clinical Chemistry  ch Neurology  ne 
Clinical Toxicology  tx Obstetrics-Gynecology  ob 
Dental  de Ophthalmic  op 
Ear, Nose, Throat  en Orthopedic  or 
General and Plastic Surgery  su Pathology  pa 
General Hospital  ho Physical Medicine  pm 
Gastroenterology/Urology  gu Radiology  ra 
Hematology  he   
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ANNEX TO CHAPTER 6 
 
Table A.6.1. R&D expenditures, MD, million € and ratio with respect to turnover  
 1995 1996 1997 1998 1999 2000 2001 2002 
 € % turn. € % turn. € % turn. € % turn. € % turn. € % turn. € % turn. € % turn. 
Belgium 0.5 0.11 0.0 0.00 n.a. n.a. 4.4 0.78 3.8 0.65 0.4 0.07 0.4 0.09 n.a. n.a. 
Czech Rep. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.5 0.27 
Germany  n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 336.3 2.19 348.6 2.69 363.7 2.69 364.6 2.54 
Estonia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.0 0.00 0.0 0.00 
Spain n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 5.9 0.97 10.5 1.59 n.a. n.a. n.a. n.a. 
France n.a. n.a. n.a. n.a. 92.8 1.86 93.9 1.90 113.6 2.15 117.2 2.12 128.1 2.13 132.9 2.14 
Italy n.a. n.a. n.a. n.a. 39.2 1.51 40.1 1.35 36.9 1.37 n.a. n.a. n.a. n.a. n.a. n.a. 
Cyprus n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0,0 0,00 0,0 0,00 0,0 0,00 
Latria n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Lithuania n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0,0 0,00 0,1 0,98 
Luxembourg n.a. n.a. n.a. n.a. n.a. n.a. 0,0 0,00 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Hungary n.a. n.a. n.a. n.a. n.a. n.a. 0.7 0.68 0.5 0.37 0.4 0.46 0.3 0.23 0.6 0.40 
Malta n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.1 0.39 0.1 0.34 n.a. n.a. n.a. n.a. 
Austria 6.2 1.42 n.a. n.a. 8.9 1.36 9.0 1.24 9.9 1.36 11.4 2.38 14.1 2.73 11.0 2.17 
Poland n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Portugal n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.4 0.48 0.1 0.10 0.0 0.00 n.a. n.a. 
Slovenia 0 0.00 n.a. n.a. 0.1 0.48 0.1 0.47 n.a. n.a. 0.1 0.43 0.4 1.32 0.4 1.08 
Slovak Rep. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.5 1.30 0.6 1.15 0.4 0.77 
Finland n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.0 0.00 
UK n.a. n.a. n.a. n.a. n.a. n.a. 28.5 1.15 38.1 1.40 48.1 1.87 56.5 2.14 n.a. n.a. 
Norway n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0.0 0.00 n.a. n.a. 
Source: Eurostat (2004). 
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Table A.6.2. Employees size distribution, firms included in the analysis, 2002  
 Number of firms Share of firms (%) 
Number of employees 1-49 50-249 250-749 >750 1-49 50-249 250-749 >750 
325413: In-Vitro Diagnostic Substance 
Manufacturing 5 16 13 11 11.11 35.56 28.89 24.44 
339111: Laboratory Apparatus and Furniture 
Manufacturing (pt) 0 4 2 2 0.00 50.00 25.00 25.00 
339112: Surgical and Medical Instrument 
Manufacturing (pt) 10 14 21 15 16.67 23.33 35.00 25.00 
339113: Surgical Appliance and Supplies 
Manufacturing 6 3 14 21 13.64 6.82 31.82 47.73 
334510: Electromedical and Electrotherapeutic 
Apparatus Manufacturing (pt) 8 32 33 17 8.89 35.56 36.67 18.89 
339114: Dental Equipment and Supplies 
Manufacturing 1 1 3 3 12.50 12.50 37.50 37.50 
339115: Ophthalmic Goods Manufacturing (pt) 0 0 1 6 0.00 0.00 14.29 85.71 
334517: Irradiation Apparatus Manufacturing (pt)       1 1 4 3 11.11 11.11 44.44 33.33 
Total 31 71 91 78 11.44 26.20 33.58 28.78 
Source: our elaborations on Standard & Poor’s Compustat® (2004b). 
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Table A.6.3. R&D Intensity Percentiles62 (indicating the share of firms that have R&D intensity greater than or equal to…), North-
American Companies 
  1993 1997 2002 
NAICS Description N.Obs. 75% 50% 25% N.Obs. 75% 50% 25% N.Obs. 75% 50% 25% 
325413 In-Vitro Diagnostic  
Substance Manufacturing 46 7.72 18.12 182.89 64 10.01 58.38 253.28 47 11.37 49.97 221.36 
339111 Laboratory Apparatus  
and Furniture Manufacturing (pt) 9 0.61 2.19 5.83 8 3.82 6.51 6.94 7 5.19 6.22 13.25 
339112 Surgical and Medical  
Instrument Manufacturing (pt) 58 3.74 6.20 18.05 74 6.28 13.36 62.13 56 5.31 9.31 51.37 
339113 Surgical Appliance  
and Supplies Manufacturing 50 2.10 5.46 10.67 47 3.17 5.80 21.90 40 1.82 4.57 6.22 
339114 Dental Equipment and  
Supplies Manufacturing                             7 1.91 2.52 17.86 10 2.27 4.36 7.55 9 1.91 5.77 13.07 
339115 Ophthalmic Goods  
Manufacturing (pt) 7 3.51 5.69 11.97 10 2.02 3.31 4.25 7 1.91 2.17 7.06 
334510 Electromedical and  
Electrotherapeutic Apparatus  
Manufacturing (pt) 99 5.73 10.98 32.56 107 7.80 13.42 55.75 86 7.34 12.18 22.11 
334517 Irradiation Apparatus  
Manufacturing (pt)                                11 7.19 8.69 12.83 15 8.42 10.77 29.18 9 4.19 8.7132 11.33 
 Total 287 4.07 8.14 21.94 335 6.28 12.36 60.99 261 5.03 10.06 25.97 
Source: Our elaborations on Standard & Poor’s Compustat® (2004b). 
                                                 
62 The percentile identifies the value that divides the cases according to a threshold below which a certain percentage of cases fall. For example, the 75th percentile corresponds to 
the value below which 75 percent of the cases fall.  
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Table A.6.4. Number of R&D licensing agreements in MD, by country of licensor and licensee 
 As licensor Partner location (%) As licensee Partner location (%) 
 N % Europe Japan Other US and Canada N % Europe Japan Other US and Canada 
US 1487 73.8 15.2 3.0 1.3 80.4 1441 71.5 12.2 0.9 2.8 84.0 
Japan 26 1.3 15.4 30.8 3.8 50.0 70 3.5 14.3 11.4 4.3 70.0 
Canada 82 4.1 11.0 4.9 0.0 84.1 65 3.2 13.8 0.0 3.1 83.1 
Denmark 10 0.5 50.0 0.0 10.0 40.0 14 0.7 28.6 0.0 14.3 57.1 
Finland 2 0.1 0.0 0.0 0.0 100.0 6 0.3 0.0 0.0 0.0 100.0 
France 27 1.3 37.0 0.0 0.0 63.0 12 0.6 50.0 0.0 8.3 41.7 
Germany 73 3.6 43.8 0.0 1.4 54.8 97 4.8 39.2 0.0 5.2 55.7 
Ireland 8 0.4 12.5 0.0 0.0 87.5 9 0.4 33.3 0.0 0.0 66.7 
Italy 6 0.3 33.3 33.3 0.0 33.3 8 0.4 12.5 25.0 0.0 62.5 
Netherlands 14 0.7 57.1 14.3 14.3 14.3 19 0.9 31.6 0.0 5.3 63.2 
Norway 2 0.1 100.0 0.0 0.0 0.0 3 0.1 100.0 0.0 0.0 0.0 
Sweden 12 0.6 50.0 0.0 0.0 50.0 14 0.7 50.0 0.0 0.0 50.0 
Switzerland 34 1.7 26.5 5.9 0.0 67.6 82 4.1 25.6 0.0 6.1 68.3 
UK 136 6.7 44.1 2.9 1.5 51.5 121 6.0 41.3 1.7 3.3 53.7 
Other EU 22 1.1 45.5 0.0 0.0 54.5 17 0.8 35.3 0.0 0.0 64.7 
Other 75 3.7 24.0 4.0 14.7 57.3 38 1.9 15.8 2.6 28.9 52.6 
Total 2016 100.0     2016 100.0     
Source: ATA (2004). 
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Table A.6.5. US Patents, by nationality of first inventor  
  1974-1983 1984-1993 1994-1998 1999-2003 1974-2003 
Country N % N % N % N % N % 
US 7952 73.81 17645 70.83 18558 79.81 38879 72.02 83034 73.53 
EU15 1134 10.53 3642 14.62 3139 13.50 7184 13.31 15099 13.37 
NMS 26 0.24 53 0.21 26 0.11 44 0.08 149 0.13 
EU25 1160 10.77 3695 14.83 3165 13.61 7228 13.39 15248 13.50 
Japan 392 3.64 2171 8.71 162 0.70 3447 6.38 6172 5.47 
Germany 421 3.91 1421 5.70 1076 4.63 2496 4.62 5414 4.79 
France 230 2.13 578 2.32 501 2.15 1031 1.91 2340 2.07 
UK 183 1.70 606 2.43 456 1.96 1063 1.97 2308 2.04 
Canada 141 1.31 315 1.26 344 1.48 801 1.48 1601 1.42 
Israel 40 0.37 182 0.73 204 0.88 1068 1.98 1494 1.32 
Sweden 63 0.58 350 1.40 371 1.60 642 1.19 1426 1.26 
Switzerland 109 1.01 311 1.25 231 0.99 626 1.16 1277 1.13 
Netherlands 78 0.72 151 0.61 222 0.95 518 0.96 969 0.86 
Italy 64 0.59 215 0.86 192 0.83 446 0.83 917 0.81 
Australia 63 0.58 190 0.76 161 0.69 391 0.72 805 0.71 
Source: ATA (2004). 
 
 208
Table A.6.6. US Patents and Publications, by nationality of assignee (patents) and main author’s institution (publications) 
  Patents Publications 
 1974-83 1984-93 1994-98 1999-2003 1974-1983 1984-1993 1994-1998 1999-2003 
  N % N % N % N % N % N % N % N % 
US 6317 75.32 17935 72.15 18989 77.50 25148 74.12 108 45.38 28336 39.26 33297 39.74 38060 35.68 
EU15 1217 14.51 3251 13.08 2678 10.93 4193 12.36 87 36.55 26573 36.81 29615 35.34 37907 35.53 
NMS 23 0.27 52 0.21 20 0.08 30 0.09 3 1.26 556 0.77 634 0.76 1118 1.05 
EU25 1240 14.78 3303 13.29 2698 11.01 4223 12.45 90 37.82 27129 37.58 30249 36.10 39025 36.58 
Japan 484 5.76 2219 8.93 1569 6.40 2052 6.05 5 2.10 5682 7.87 7143 8.52 8522 7.99 
Germany 536 6.39 1309 5.26 938 3.83 1472 4.34 16 6.72 5692 7.89 6848 8.17 9169 8.59 
UK 291 3.47 544 2.19 369 1.50 530 1.56 16 6.72 6678 9.25 7211 8.61 8690 8.15 
France 162 1.93 504 2.03 431 1.76 594 1.75 19 7.98 3110 4.31 3468 4.14 4214 3.95 
Switzerland 102 1.21 371 1.49 225 0.92 533 1.57 9 3.78 1445 2.00 1539 1.84 1819 1.71 
Canada 62 0.74 296 1.19 310 1.26 464 1.37 7 2.94 2977 4.12 3090 3.69 3270 3.07 
Sweden 78 0.93 271 1.09 337 1.38 434 1.28 3 1.26 2132 2.95 1945 2.32 1936 1.81 
Netherlands 56 0.67 166 0.67 156 0.64 450 1.33 1 0.42 1982 2.75 2173 2.59 2647 2.48 
Israel 33 0.39 165 0.66 180 0.74 435 1.28 2 0.84 809 1.12 774 0.92 1100 1.03 
Italy 36 0.43 190 0.76 172 0.70 215 0.63 20 8.40 1978 2.74 2508 2.99 3758 3.52 
Australia 47 0.56 154 0.62 139 0.57 211 0.62 2 0.84 1689 2.34 1907 2.28 2315 2.17 
Total 8284 98.77 24441 98.33 24110 98.40 33066 97.45 223 98.06 223 93.70 68067 94.30 77999 93.09 
Total (a) 10799 100.00 24912 100.00 24675 100.00 53792 100.00 238 100.00 72183 100.00 83792 100.00 106681 100.00 
Unknown (b) 2412  56  174  49  120743  110697  28409  286314  
 (a) with known assignee/affiliation. (b) The share is computed over the total number of patents/publications.  
Source: ATA (2004). 
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Table A.6.7. Citation received (US Patents), by nationality of assignee; Total Impact Factor (Publications), by nationality of institution 
 Patents Publications 
 1974-83 1984-93 1994-98 1999-2003 1974-1983 1984-1993 1994-1998 1999-2003 
 N % N % N % N % N % N % N % N % 
US 143251 78.85 478309 79.78 298958 84.85 81966 83.95 228 71.73 59337 48.97 69887 46.36 77151 40.78 
EU15 20799 11.45 56545 9.43 26413 7.50 7503 7.68 70 21.97 37343 30.82 49923 33.11 66792 35.30 
NMS 333 0.18 627 0.10 165 0.05 40 0.04 0 0.00 500 0.41 697 0.46 1391 0.73 
EU25 21132 11.63 57172 9.54 26578 7.54 7543 7.73 70 21.97 37843 31.23 50619 33.58 68183 36.04 
Japan 9748 5.37 36656 6.11 13830 3.93 3226 3.30 4 1.25 7282 6.01 10541 6.99 13898 7.35 
Germany 9351 5.15 21943 3.66 9076 2.58 2426 2.48 9 2.96 5823 4.81 10080 6.69 15477 8.18 
UK 4508 2.48 9223 1.54 3800 1.08 1497 1.53 21 6.53 11213 9.25 12649 8.39 14938 7.90 
France 2801 1.54 8715 1.45 5595 1.59 1125 1.15 10 3.28 4559 3.76 6316 4.19 8275 4.37 
Switzerland 2138 1.18 8655 1.44 2358 0.67 961 0.98 6 1.98 1863 1.54 2486 1.65 3194 1.69 
Canada 1689 0.93 5809 0.97 3320 0.94 1239 1.27 6 2.03 6077 5.02 6126 4.06 6509 3.44 
Sweden 1345 0.74 4918 0.82 2321 0.66 716 0.73 17 5.42 2986 2.46 3131 2.08 3302 1.75 
Israel 781 0.43 3114 0.52 2575 0.73 844 0.86 1 0.25 1193 0.98 1513 1.00 1963 1.04 
Netherlands 1039 0.57 3596 0.60 1643 0.47 425 0.44 0 0.00 3528 2.91 4739 3.14 5543 2.93 
Australia 1195 0.66 2897 0.48 1589 0.45 412 0.42 2 0.55 2855 2.36 2778 1.84 3821 2.02 
Italy 594 0.33 3648 0.61 1455 0.41 371 0.38 2 0.51 2763 2.28 4371 2.90 6124 3.24 
Total 179934 99.04 592612 98.85 349208 99.11 96191 98.52 318 99.75 116450 96.11 143950 95.48 174718 92.35 
Total (a) 180592 100.00 597812 100.00 352130 100.00 103846 100.00 318 100.00 121162 100.00 150760 100.00 189194 100.00 
Unknown (b) 43728  952  2581  314  173448  137176  39118  33452  
 (a) with known assignee/affiliation. (b) The share is computed over the total number of patents/publications.  
Source: ATA (2004). 
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